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1. General introduction 
 
1.1. Hematopoiesis and leukemia 
Daily, each person produces approximately 1011–1012 blood cells to maintain the number of cells 
in the peripheral circulation.[1] The continuous production of mature blood cells is essential as 
these cells have a limited lifespan. This renewal process is supported by hematopoietic stem 
cells (HSC) that are located in the medulla of the bone (bone marrow), especially in the pelvis, 
femur, and sternum. Although in smaller numbers, they can also be found in umbilical cord blood 
(UCB) and in peripheral blood. HSCs give rise to all types of mature blood cells (Figure 1) and 
have the capacity of self-renewal, since upon cellular division some of the daughter cells remain 
as HSCs.[2] Instead, the other daughters of HSCs differentiate into myeloid and lymphoid 
progenitor cells that further give rise to the development of all blood cell types. These changes 
can often be tracked by monitoring the presence of proteins on the surface of the cell, usually 
determined as Cluster of Differentiation (CD) markers. HSCs express CD34 and lack markers 
that are lineage-specific, such as the expression of CD3 in T-cells, CD19 in B-cells, CD33 in 
myeloid and CD56 in NK-lineage cells. The process of maturation from HSC to effector blood 
cells occurs in the bone marrow and/or secondary lymphoid organs, including thymus and 
spleen. Following specific stimuli, such as growth factors, chemokines and contact with cells 
present in different microenvironments, the hematopoietic precursor cell undergoes changes in 
chromatin organization and gene expression that promote the differentiation of the cell towards a 
specific cell type, limiting the potential for differentiation into alternative lineages. [2] 
 However, during the process of maturation, the blood precursor cells may acquire 
mutations, chromosomal rearrangements and epigenetic changes that prompt the cells to 
uncontrollable proliferation called leukemia.[3] As leukemic cells continue to grow and divide, 
they eventually outcompete the normal blood cells, which results in defective protection against 
infections and pathogens, and hemorrhages.[4] Clinically and pathologically, leukemias can be 
classified in four main categories. The first division is between acute and chronic leukemias. 
Acute leukemias are the most common forms of leukemia in children, which are characterized by 
a rapid increase in the number of leukemic cells.[5] Immediate treatment is required due to the 
rapid progression and accumulation of malignant cells that are released into the bloodstream 
and spread to other organs. Other symptoms can be manifested according to the tissue 
occupied; infiltration of the lymph nodes causes lymphadenopathy and infiltration of the central 
nervous system may provoke headaches. Chronic leukemia is characterized by the excessive 
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accumulation of relatively more mature leukemic cells, and typically it takes months or years to 
progress. Chronic leukemia mostly occurs in adults. In addition, leukemias can be classified into 
myeloid or lymphoblastic leukemia, according to the blood lineage of the affected cell. 
Furthermore, lymphoblastic leukemias can be further divided into B-cell or T-cell lymphoblastic 
leukemia.  
 
1.2. Acute lymphoblastic leukemia  
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children, comprising 
approximately 25% of all childhood malignancies.[6] Almost three-fourths of childhood leukemia 
(ages 0-18) is ALL, while the most common form of acute leukemia in adults is acute myeloid 
leukemia (AML). In the majority of the cases the leukemic blasts are detected on a blood smear. 
Blood and bone marrow are used for further classification by immuno-phenotyping and 
genotyping. A lumbar puncture is performed to detect central nervous system involvement. 
Immunophenotypic analysis of the blasts indicates whether the leukemia is from myeloid 
(neutrophils, eosinophils, or basophils) or lymphoblastic origin (B- or T-lymphocytes). Genomic 
analysis is used to determine the underlying genetic abnormalities, which are associated with 
specific risks for relapse and survival.[6] Treatment protocols are based on combination 
chemotherapy, including different classes of drugs. Survival rates of ALL patients improved from 
less than 10% before 1970 to over 80%.[7]  
 
1.3. T-cell acute lymphoblastic leukemia  
T-cell acute lymphoblastic leukemia (T-ALL) results from the malignant transformation of 
lymphoid precursor cells residing in the thymus that are primed towards T-cell development. T-
ALL represents about 15% of pediatric ALL cases and 25% of adult ALL cases,[8] and is 
typically more frequent in males than females. Clinically, T-ALL patients show diffuse infiltration 
of the bone marrow by immature T-cell blasts, high white blood cells counts, mediastinal masses 
with pleural effusions, and frequent infiltration of the central nervous system at diagnosis.[9] 
Despite the advances in our understanding of the molecular genetics of T-ALL, current 
treatments are mostly based on multi-agent chemotherapy and stem cell transplantation in part 
of the patients. Although these treatment regimens are highly effective with overall survival 
reaching 85% on current treatment protocols, they are often associated with severe toxicity and 
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long-term side effects such as cardiomyopathy, bone necrosis, chronic graft versus host 
disease, infertility or secondary malignancies, impairing the quality of adult life. In addition, about 
15% of pediatric T-ALL patients still relapse due to therapy resistance and those cases are 
associated with very dismal survival perspectives.[5, 10] Therefore, current research efforts are 
focused on the search for targets that will eventually lead to more effective and less toxic 
antileukemic drugs. In order to achieve more specific or individualized therapies it is crucial to 
improve our understanding of the molecular events that lead to the disease, and the 
mechanisms involved in disease progression and relapse.            
 
1.3.1. T-cell development in the thymus  
T-cells can be distinguished between αβ- or γδ-cells based on the composition of the T-cell 
antigen receptor (TCR). While αβ T-cells comprise the majority (95%) of T-cell populations in 
lymphoid organs, γδ T-cells only represent a small fraction of T-cells that are mainly located in 
the gut mucosa. Normal T-cell development is a strictly regulated, multistep process in which 
lymphoid precursor cells differentiate into functionally diverse T-lymphocyte subsets in the 
thymus microenvironment. The different checkpoints are orchestrated by diverse transcriptional 
regulatory networks[11] and transitions between epigenetic states[12] that are triggered through 
the activation of membrane receptors by signalling molecules present in thymus, such as 
cytokines, chemokines and ligands from stromal cells. During this fine-tuned developmental 
process, inappropriate activation of T-ALL oncogenes and loss of tumor suppressor genes in 
thymic precursors may provoke uncontrolled clonal expansion and T-ALL. To better understand 
the disease, it is therefore essential to understand the normal T-cell development in the thymus 
and to distinguish eventual functions of proto-oncogenes in the transcriptional networks that 
regulate normal developmental progression.  
Currently, our understanding of normal T-cell development in the thymus is mostly 
derived from mouse model studies. Based on these studies,[11] Yui and Rothenberg suggest 
that T-cell development can be divided in three major regulatory phases, which are divided by 
the T-cell commitment and the β-selection checkpoint. Those phases are named pre-
commitment (phase-1), T-cell identity (phase-2) and post β-selection (phase-3), and are 
characterized by unique gene networks and cellular features (Figure 2). Each phase is 
characterized by the expression of certain transcription factors that ensure key developmental 
and consecutive processes, namely the recruitment of progenitor cells to the thymus, their 
proliferation, the commitment to T-cell lineage, the response to T-cell receptor signals, and 
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finally the restrain to a particular effector programme.[11] In addition, these developmental 
stages can be divided according to their dependency to NOTCH- and TCR- signalling programs. 
For instance, in mice cells in phase-1 and -2 do not express a functional TCR and depend on 
Notch-signalling to proliferate and differentiate, while cells in phase-3 require the expression of a 
functional TCR rather than NOTCH signalling (Figure 2A).[11]  
Although the similarity in the core T-cell transcriptional networks that are activated in 
humans and mouse, there are some species-specific differences in kinetics and function. For 
instance, there are clear differences in NOTCH activation status between human and mice T-cell 
development. The highest level of NOTCH activation in humans occurs at T-cell commitment 
and decreases thereafter, while in mice there is an increase of NOTCH signalling until the cells 
reach the β-selection (Figure 2A-B). In line with this, while uncommitted early T-cell precursor 
cells (ETPs) in humans differentiate preferentially into αβ- lineage DP thymocytes after T-cell 
commitment [13, 14], in mice it only occurs after β-selection stage[15].  
The expression of characteristic cell surface markers during T-cell development allows to 
distinguish the different phases. Thymocytes can be subdivided into double-negative (DN), 
double-positive, or single-positive (SP) based on the expression of both T-cell markers CD4 and 
CD8. In mice, the DN stage can be divided into four distinct subsets based on the expression of 
CD44 and CD25 (Figure 2A). Although the DN stage in humans has not been clearly defined, it 
is characterized by consecutive acquisition of CD7, CD5, and CD1a (Figure 2B). [16, 17]  In 
addition, the immature single-positive stage that precedes the DP stage is characterized by the 
expression of CD8 in mice and CD4 in humans. [18, 19] 
 
1.3.1.1. Programs in pre-committed, early T-cell progenitor cells  
In phase-1, human thymus-seeding progenitors are DN, express CD34 and CD7 and do 
not express CD1a. The mouse counterpart is the DN1 stage, when cells are CD44+CD25-. The 
T-cell specific developmental program is activated when NOTCH-1 receptors on the surface of 
the lymphoid precursors interact with Notch ligands in the thymic microenvironment.  
During phase 1 until beginning of phase 2, Notch signalling interacts with a stem cell 
and/or progenitor cell gene network that is inherited from multipotent precursors, resulting in the 
downregulation of phase 1‑ restricted genes and the activation of Notch target genes. The most 
restricted initial subset of phase 1 regulators (GATA2, MEIS1 and HOXA9) is predominantly 
expressed in the early T-cell precursor cells (ETPs) and is possibly involved in supporting 
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engraftment in the thymus. Compared to ETP genes, expression of genes such as MEF2C, 
LMO2, SPI1/PU.1, HHEX, BCL11A, GFI1B, ERG and LYL1 are expressed throughout the whole 
pre-commitment stage (phase-1) and persist until the transition to the commitment phase 
(phase-2). LMO2, MEIS1, and NMYC are associated with stem-cell like features in early T-
cells,[20, 21] similar to ERG and HHEX that are described to contribute for self-renewal of 
normal and malignant cells.[21, 22] LYL1 is associated with the expression of the growth factor 
receptor KIT, and the regulatory factor GFI1 that is essential for the generation of ETPs and for 
the regulation of Notch signalling.[23, 24] Therefore, albeit transient, the expression of those 
transcription factors is essential for normal T-cell development. 
The major landmark in the developmental process, which occurs at the transition 
between phase-1 and -2, is known as T-cell lineage commitment. According to literature the 
commitment occurs in humans when cells acquire CD1 (Figure 2B), and in mice when KIT 
and/or CD44 expression is downregulated between DN2a and DN2b stages (Figure 2A). 
Although expression of CD1a has been used to define human T-lineage commitment,[25] the 
exact T-cell commitment point has not been clearly defined. 
Upon commitment, developing cells adopt an intrinsically irreversible T-cell fate that is 
caused by the “shut down” of transcription factors and gene regulatory networks, impeding cells 
to differentiate into alternative lineages even under permissive conditions. (reviewed in [26]) This 
process is initiated by existing ligands in the thymus that support differentiation of progenitor 
cells in the T-cell lineage. The activation of NOTCH signalling results in upregulation of many T-
cell genes and the loss of progenitor-specific gene expression, and therefore cells cannot 
differentiate into alternative lineages, such as dendritic cell, myeloid cell, NK cell, innate 
lymphoid cell or mast cell.  
 
1.3.1.2. Programs that promote T-cell commitment 
The gene network exhibited in phase-2 is initiated during phase-1, as the activation of NOTCH 
signalling in ETPs prompts the expression of crucial regulatory transcription factors, such as 
TCF1 and GATA3.[27, 28] Besides their role in inhibiting phase-1 progenitor specific factors, 
TCF1 and GATA3 also collaborate with regulators derived from a pre-thymic stage (e.g. E2A, 
GFI1, RUNX1, MYB and Ikaros) that are essential for T-cell development. TCF1 is a 
“gatekeeper” of T-cell fate that is directly activated by NOTCH signals and drives the expression 
of important T-cell specific regulators including GATA3 and BCL11B. [28, 29] GATA3 has critical 
roles during different developmental stages, namely in early T-cell survival and growth, T-cell 
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lineage commitment, and in T-cell subset diversification that follows TCR expression and antigen 
stimulation. ([30], reviewed in [31]) Accordingly, GATA3 is responsible to exclude access to B-
cell lineage explaining the loss of B-cell potential nearly at the ETP stage, [32] and it is 
necessary to trigger BCL11B expression during T-cell commitment as well as to prompt the cells 
for β‑ selection. The transition from phase-1 to phase-2 is especially well characterized in mice, 
and seems marked by various events: silencing of the majority of phase-1 genes, cells become 
strictly dependent on NOTCH signalling to survive, proliferation rates are reduced and BCL11B 
expression is activated.[33] While cells progress to the DN2b stage (equivalent to CD1+ stage in 
humans), ETS1 and ETS2 are immediately expressed, LEF1 is induced by increased NOTCH 
signalling, E2A activity is boosted, and the expression of E-dependent and NOTCH-dependent 
genes (e.g. RAG1, RAG2, PTCRA, TDT and CD3E) is considerably higher.[34] This transition 
from phase-1 to phase-2 is not well described in human thymocytes, because one of the 
requirements for T-cell commitment is reduction of NOTCH signalling. However, recent studies 
indicate that GATA3 is responsible to induce human T-cell commitment by upregulation of T-cell 
lineage genes, restraining of Notch activity and repressing NK-cell fate. [30] Consistently, Notch 
target genes that require strong NOTCH signalling are downregulated during T-cell commitment 
(e.g. NRARP, DTX1), while others such as HES1 and MYC are expressed until the β-selection 
checkpoint. [30] 
During phase-2, many cells enter a G1 arrest and RAG-mediated TCR gene 
recombinations occur until cells successfully rearrange their TCR-β gene. Beyond the key roles 
at phase-2 gene network, E proteins, NOTCH signalling and BCL11B seem to have a tight 
collaboration as well. For instance, E proteins are required to promote and sustain NOTCH-1 
signalling, which can be antagonized by ID2, an E protein antagonist. [35, 36] In turn, BCL11B 
may support the phase-2 stage by suppressing ID2 expression.[37] Importantly, the potential of 
those cells to become αβ instead of γδ T-cells can be related to their distinctive requirement for 
BCL11B and NOTCH signalling, which is different in mouse and human.   
In mouse, the inhibition of NOTCH signalling by ID3 or ID2 factors promotes the 
development of γδ T-cell lineages.[38] For that reason, the impact of BCL11B deletion is 
especially prominent in αβ T-cells, in contrast to γδ T-cell lineages,[39] and consequently the 
timing of BCL11B activation and expression is crucial for T-cell lineage commitment. 
Furthermore, BCL11B is possibly involved in direct repression of KIT, and BCL11B expression 
itself may be activated by TCF1, RUNX1 and perhaps GATA3, since the BCL11B promoter and 
a far-distant enhancer contain binding sites for these factors.[40] Although these positive 
regulators are expressed before BCL11B, perhaps it needs to reach a certain level of combined 
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expression to remove initial DNA methylation and H3K27me3 marks from both the promoter and 
the enhancer of BCL11B. Contrarily to mouse thymocytes, high NOTCH activation in human 
thymocytes during phase 2 promotes γδ T cell development, while lower levels of NOTCH 
activation promote αβ-lineage differentiation. In this case, specific Notch receptor-ligand 
interactions control human TCR-αβ or -γδ development, as they exhibit different Notch signal 
strength.[13] At the final stage of phase-2 regulatory activity, the cells are commited to T-cell 
lineage, α-lineage biased and undergo further TCR-α gene rearrangements.  
 
1.3.1.3. The β-selection program 
The transition to phase-3 occurs at the β‑ selection checkpoint, when thymocytes that have not 
functionally rearranged the TCR-β gene are eliminated. The expression of a functional TCR-β 
chain activates the phase-3 gene network and promotes growth and differentiation beyond 
β‑ selection. At the checkpoint, TCRβ proteins assemble at the cell membrane beside TCR 
complex components that are already expressed during phase-2, namely pre-Tα, CD3 co-
receptor and TCRζ. The newly assembled pre-TCR complex stimulates accelerated cell cycle, 
enlargement of the cells and increased expression of the co-stimulatory molecule CD28.[41, 42] 
Analysis of TCR arrangements indicates that recombination events occur in the following 
order during human and mouse T-cell development: TCR-δ, TCR-γ, TCR-β and TCR-α.[43] In 
recent studies, transplantation of CD34+ cells from patients with severe combined 
immunodeficiency (SCID) in xenograft mouse models revealed that rearrangement of TCR-γ 
starts at the DN CD7+ stage. The TCR-β rearrangements are already initiated at the DN 
CD7+CD5+ stage (before T-cell commitment),[44] which is an earlier stage than the previously 
suggested immature SP CD4+.[45, 46] In mice, rearrangement of TCR-γ starts at DN1 stage and 
TCR-β rearrangements start at DN2, but occur mainly at the DN3 stage (after T-cell 
commitment). [47]  
Following β‑ selection, cells are able to signal through pre-TCR, which results in loss of 
NOTCH-dependency (in mice) and downregulation of NOTCH-target genes and IL7R. Ikaros 
plays a crucial function at this stage, operating as a tumor suppressor gene by suppressing 
Notch target genes.[48, 49]. As a response to the inhibition of those signaling pathways that 
promote growth, the cells activate PI3K by becoming highly responsive to chemokine signaling 
through CXCR4, [50] and therefore initiate a new stage of very rapid proliferation. Until the end 
of phase-3 and start of the DP stage, cells further increase the expression of ETS1, TCF7, 
LEF1, ETS2 and TCF12 (canonical HEB). Also, the stable expression of new transcription 
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factors is activated (RORγt, NFAT3, POU6F1 and IKZF3), while others (EGR2 and ID3) are only 
transiently activated in response to the TCR signal during the rapidly proliferating stage.  
When cells reach the DP stage, the interaction of RORγt with MYB promotes cell survival 
through the induction of BCLXL and impairs conventional effector responses such as 
proliferation and cytokine production.[51] At this stage, the regulatory functions of TCF1 and 
LEF1 may be altered by specific interactions with β-catenin, which is a mediator of the canonical 
WNT pathway. This alteration is responsible for the expression of CD4 and CD8, and supports 
the replacement of the pre-TCR α-chain with a new functionally rearranged TCR α-chain, which 
yields a complete αβTCR. [52, 53] As a result, DP thymocytes become prepared for the positive 
and negative selection events. DP αβTCR+ cells that are positively selected on the basis of 
specific TCR recognition can further differentiate into effector T cell subsets, such as CD4+ T 
cells, CD8+ T cells, natural killer T (NKT) cells or regulatory T cells.  
 
1.3.2. Genetic aberrations in T-ALL 
T-ALL is a heterogeneous disease that arises from the oncogenic transformation of immature 
thymocytes. Different subtypes of T-ALL have been identified on the basis of genetic aberrations 
(Figure 3).[54] The genetic aberrations are characterized by chromosomal rearrangements that 
lead to the aberrant activation of oncogenic transcription factors, including TAL1 and LMO2 (and 
related family members), TLX1, TLX3, NKX2-1, HOXA, and MEF2C, and also by particular 
oncogenic fusion proteins that directly activate the HOXA or MEF2C genes.[54-56] We have 
denoted these chromosomal rearrangements as type A aberrations, because they are generally 
considered to be the driving oncogenic event associated with unique expression profiles.[55] 
Based on their gene expression signatures, T-ALLs can be classified into four major subtypes: 
ETP-ALL, TLX, proliferative, and TALLMO (Figure 4).[56] These subtypes are associated with 
specific and sequential T-cell maturational arrest.[8, 45, 54] For instance, the immature cluster is 
associated with a very early arrest (CD34+cells), similar to an early T-cell precursor (ETP) 
profile.[57] In addition, the TLX cluster includes γδ-lineage arrested cells; the proliferative cluster 
is associated with a cortical stage arrest (CD1+cells); and the TALLMO cluster consists of cells 
arrested at a mature stage (CD4+ and/or CD8+cells).[54]  
 The maturational arrest of the cells generates a premalignant condition that facilitates the 
rapid acquisition of additional genetic hits, which we denoted as type B mutations.[55] These 
mutations are prevalent among all T-ALL subtypes and do not necessarily occur in the entire 
leukemic cell population. Instead, they can appear in subclones that are often either selected or 
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lost during disease progression or post-treatment relapse. [58, 59] Type B mutations affect 
different signal transduction pathways, including the NOTCH1, IL7R-JAK-STAT, RAS-MEK-ERK 
and PTEN-PI3K-AKT pathways, and are therefore associated with a variety of cellular 
processes, including survival and proliferation, cell cycle progression, and epigenetic events. 
The most frequent genetic hit in pediatric T-ALL is the deletion of the CDKN2A locus, which 
encompasses the p16/INK4A and p14/ARF suppressor genes, and is present in more than 70% 
of T-ALL cases. In addition, constitutive activation of NOTCH1 signaling is one of the most 
prominent oncogenic pathway in T-cell transformation, represented in more than 60% of T-ALL 
cases.   
However, increasing evidence suggests that some of the signaling pathways are 
preferentially mutated in certain T-ALL subtypes. This may be related to the natural activation of 
a certain pathway at the stage where the pre-leukemic clone is arrested. For instance, IL7-
Receptor (IL7R) signaling is required for early thymocyte progenitor (ETP) development,[60] and 
mutations in IL7R—or the downstream molecules JAK or RAS—are prevalent among ETP-ALL 
and TLX patients.[61, 62](our own observations) Moreover, PTEN inactivation events are 
preferentially associated with the TALLMO subtype,[63] while NOTCH1 mutations are more 
prevalent in the TLX cluster, but have a lower incidence in ETP-ALL and TALLMO subtypes.[64] 
Although strategies targeting oncogenic type A transcription factor complexes are emerging,[65] 
multiple selective compounds inhibiting pathways that are activated by type B hits are readily 
available.  
 
1.3.3. The importance of an in vitro culture system to study T-ALL 
Although T-ALL genetic signatures provide clues about the primary and cooperating genetic 
lesions in the multi-step process that drives malignant transformation, in vivo and in vitro models 
remain valuable tools to investigate the sequential genetic lesions that can initiate and sustain T-
ALLs. In this respect, it is crucial to compare human and mouse T cell development not only at 
the levels of surface marker expression (e.g. CD markers), but also at the requirements of 
NOTCH and cytokines signalling as well as the underlying transcriptional networks during 
differentiation. This will assess the conservation of T-cell developmental programs between both 
species and is also important to understand the relevance of mouse model studies for human T-
ALL. While T-cell development has been extensively studied in mice, the restricted availability of 
human thymus material has limited a detailed insight of human T-cell development. For that 
reason, research has focused on mimicking the thymus environment using in vitro differentiation 
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cultures starting with hematopoietic stem cells (HSCs) derived from human cord blood or bone 
marrow. Early studies were performed by seeding of HSCs in lobes of the mouse fetal thymus, 
cultures that are denoted as fetal thymus organ cultures (FTOCs) and allow intrathymic T-cell 
development in vitro.[66] Although this system provided important understanding of 
developmental processes, the capacity to evaluate specific progenitor populations has remained 
difficult, since this approach only provides a limited number of T cells. In addition, the procedure 
with FTOCs is a time-consuming and technically demanding method.  
 As an alternative, the OP9 stromal cells co-culture system is available to support T-cell 
development in vitro. In particular, the expression of the Delta-like 1 ligand on these bone 
marrow-derived stromal cells from op/op M-CSF deficient mice induces NOTCH signalling in 
target cells of the hematopoietic lineage.[67] NOTCH signalling results in inhibition of B-cell 
differentiation while T-cell differentiation is promoted. Umbilical cord blood-derived HSCs in this 
co-culture system are primed to develop into the T-cell lineage, and the OP9-DL1 system 
recapitulates in vivo T-cell development as measured by sequential acquisition of surface 
markers CD7, CD5, CD1a, and the achievement of the CD4, CD8 double-positive (DP) 
stage.[16, 17] These results establish an efficient and versatile in vitro system for the generation 
of relatively larger numbers of human T-lineage cells and offer a model system to investigate the 
factors that influence human T-cell–lineage commitment and differentiation. In addition, this 
system may be a valuable tool for investigating the sequential genetic lesions that can initiate 
and sustain T-ALL, as it is easy to manipulate many factors involved in lymphocyte 
differentiation, including cytokines, Notch signaling pathway and the expression of specific 
(onco)genes.  
 However, the OP9-DL1 system also has some limitations like any in vitro system. T-cell 
development can only induce efficient lymphopoiesis until the CD4+ CD8+ DP stage, and does 
not support positive/negative selection due to lack of proper MHC expression. T-cell 
development in this system is very sensitive to subtle differences in cytokines and to culture 
media changes.[68] Also, the effect of thymic epithelial cells (TECs) such as the presentation of 
different ligands and release of chemokines that create the thymus environment is ignored. 
Other issues as cell emigration and trafficking cannot be addressed using this system. To 
address these questions different immunodeficient mice models can be used, namely 
NOD/SCIDγc−/− (NSG) and Rag2−/−γc−/− strains. Transplantation of human CD34+ HSCs into 
these conditioned neonatal mice supports multi-lineage human hematopoiesis leading to the 
production of T cells, B cells and dendritic cells. [69] 
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2. Aims of the Thesis   
 The aims of this thesis are:  
I. to identify additional PTEN aberrations that may provide survival and proliferation 
advantage to (pre)-leukemic cells, and understand their clinical impact in T-ALL 
(Chapters 1 and 2),  
  
II. to optimize a lentivirus system that supports transduction and stable expression of 
oncogenes in human and mouse HSCs (Chapter 3),    
 
III. to establish an in vitro co-culture system (OP9-DL1) that supports T-cell development 
from human umbilical cord blood-derived hematopoietic stem cells (HSCs) in order to 
define distinct human T-cell development stages in relation to the expression of cell 
surface markers and underlying transcripitonal programs, and in relation to mouse and 
human in vivo T-cell development (Chapter 4),   
 
IV.  to study the impact of ETP-ALL expressed oncogenes (such as MEF2C, LYL1 or LMO2) 
on human T-cell development (Chapter 5).  
 
3. Short outline of the Thesis 
In chapter 2, we review the incidence of inactivating mechanisms of the PTEN tumor 
suppressor and we discuss relationships to other recurrent aberrations in T-ALL, such as driving 
oncogenic rearrangements and mutations affecting the NOTCH1, MYC and AKT pathways. We 
further investigate the role of PTEN aberrations in causing cellular resistance to NOTCH1-
directed therapy, suggesting a new hypothesis that explains conflicting data in literature. Finally, 
we suggest the use of specific signaling pathway inhibitors to prevent resistance to NOTCH-
directed therapy in NOTCH1-mutated T-ALL.  
 In chapter 3, we identify microdeletions as an additional and novel mechanism for PTEN 
inactivation in T-ALL. The breakpoints of these microdeletions are caused by illegitimate RAG-
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mediated recombination events. The identification of subclonal PTEN microdeletions indicates 
that RAG activity may be ongoing in (at least part of) the leukemic cell population, and could 
therefore be responsible for the clonal diversity and/or selection observed in T-ALL during 
disease progression. The discovery of PTEN microdeletions adds a new level of complexity that 
should be addressed in the development of future antileukemic strategies for ALL.  
 In chapter 4, we generate a strategy for the cloning, production and transduction of a 
lentiviral vector with the aim of studying the leukemogenic effects of T-ALL oncogenes during T-
cell development. Hence, we optimize the transduction of murine and human HSCs by 
optimizing both vector design and serum-free virus production as well as by developing a qRT-
PCR to quantify viral batches. We suggest that proviral RNA length is an important factor that 
determines transfection and viral productions as well as transduction efficiencies.  
 In chapter 5, we validate the OP9-DL1 co-cultures as an in vitro system that mimics 
thymic αβ T-cell lineage development. In particular, we perform gene expression arrays of in 
vitro differentiated early T-cell subsets at consecutive stages of development. As validation, we 
compare expression profiles of the in vitro generated T-cell subsets with different stages of 
human and mouse thymocyte development in vivo. In addition, we define a gene signature that 
clearly distinguishes two major T-cell differentiation stages, and that correlates with in vivo pre- 
and post-commitment T-cell profiles. We further demonstrate that loss of CD44 functionally 
marks human T-cell commitment, which is supported by analysis of TCR-β rearrangements as 
well as by multi-lineage differentiation experiments.  
 In chapter 6, we show that T-ALL subtypes are strongly associated with consecutive T-
cell developmental programs. We demonstrate that immature and TLX subtypes are associated 
with a pre-commitment program, and the proliferative and TALLMO subtypes with a post-
commitment program. Detailed analysis of T-ALL gene expression profiles indicates that T-ALL 
oncogenes interfere with T-cell developmental programs. Finally, we demonstrate that ectopic 
expression of typical ETP-ALL oncogenes (such as MEF2C, LYL1 or LMO2) promotes 
developmental arrest of early thymic progenitor (ETP) cells.     
 In Chapter 7, we discuss all findings presented in the thesis and put these into 
perspective. In Chapter 8 we summarize the content of the thesis (in English and Dutch).        
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Figure 1. Schematic representation of human hematopoiesis. Multipotent hematopoietic stem 
cell have self-renewal capacity and differentiate into all blood cell types. 
 
Figure 2. Schematic overview of mice (A) and human (B) αβ T-cell development. The sequential 
stages from a pre-thymic progenitor to the double-positive (DP) stage are depicted in the figures. 
The mice developmental stages are accompanied of associated expression of surface markers 
and transcription factors. The variation in colour intensity represents their level of expression. 
Obtained from Yui and Rothenberg, Nat Rev Immunol, 2014. 14(8): p. 529-45.  
 
Figure 3. Schematic overview of T-ALL genetic subgroups ETP-ALL, TLX3, TLX1, HOXA and 
TAL/LMO in relation to their T-cell developmental stage based on EGIL or TCR classification 
systems. * LMO2 is ectopically expressed in LMO2-rearranged cases but is not included in this 
figure. Adapted from Meijerink et al, Best Pract Res Clin Haematol, 2010. Sep;23(3):307-18. 
 
Figure 4. Unsupervised hierarchical cluster analysis of 117 pediatric T-ALL samples and 7 
normal bone-marrow (NBM) controls based on 435 probesets. Cytogenetic rearrangements 
indicated are: S, SIL-TAL1; T, TAL1; t, TAL2; O, LMO1; L, LMO2; $, TAL2/LMO1; N, SET-
NUP214; C, CALM-AF10; M, MYB; A, Inv(7)(p15q34); 1, TLX1; 3, TLX3; and n, normal bone 
marrow controls. The samples with the highest TAL1 or LYL1 expression, positivity for TLX1 and 
TLX3 expression, and expression of the immunophenotypic markers CD13 and/or CD33, CD4 or 
CD8 are indicated; u, no data available. Obtained from Homminga et al, Cancer Cell, 2011. 
19(4): p. 484-97. 
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Abstract 
The tumor suppressor phosphatase and tensin homolog (PTEN) negatively regulates 
phosphatidylinositol 3-kinase (PI3K)-AKT signaling and is often inactivated by mutations 
(including deletions) in a variety of cancer types, including T-cell acute lymphoblastic leukemia. 
Here, we review mutation-associated mechanisms that inactivate PTEN together with other 
molecular mechanisms that activate AKT and contribute to T-cell leukemogenesis. In addition, 
we discuss how Pten mutations in mouse models affect the efficacy of gamma-secretase 
inhibitors to block NOTCH1 signaling through activation of AKT. Based on these models and on 
observations in primary diagnostic samples of T-cell acute lymphoblastic leukemia patients, we 
speculate that PTEN-deficient cells employ an intrinsic homeostatic mechanism in which PI3K-
AKT signaling is dampened over time. As a result of this reduced PI3K-AKT signaling, the level 
of AKT activation may be insufficient to compensate for NOTCH1 inhibition, resulting in 
responsiveness to gamma-secretase inhibitors. On the other hand, de novo acquired PTEN 
inactivating events in NOTCH1-dependent leukemia could result in temporal, strong activation of 
PI3K-AKT signaling, increased glycolysis and glutaminolysis, and consequently gamma-
secretase inhibitor resistance. Due to the central role of PTEN-AKT signaling and in the 
resistance to NOTCH1 inhibition, AKT inhibitors may be a promising addition to current 
treatment protocols for T-cell acute lymphoblastic leukemia.  
 
T-cell acute lymphoblastic leukemia 
 
T-cell acute lymphoblastic leukemia (T-ALL) is a cancer of developing T-cells in the thymus. T-
ALL is characterized by chromosomal rearrangements. These rearrangements can lead to the 
aberrant activation of oncogenic transcription factors by placing their genes under the control of 
promoters and/or enhancers of T-cell receptor genes, the BCL11B gene, or other genes; 
occasionally, these rearrangements can give rise to oncogenic fusion proteins. The activated 
oncogenic transcription factors include TAL1 and LMO2 (and related family members), TLX1, 
TLX3, NKX2-1, HOXA, and MEF2C; in addition, certain oncogenic fusion proteins can directly 
activate the HOXA or MEF2C genes.(1, 2) Oncogenic proteins facilitate the developmental 
arrest of pre-leukemic immature T-cells. We previously proposed that these chromosomal 
rearrangements should be classified as type A aberrations, as they are generally considered to 
be the driving oncogenic event associated with unique expression profiles.(2) Based upon their 
gene expression signatures, T-ALL can be classified into the following four major subtypes: 
ETP-ALL, TLX, proliferative, and TALLMO.(3-5)  
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Maturation arrest induces a pre-leukemic condition in which additional mutations can give 
rise to T-ALL.(1, 2) These secondary mutations are not necessarily clonal events and are often 
selected during disease progression or post-treatment relapse.(6, 7) We therefore proposed that 
these mutations should be classified as type B aberrations.(2) Type B mutations are prevalent 
among all T-ALL subtypes and affect a wide variety of cellular processes, including survival and 
proliferation, cell cycle progression, and epigenetic events. Type B mutations often affect signal 
transduction pathways, including the NOTCH1, IL7R-JAK-STAT, RAS-MEK-ERK, and PTEN-
PI3K-AKT pathways. A growing body of evidence suggests that some of these signaling 
pathways are preferentially mutated in specific T-ALL subtypes, presumably due to the fact that 
developing T-cells are dependent on these pathways in specific stages. For example, mutations 
in IL7 receptor (IL7R) and the downstream molecules JAK or RAS are prevalent among TLX and 
ETP-ALL patients.(8-10) Although new therapeutic strategies that target oncogenic transcription 
factor complexes are emerging,(11) several compounds that selectively inhibit altered signaling 
pathways are currently available. Thus, inhibiting signaling proteins such as NOTCH, IL7R, RAS 
and/or AKT may provide a promising new therapeutic approach for T-ALL.  
In this review, we describe the role of PTEN as a tumor suppressor and we discuss 
various PTEN inactivating mechanisms observed in different human cancers and T-ALL. 
Besides PTEN inactivation, we describe other mechanisms that contribute to AKT activation and 
leukemogenesis. Finally, we discuss PTEN-AKT signaling in relation to future NOTCH1-directed 
therapies and provide a rationale for the use of AKT inhibitors in addition to current treatment 
protocols. 
 
The PTEN tumor suppressor   
 
Mutations in the tumor suppressor gene PTEN (phosphatase and tensin homolog), which is 
located on chromosomal band 10q23, are highly common among a wide range of cancers.(12, 
13) The PTEN gene contains nine exons, and the encoded protein includes an N-terminal 
phosphatase domain, a central C2 lipid membrane-binding domain, and a C-terminal tail domain 
(Figure 1). PTEN is a phosphatase that dephosphorylates PIP3 (phosphatidylinositol (3,4,5)-
triphosphate) to produce PIP2 (phosphatidylinositol (4,5)-bisphosphate), thereby opposing the 
function of PI3K (phosphatidylinositol 3-kinase). PI3K converts PIP2 into PIP3, which in turn 
activates key downstream kinases, including PDK1 and AKT (Figure 2). Thus, PTEN is an 
important negative regulator of PI3K-AKT signaling. Because AKT plays key roles in cellular 
metabolism, proliferation and survival, inactivation of PTEN by genetic aberrations drives 
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survival and uncontrolled proliferation, ultimately leading to cancer.(14) A recent study identified 
an alternate translation initiation site located upstream of the coding region of canonical PTEN 
that generates a larger form of PTEN.(15) This isoform is known as PTENα and is described to 
be involved in mitochondrial energy metabolism.(15) 
 
PTEN aberrations in cancer  
 
Heterozygous germline mutations in PTEN were identified initially in 60-80% of patients 
belonging to a group of rare syndromes, including Cowden syndrome, Bannayan-Riley-
Ruvalcaba syndrome, and PTEN-related Proteus syndrome; these disorders are known 
collectively as PTEN hamartoma tumor syndrome (PHTS).(16) With respect to sporadic (i.e., 
non-hereditary) tumors, heterozygous PTEN mutations occur in 50-80% of prostate, 
glioblastoma, and endometrial cancers and 30-50% of lung, colon, and breast cancers.(17) Loss 
of both functional PTEN alleles is common among prostate and breast cancer patients, as well 
as melanoma and glioblastoma patients.(18) The majority of these aberrations are caused by 
point mutations, small insertions, or deletions, all of which can occur throughout the entire PTEN 
gene. At the transcriptional and post-transcriptional levels, PTEN inactivation can occur via 
promoter methylation and through the expression of PTEN-directed microRNAs.(19) PTEN 
activity is also regulated at the post-translational level: phosphorylation, ubiquitination, oxidation, 
and acetylation can regulate the phosphatase activity, subcellular localization, and degradation 
of PTEN.(17) Defects in any of these processes may explain the absence of functional PTEN in 
cancer patients who apparently lack genetic aberrations in PTEN.(20-22) Several ALL cases 
have been identified in which high levels of inactive PTEN are accompanied by an active PI3K-
AKT pathway.(23, 24) Although the majority of prevalent pathogenic mechanisms affect the loss 
of one or both PTEN alleles, subtle changes in PTEN protein levels can have a powerful effect 
on cancer susceptibility and/or tumor progression, as exemplified by the Pten hypomorphic 
mouse model.(25) Therefore, the level of functional PTEN affects tumor susceptibility, and PTEN 
function can be compromised at the DNA, mRNA, and/or protein levels. 
 
PTEN aberrations in T-ALL  
 
PTEN deletions and mutations were initially identified in cell lines.(26, 27) Restoring PTEN levels 
in these cell lines decreases cell size and induced apoptosis by suppressing the PI3K-AKT 
pathway.(28) Studies by others(29-34) and our group(21, 35) revealed aberrations in the PTEN-
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PI3K-AKT pathway in approximately 23% of primary samples obtained from pediatric T-ALL 
patients. With respect to T-ALL subtypes, we have shown that PTEN aberrations are strongly 
associated with TAL- or LMO- rearranged patients in children (21) and the same was observed 
in adult T-ALL cohorts.(36) The vast majority of PTEN aberrations include nonsense mutations 
in exon 7 (which truncate the C-terminal domain) and deletions that affect nearly the entire locus 
(Figure 1). Although truncated PTEN proteins that lack the lipid-binding C-terminal domain retain 
their phosphatase activity, they are highly unstable and are degraded rapidly.(37) In mice, 
truncated PTEN leads to decreased genomic stability and the development of multiple 
cancers.(38) Recently, we reported that approximately 8% of T-ALL patients have a RAG-
mediated microdeletion in the phosphatase domain that disrupts the reading frame (Figure 
1).(35) In addition, mutations have been identified in PI3K and AKT; specifically, 9% of pediatric 
T-ALL patients have a mutation in either the catalytic (PIK3CA) or regulatory (PIK3R1) subunit of 
PI3K, and 2% of patients have a mutation in AKT itself (Figure 2A).(21, 30) Many T-ALL patients 
with a heterozygous PTEN mutation also acquire a deletion(21) or microdeletion(35) in their 
remaining wild-type allele in leukemic subclones(29) that may give rise to relapse. This 
phenomenon was demonstrated functionally by Clappier et al. who used an elegant human T-
ALL xenograft transplantation model in mice and found the selection and preferential outgrowth 
of PTEN-inactivated leukemic cells.(39). In line with this, heterozygous Pten knockout mice 
develop T-cell leukemia in which the remaining wild-type allele is frequently deleted.(40-42) 
Another leukemogenic mechanism that can inactivate PTEN at the protein level is both the 
increased expression of casein kinase 2 (CK2) or the production of reactive oxygen species 
(ROS) that stabilize inactive forms of PTEN proteins and lead to impaired phosphatase 
activity.(23, 43) Together, these findings indicate the existence of ongoing pathogenic pressure 
to inactivate both PTEN alleles during disease progression, and the resulting loss of PTEN 
activity in turn activates the PI3K-AKT pathway.  
 
Clinical implications 
 
We have reported that aberrations in PTEN represent a significant, independent risk factor for 
relapse in T-ALL patients treated using either the DCOG (Dutch Childhood Oncology Group) or 
COALL (German Cooperative Study Group for Childhood ALL) protocol.(21, 35) Similar results 
were reported for other pediatric T-ALL patient cohorts treated using other protocols.(32, 33) In 
the BFM (Berlin-Frankfurt-Munster) study, the presence of NOTCH1-activating mutations in 
addition to PTEN-inactivating mutations predicts for good outcome similar to patients harboring 
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NOTCH1-activating mutations only,(32) suggesting that NOTCH1-mutations can antagonize the 
unfavorable effect of PTEN aberrations. In the French GRAALL (Group for Research in Adult 
ALL) study of adult T-ALL, patients with aberrations in RAS and/or PTEN had significantly worse 
outcome compared to patients without such mutations.(36) This was not confirmed in the MRC 
UKALL2003 trial for pediatric T-ALL; RAS and/or PTEN aberrations also did not change the 
favorable outcome of patients with NOTCH1/FBWX7 mutations.(44) Taken together, these 
findings suggest that PTEN aberrations may represent a general poor prognostic factor in T-
ALL.   
 
NOTCH1 mutations lead to activation of AKT 
 
More than 65% of T-ALL patients have aberrant activation of the NOTCH1 pathway due to 
mutations either in the NOTCH1 gene itself or in FBXW7, which encodes E3-ubiquitin ligase.(45, 
46) Thus, the NOTCH1 pathway may be an ideal target for therapeutic intervention. 
Furthermore, NOTCH1-directed therapies are clinically important, as they can also boost the 
cellular response to steroids.(47, 48)  Gamma-secretase inhibitors (GSIs), which inhibit the 
presenilin gamma-secretase complex, block the cleavage of NOTCH1 at its S3 site; this 
cleavage step is required to release the active, intracellular NOTCH1 domain (ICN1) upon ligand 
binding (Figure 2B). Several groups have applied GSI to cell lines derived from T-ALL patients 
with NOTCH1 activating mutations; although GSI treatment initially induces cell cycle arrest, the 
majority of cell lines adapt and ultimately stop responding to the treatment (i.e., develop GSI 
resistance).(45, 49) Nevertheless, GSI treatment effectively blocks gamma-secretase activity, 
resulting in reduced intracellular levels of the ICN1 domain and reduced expression of 
NOTCH1’s target genes.(29) Therefore, GSI resistance is caused by other mechanisms that 
circumvent NOTCH1 inhibition.(50, 51) Consistent with this notion, Palomero and co-workers 
found that decreased PTEN levels in cell lines are correlated with GSI resistance, and GSI-
resistant lines have increased levels of activated AKT.(29) Restoring the expression of functional 
PTEN in these GSI-resistant lines restored a GSI sensitivity response, whereas constitutively 
activated AKT or using shRNA to knockdown PTEN expression provoked GSI resistance in a 
GSI-responsive line.(29) This seminal study identified two important NOTCH1 downstream 
targets that regulate PTEN expression: HES1 and MYC. HES1 is a robust transcriptional 
repressor, whereas MYC is a weak transcriptional activator. Because the negative effect of 
HES1 prevails over the positive effect of MYC, PTEN expression is suppressed (Figure 2B).(29) 
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However, GSI resistance by leukemic cells resulted in disappointing results upon testing 
the GSI inhibitor MK-0752 in clinical trial (DFCI-04-390).(52) This trial was unsuccessful due to 
the compound’s limited efficacy in leukemic cells and severe gastrointestinal toxicity. To 
overcome these issues, next-generation NOTCH1 inhibitors with reduced off-target toxicity are 
currently in development.(53) For example, promising strategies include selectively blocking 
NOTCH1 using anti-NOTCH1 antibodies(54, 55) or chemically modified peptides that block the 
NOTCH transcriptional complex in the nucleus.(56)  
 
PTEN is not a priori linked to GSI resistance in human T-ALL 
 
Despite the initial report by Palomero and co-workers,(29) subsequent studies have not 
confirmed that loss of PTEN activity is intrinsically linked to GSI resistance.(21, 57, 58) For 
example, GSI sensitivity was similar between NOTCH1-driven T-cell leukemia cells obtained 
from wild-type mice and from PTEN knockout mice.(58) However, PTEN deficiency does 
accelerate the disease progression of NOTCH1-driven leukemia.(58) Using a different Pten 
knockout mouse model (Ptenflox/flox/Lck-Cre), Hagenbeek et al. found that PTEN-deficient 
thymocytes were just as sensitive to in vitro GSI treatment as wild-type thymocytes.(57) 
Moreover, several human T-ALL cell lines with mutant alleles of PTEN —other cell lines than 
those used by Palomero et al.—were actually sensitive to GSI.(21) In TALLMO diagnostic 
patient samples, PTEN is frequently inactivated in the absence of NOTCH-activating 
mutations.(21, 32, 36, 59) Thus, mutations in PTEN and NOTCH1/FBXW7 mutations are 
frequently independent genetic events and only co-occur in a small number of primary patient 
samples. In those patients that harbor both PTEN mutations and NOTCH1/FBXW7 mutations, 
the NOTCH1 mutations are usually weakly activating mutations. Because PTEN and NOTCH1 
mutations are mostly independent genetic events in primary T-ALL, PTEN-deficient leukemic 
cells in T-ALL patients likely do not have intrinsic GSI resistance at disease presentation. 
Perhaps one way that PTEN-deficient T-ALL can be linked to GSI resistance is upon relapse, 
when NOTCH1-dependent leukemic cells may have lost PTEN activity, possibly due to clonal 
selection following treatment. However, there is currently no evidence to support this notion. 
The question remains, is it possible that immediately following PTEN loss, NOTCH1-
dependent T-ALL becomes NOTCH1-independent and develops GSI-resistance? Recently, 
Adolfo Ferrando’s group addressed this intriguing question by generating an elegant mouse 
model of NOTCH1-induced T-ALL in which the Pten gene is deleted only in established 
tumors.(60) Unlike previous Pten knockout models,(57, 58) deletion of Pten in this new model 
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conferred strong resistance to dibenzazepine (DBZ), a potent GSI. In this model,(60) Pten loss 
activated expression of genes involved in cell metabolism, ribosomal RNA processing, and 
amino acid and nucleotide biosynthesis, genes that are normally suppressed following NOTCH1-
inhibiting GSI treatment. Moreover, GSI treatment increased leukemic cells’ dependency on 
autophagy in order to recycle essential metabolites. Pten loss also relieved the GSI-instigated 
block of glycolysis and glutaminolysis, a phenotype that was copied by expressing the 
constitutively active myrisoylated AKT. Because both the GSI DBZ and the glutaminase inhibitor 
BPTES (bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3) act in a synergistic 
fashion in inducing anti-leukemic effects, the authors proposed glutaminolysis as a major 
therapeutic target for treating NOTCH-activated T-ALL.(60) 
An unanswered question remains: why the loss of Pten in an established NOTCH1-
driven tumor causes GSI resistance,(60) while NOTCH1-driven tumors that are generated in 
Pten knockout mice remain GSI-sensitive?(57, 58) The answer may lie in the ability of cells to 
adapt to PTEN loss by dampening PI3K-Akt signaling over time to a level that is still of 
advantage to leukemic cells. Unlike progressive reduction in PI3K-Akt signaling, the loss of 
PTEN may initially drive the rapid, high activation of Akt, resulting in cell proliferation, survival, 
and GSI resistance. This hypothesis predicts two consequences of GSI or other NOTCH1-
inhibiting treatment. First, T-ALL patients who lack PTEN activity at disease onset may still 
respond to NOTCH1 inhibition. Second, NOTCH1 inhibition may trigger leukemic cells to acquire 
mutations such as PTEN deletions, which leads to activation of AKT and resistance to NOTCH1 
inhibitors. Several key observations provide support for this hypothesis of reduced PI3K-AKT 
signaling over time in the absence of PTEN. For example, we found no difference in AKT 
phosphorylation between primary T-ALL patients with aberrant PTEN and patients without such 
mutations,(21) indicating that patients with PTEN-defective leukemia may have adapted and 
reduced PI3K-AKT signaling. Reduced AKT activation may explain why primary PTEN-defective 
T-ALL cells are NOTCH1-dependent and remain GSI-sensitive.(58) Although this hypothesis has 
not been tested formally, future NOTCH-inhibiting therapies may be more effective when 
combined with inhibitors of PI3K or AKT. Consistent with this, the PI3K/mTOR dual inhibitor PI-
103 resulted in enhanced NOTCH-MYC activity in T-ALL cell lines.(61) Additionally, T-ALL 
induced by retroviral insertional mutagenesis in wild-type or RasG12D-mutant mice 
demonstrated an initial response to PI3K-inhibitor GDC-0941 treatment.(62) However, this 
treatment led to the survival and outgrowth of drug resistant clones with active PI3K-AKT 
signaling that frequently had reduced Notch1 signaling.(62) To avoid resistance when combined 
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with NOTCH1 inhibitors, the authors propose a sequential treatment using a NOTCH1 inhibitor 
at diagnosis to eliminate NOTCH1 mutant clones followed by PI3K/AKT inhibitor treatment.(62)   
 
Other mechanisms that can activate AKT and lead to GSI resistance  
 
Eighty-five percent of T-ALL patients have an activated AKT pathway accompanied by increased 
phosphorylation of AKT and its downstream targets GSK-3β and FOXO3a.(23) Notably, this 
percentage is higher than the frequency of PTEN aberrations (23% of the patients) and therefore 
has to be explained by the activation of AKT through other mechanisms. 
MYC may provide an alternative mechanism to activate AKT either directly or indirectly 
(e.g. MYC activates the expression of mir-17-92 and mir-19 that target PTEN mRNA)(63-65) 
(Figure 2C). Using an inducible MYC-dependent zebrafish T-ALL model, Gutierrez et al. found 
that established tumors regressed when MYC expression was turned off. This effect was 
circumvented by activating PI3K-AKT signaling, (66) showing that AKT activation is an important 
downstream effector of MYC that may drive GSI resistance. Moreover, the MYC gene is an 
important downstream target of NOTCH1, and T-ALL patients with activating mutations in 
NOTCH1 overexpress MYC.(67, 68) NOTCH binds a distal enhancer located far downstream of 
the MYC locus.(69, 70) This NOTCH-MYC enhancer region (N-Me) is duplicated in 
approximately 5% of T-ALL patients, acting as a “super-enhancer”.(69) In another 6% of adult 
and childhood T-ALL patients, MYC is ectopically activated due to a MYC translocation; 
importantly, these patients usually do not have NOTCH1-activating mutations.(71) MYC may 
also activate NOTCH1 via a positive feedback mechanism, as MYC suppresses the expression 
of miRNA-30, which targets the 3’ UTR of NOTCH1 (Figure 2C).(72) Accordingly, treatment of T-
ALL xenografted mice with the bromodomain protein inhibitor JQ1 results in decreased MYC 
levels and also reverses MYC-induced resistance to GSI. (73, 74) Also, in human T-ALL cell 
lines, GSI-sensitive cells can be converted to GSI-resistant by the ectopic expression of 
MYC.(68, 75) Under normal conditions, MYC is phosphorylated by the kinase GSK-3β; 
phosphorylated MYC is then subjected to ubiquitination by FBXW7 and proteasome-mediated 
degradation (Figure 2C).(76, 77) Conversely, activated AKT can stabilize MYC protein by 
phosphorylating—and thereby inactivating—GSK-3β. Also, these findings may explain the 
observation that MYC and PTEN are reciprocally expressed in T-ALL.(78)  
Apart from enhancing cellular resistance to NOTCH1 inhibitors, MYC also enhances 
leukemia-initiating cell (LIC) activity and poor outcome in various mouse models of T-ALL. 
Mutant Fbxw7-R465C mice develop aggressive leukemias that acquire Notch1 mutations.(79) In 
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these mice, Myc levels are stabilized resulting in the expansion of leukemia cells that have 
enhanced self-renewal capacity and that express a stem cell-like expression profile.(79) The 
Tal1/Lmo2 transgenic mouse model develops spontaneous T-cell tumors that also acquire 
Notch1 mutations. Because Myc is a Notch target, Notch inhibition led to reduced LIC activity in 
these mice.(80) Reducing endogenous Myc levels led to increased survival and reduced 
numbers of leukemia cells with LIC potential in both models.(79, 81) Overall, these positive 
feedback loops between NOTCH, MYC, and AKT suggest that inhibitors of MYC or PI3K/AKT 
may help prevent resistance to NOTCH1-inhibiting therapies,(82) and also eliminate LIC activity 
in T-ALL. Co-targeting the PI3K pathway and MYC remarkably enhanced the elimination of 
LICs.(83) 
Another AKT activation mechanism is via the gene that encodes the IL7 receptor 
(IL7Ra), that also represents a direct target gene of NOTCH1.(84, 85) The IL7R gene is mutated 
in nearly 10% of T-ALL patients. These mutations cause the constitutive activation of STAT5 and 
AKT,(8, 86, 87) and can provoke GSI resistance (Figure 2D). For instance, expressing the IL7Ra 
can overcome the effects of NOTCH1 inhibition on the cell cycle and survival, thereby 
contributing to resistance.(84) Similar results were obtained by overexpressing IGF1R, which 
encodes insulin-like growth factor 1 receptor and is another NOTCH1 target (Figure 2D).(88) 
Also in these cases, NOTCH-inhibiting therapies may be more effective when combined with 
AKT inhibitors. Furthermore, enhanced AKT activity may limit leukemia sensitivity to steroid 
treatment,(89, 90) one of the cornerstone drugs in the treatment of human T-ALL. AKT was 
shown to directly phosphorylate (S134) and inactivate the steroid receptor NR3C1.(89) 
Combined steroid treatment with the dual PI3K-mTOR inhibitor BEZ235 (91) or the MK2206 AKT 
inhibitor (89) sensitized AKT-activated leukemic cells to steroid treatment. 
 
Conclusion  
As a potent tumor suppressor, PTEN is considered to be the principal negative regulator of 
PI3K-AKT signaling. Inactivation of PTEN indirectly activates PI3K-AKT signaling, causing the 
uncontrolled proliferation of thymocytes, ultimately leading to T-ALL. Regardless of PTEN, AKT 
can be over-activated by a variety of signaling molecules, including PI3K, AKT, MYC, IL7R and 
IGF1R (Figure 2). Initial activation of AKT causes resistance to NOTCH1-inhibiting therapies. 
However, on the long-term, we suggest that AKT signaling may be dampened, thereby restoring 
responsiveness to NOTCH-inhibiting therapies. Overall, because AKT activation is central to a 
variety of leukemogenic mechanisms and crucial in the resistance to NOTCH1 inhibition, using 
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AKT inhibitors in current treatment protocols may be a promising strategy to treat NOTCH1-
mutated T-ALL.    
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Figure Legends   
 
Figure 1. Schematic representation of the human PTEN gene located on chromosome 10q23. 
The PTEN gene contains nine exons, and the PTEN protein contains several functional 
domains, including a phosphatase domain (dark gray) and a C2 lipid-binding domain (light gray). 
The positions of nonsense insertion and deletion mutations are indicated by closed triangles, 
and missense mutations are indicates by open triangles. Microdeletions and deletions in the 
PTEN gene are shown below the exons. The number of patients with each mutation/deletion in 
our cohort of T-ALL patient samples is indicated.(21, 35)    
 
Figure 2. Schematic overview of the upstream and downstream effectors of PTEN and 
associated molecular mechanisms that can activate AKT and lead to GSI resistance. (A) PTEN-
PI3K-AKT mutations. (B) NOTCH mutations and AKT activation. (C) MYC signaling and AKT 
activation. (D) IL7R/IGF1R signaling and AKT activation. The molecules with activating and 
inactivating mutations are indicated in dark gray and light gray, respectively. Dashed 
lines/arrows represent processes that contribute to cellular GSI sensitivity, and that are 
frequently inactivated by inactivating mutations/rearrangements in PTEN or FBXW7. Solid 
lines/arrows represent GSI resistance mechanisms. 
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Abstract  
PTEN inactivating mutations and/or deletions are an independent risk factor for relapse just like 
NOTCH-activating mutations or male gender for T-cell acute lymphoblastic leukemia (T-ALL) 
patients treated on DCOG or COALL protocols. Some monoallelic mutated or PTEN wild-type 
patients lack PTEN protein, implying that additional PTEN inactivation mechanisms exist. We 
show that PTEN is inactivated by small deletions affecting only a few exons in 8% of pediatric T-
ALL patients. These microdeletions were clonal in 3% and sub-clonal in 5% of patients. 
Conserved deletion breakpoints are flanked by cryptic RAG-recombination signal sequences 
(cRSS) and frequently have non-template derived nucleotides inserted in between breakpoints, 
implying that microdeletions are the result of illegitimate RAG recombination activity. Identified 
cRSSs drive RAG-dependent recombination in a reporter system as efficiently as bona fide 
RSSs that flank gene segments of the T-cell receptor locus. Remarkably, equivalent 
microdeletions were also detected in thymocytes of healthy individuals. Similar to other PTEN 
aberrations, microdeletions strongly associate with the TALLMO-subtype characterized by TAL1 
or LMO2 rearrangements. Primary and secondary xenotransplantation of TAL1-rearranged 
leukemia allowed development of leukemic subclones with newly acquired PTEN microdeletions. 
Ongoing RAG activity may therefore actively contribute to the acquisition of pre-leukemic hits, 
clonal diversification and disease progression.  
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Introduction  
 
T-cell acute lymphoblastic leukemia (T-ALL) represents 10-15% of pediatric acute leukemias. 
Despite major therapeutic improvements due to treatment intensification and refined risk-
adapted stratification during the past decade, ~30% of T-ALL cases relapse with very poor 
prognosis.1  
T-cell transformation is characterized by aberrant expression of oncogenic transcription 
factors combined with inactivation of tumor suppressor genes (e.g. PTEN, CDKN2A) and/or 
activation of the NOTCH1 pathway.2 The ectopic expression of oncogenes is typically caused by 
chromosomal rearrangements—the so-called type A hits—that place oncogenes under the 
control of T-cell specific promoters or enhancer elements.3,4 The analysis of translocation 
breakpoints revealed frequent involvement of illegitimate V(D)J recombination in these 
translocations by binding of recombination activating gene (RAG)-1/2 proteins to sequences that 
resemble authentic recombination signal sequences (RSS).5 These recurrent chromosomal 
rearrangements activate several oncogenes, such as TAL1, LMO2, TLX3, TLX1 or NKX2-
1/NKX2-2, which are believed to represent the clonal disease drivers.2,6  
Besides near mutually exclusive type A mutations, recurrent genetic aberrations that 
affect cell viability and/or proliferation—the so-called type B hits—are found in nearly all T-ALL 
genetic subgroups. Type B mutations include NOTCH1-activating mutations affecting NOTCH1 
and FBXW7 that are found in over 60% of pediatric T-ALL patients 7-11 (reviewed in Ferrando 
12), as well as less frequent events such as IL7R mutations in around 10% of T-ALL cases.13,14 In 
addition, mutations in the phosphatase and tensin homolog (PTEN) tumor suppressor gene have 
been associated with poor prognosis,15-18 resulting in overactive PI3K–AKT signaling that drives 
enhanced cell proliferation and cell metabolism, and impairs apoptosis.16,19,20 PTEN is 
considered to be a haploinsufficient tumor suppressor gene, because PTEN dose determines 
cancer susceptibility.21-23 The majority of PTEN aberrations in T-ALL are deletions affecting the 
entire PTEN locus or mutations that truncate the membrane binding C2-domain.15,18  
In our previous studies, we detected PTEN aberrations in 13-20% of T-ALL patients18,24 
and revealed that those mutations are especially associated with TAL or LMO rearrangements 
and nearly absent in TLX3-rearranged T-ALL.18 In general, PTEN mutated T-ALL appears to be 
devoid of NOTCH1-activating mutations.18 Interestingly, we did not observe differential AKT 
activation when comparing PTEN mutant/deleted with wild-type patient samples, indicating that 
other mechanisms may influence the PI3K-AKT pathway. In this respect, non-deletional 
posttranslational inactivation of PTEN,24 rare mutations in PIK3CA (encoding PI3K) and AKT  
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themselves16, or PI3K-AKT pathway activation downstream of activated NOTCH1 have been 
described.15 However, none of these mechanisms explain the absence of PTEN protein in some 
T-ALL patient samples that have retained at least one PTEN wild-type allele.18 
In this study, we have used multiplex ligation-dependent probe amplification (MLPA) to 
investigate copy-number variations among PTEN exons to detect potential additional PTEN 
deletions. We identified PTEN microdeletions in T-ALL patient samples and we provide evidence 
that these are driven by illegitimate RAG-mediated recombination events. 
 
Materials and Methods  
 
Patients 
A total of 146 primary pediatric T-ALL patient samples were enrolled in the Dutch Childhood 
Oncology Group (DCOG) protocols (n=72)25-27 or the German Co-Operative Study Group for 
Childhood Acute Lymphoblastic Leukemia study (COALL-97) (n=74) were included in this 
study.28 Normal thymocytes were isolated from thymic tissue obtained from children undergoing 
cardiac surgery.24,30 Informed consents were in accordance with the Institutional Review Boards 
of the ErasmusMC (Rotterdam, the Netherlands), the Ethics Committee of the City of Hamburg, 
Germany, the Hospital Sta. Cruz, Centro Hospitalar de Lisboa Ocidental (Lisboa, Portugal) and 
the Declaration of Helsinki.  
 
Computational detection of putative RAG recombination signal sequences 
The human PTEN gene (ENSG00000171862) was screened for the presence of cryptic RAG 
recombination signal sequences (cRSS) using the PERL software algorithms developed by 
Cowell et al.29 
 
Generation of GFPi-PTEN cRSS reporter constructs and recombination assay 
To measure efficiencies of predicted cRSSs in mediating recombination of GFPi-mRFP reporter 
constructs, PCR amplified PTEN cRSS1-4 or defined RSS control sequences were cloned into 
this reporter construct and recombination assays were carried out as described.30 
 
Statistics 
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Statistics was performed using IBM SPSS Statistics 21 software (IBM, Armonk, NY, USA). The 
Pearson’s Chi-square was used for nominal distributed data, the Fisher’s exact test was 
alternatively used in case the number of patients in individual groups was lower than five. The 
Mann-Whitney-U test was used for continuously distributed data. Differences in relapse-free 
survival were tested using the log-rank test. Proportional risk for relapse was done by univariate 
and multivariate Cox regression analyses. The recombination efficiencies of cRSSs were 
compared using a one-way ANOVA with the Bonferroni´s multiple comparison post-test. Data 
were considered significant when p≤0.05 (two-sided). 
 
See Supplementary Materials and Methods for further experimental details. 
 
Results  
PTEN microdeletions in T-ALL patients 
In our previous study, we identified various T-ALL primary patient samples that lack PTEN 
protein expression and seemed PTEN wild-type or that contained an inactivating mutation or 
PTEN deletion in only one allele (summarized in Table 1).18 To identify additional PTEN 
inactivating mechanisms, we performed MLPA analysis to screen for potential microdeletions 
affecting single or a few PTEN exons that had been missed by array-CGH and FISH analyses. 
We analyzed 146 T-ALL patient samples for copy-number alterations in any of all 9 coding 
exons. Heterozygous microdeletions were detected in 3 T-ALL patients (Figure 1A), 
encompassing exons 2 and 3 in 2 patients (#21, #11) and exons 4 and 5 in another patient 
(#20). Accordingly, 2 out of the 3 patients (#11, #20) demonstrated defective PTEN-splicing with 
previously unknown underlying genetic aberrancies.18 A fourth patient (#12) was identified with a 
homozygous deletion of exons 2 and 3 that was confirmed by high-resolution array-CGH 
analysis (Figure 1A,B).  
In order to clone the breakpoint regions of these microdeletions, a PCR-based strategy 
was designed for introns 1 and 3 (patients #21, #11 and #12) and intron 3 and 5 (patient #20) 
(Figure 2A,B), and resulting positive reactions were cloned and sequenced. These analyses 
predicted microdeletions of ~65Kb that encompassed exons 2-3 and of ~11Kb that 
encompassed exons 4-5 (Figure 2B). The homozygously deleted patient (#12) revealed different 
breakpoints that point to independent deletion events for each allele, with insertion of random 
bases in between breakpoints for one allele (Figure 2B). Breakpoints for the exon 2-3 
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microdeletion in patient #21 were identical to breakpoints of one allele of patient #12 and also 
lacked insertion of random bases. T-ALL patient #11 had a similar exon 2-3 deletion that shared 
the identical breakpoint in intron 3 but had an alternate breakpoint in intron 1 (Figure 2A-C). 
Breakpoints for the fourth T-ALL patient #20 with a microdeletion that affected exons 4 and 5 
were located in introns 3 and 5 (Figure 2B). All three types of microdeletions result in out-of-
frame PTEN transcripts (Figure 2C). 
As MLPA does not allow for sensitive detection of subclones with microdeletions, we 
performed PCR analysis to screen the T-ALL cohort for similar microdeletions. Seven additional 
patients were identified with deletions affecting exons 2-3 that were similar to the breakpoints as 
observed in patients #21 and #12 (Figure 2B). Based on the conservation of breakpoints, this 
microdeletion was denoted as a type I microdeletion. One additional patient was identified with 
breakpoints similar to patient #11, therefore this deletion was denoted as a type II microdeletion. 
The deletion affecting exons 4 and 5 as identified in patient #20 was accordingly denoted as a 
type III microdeletion. These deletions had not been detected before by array-CGH, FISH or 
MLPA analyses. One patient sample (#20) had already been identified by MLPA as having a 
clonal microdeletion affecting exons 4 and 5, but also contained a subclonal type I microdeletion 
in exons 2 and 3 as detected by PCR (Figure 2B and Table 1). In another case (#19), array-
CGH had revealed a heterozygous PTEN deletion of exons 3-9, but now PCR also revealed a 
subclonal type I exon 2-3 microdeletion (Table 1). Sequencing of the breakpoints in these 
additional T-ALL cases revealed that five out of the seven type I deletions and the type II 
deletion involved the insertion of unique, random nucleotide sequences, thereby excluding false 
positives due to PCR contamination. Notably, the PCR product for these patient samples as 
visualized by gel electrophoresis was much weaker than those for the 4 patient samples with 
clonal microdeletions (data not shown). This strongly indicates that these deletions must be 
present on the subclonal level and therefore only detectable by specific PCRs. Overall, we have 
identified PTEN microdeletions in 11 out of 146 T-ALL patients (8%), comprising a total of 13 
deletional events. Only 4 patients presented these mutations at the clonal level.  
 
Microdeletion breakpoints are flanked by cryptic RAG recombination signal sequences 
The conservation of breakpoints among patient samples and the inclusion of non-template 
derived nucleotides by terminal deoxynucleotidyltransferase (TdT)31 in most breakpoint regions 
pointed to a RAG-mediated deletion mechanism. We then searched for the presence of cryptic 
RAG recombination signal sequences (cRSS) that could function as putative RAG-mediated 
recombination signals, such as the RSS involved in T- or B-cell receptor gene segment 
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rearrangements.32 Analysis of sequences directly flanking the breakpoints immediately revealed 
typical CAC canonic trinucleotides (Figure 2B and Table S5), which is a hallmark of the 
heptamer sequences of RSSs. The search for nearby nonamer sequences with A-nucleotide 
enrichment revealed a putative 12-spacer cRSS in intron 3 with a 5' to 3' orientation (cRSS1). A 
23-spacer RSS was identified that directly flanks the breakpoint in intron 5 (cRSS2), and two 
others were identified flanking both breakpoints in intron 1 (cRSS3 and cRSS4; Figure 2A,B and 
Table S5). All 23-spacer cRSSs (cRSS2, cRSS3 and cRSS4) are present in a 3' to 5' orientation 
with respect to the PTEN reading frame orientation, and are therefore correctly positioned to 
allow illegitimate RAG-mediated recombinations with cRSS1 (Figure 2A,C). In this scenario, 
RAG1/2 molecules bind a pair of 12- and 23-RSSs resulting in two DNA double-strand breaks 
adjacent to each heptamer. Most microdeletion breakpoints are the consequence of heptamer-
to-heptamer sequence fusions resembling signal joints of excision circles that are generated 
during normal T- or B-cell receptor gene segment rearrangements (Figure 2D, top): Types I and 
II microdeletions result from cleaved DNA sequences 3-prime of cRSS3 or cRSS4, respectively, 
that are fused to sequences 5-prime of cRSS1. This retains both cRSSs in the genomic 
sequences that flank the deletion breakpoints as depicted in Figure 2D. The type III deletion 
resembles a typical coding joint that results from cleaved DNA sequences 5-prime of cRSS1 that 
are fused to sequences 3-prime of cRSS2 resulting in the loss of cRSSs from the genomic 
sequence (Figure 2D, bottom). T- or B-cell receptor coding joints give rise to fused gene 
segments with potential exonuclease processing of both ends and incorporation of random 
nucleotides whereby directly flanking RSSs and intervening DNA sequences are lost as excision 
circles. For the type III deletion of patient #20 (Figure 2B), this led to the fusion of sequences 5-
prime of cRSS1 to sequences of 3-prime of cRSS2 with loss of 14 nucleotides and incorporation 
of 17 GC-rich N-nucleotides. 
 
Prediction of cRSSs 
To further characterize these cRSSs and estimate their recombination potential, we calculated 
RSS Information Content (RIC) scores.29 Cryptic RSSs with RIC scores close to RIC score 
threshold levels that discriminate bona-fide functional RSSs flanking gene segments of antigen 
receptor loci from cRSSs (i.e. -38.81 for 12-spacer RSSs and -58.45 for 23-RSSs) were further 
investigated.29 This search in the PTEN locus predicted a 12-spacer cRSS1 with a strong RIC 
score of -34.23 as well as 23-spacer cRSS2 (-55.59) and cRSS3 (-59.78) with RIC scores that 
were close to the threshold levels separating RSSs from cRSSs. A 23-spacer cRSS4 was 
predicted with a RIC score of -75.59 that is barely above the mean background RIC score value 
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for 39-nucleotide non-RSS DNA sequences (-77.76). Thus, the obtained RIC scores for cRSS1, 
cRSS2 and cRSS3 strongly support PTEN microdeletions as RAG-mediated recombination 
events with similar recombination potential to that of bona-fide RSSs flanking immunoglobulin 
V(D)J gene segments.  
 
Cryptic RSS1-4 support RAG-mediated recombination 
We then tested whether the predicted cRSS1-4 could functionally mediate RAG recombinations. 
We used the GFPi-mRFP RAG reporter construct30 (Figure 3A), in which the 12-spacer cRSS1 
was cloned in combination with a consensus 23-spacer RSS. Also, the 23-spacer RSSs 
(cRRS2, cRSS3 and cRRS4) were cloned in combination with a consensus 12-spacer RSS. 
Recombination efficiency of each variant GFPi-cRSS-mRFP construct was measured by flow 
cytometry as the frequency of GFP-positive (recombination-positive) HEK293T cells within the 
population of RFP-positive (transfected) cells (Figure 3A). Indeed, all four PTEN cRSSs were 
able to mediate RAG-dependent recombination of the GFPi substrate (Figure 3B). 
Recombination efficiencies were 7.5±0.19% for cRSS1 (Figure 2B, left panel), 2.2±0.15% for 
cRSS2, 4.1±0.21% for cRSS3 and 2.1±0.16% for cRSS4 (right panel). For comparison, the 
putative 12-spacer cRSS SCL(12)30 or the 23-spacer cRSS SCL(23)33 from the human SCL 
gene  yielded 1.3±0.09% and 1.1±0.13% of GFP-positive cells, respectively. Both of these SCL 
cRSSs were used as references for the lower limit of detection in the GFPi-mRFP RAG reporter 
assay, as these do not give rise to distinct GFP-positive cell populations in the reporter assay. In 
contrast, the 12-spacer RSS that flanks the Jβ2-2 gene segment of the mouse TCRβ locus 
yielded 8.0±0.31% of GFP-positive cells. Also, the 12-spacer cRSS that is involved in recurrent 
LMO2 translocations in T-ALL5 yielded 11.4±0.30% of GFP-positive cells. These reporters 
highlight the capability of the recombination assay to measure low-efficiency RSS and cRSS 
activities. Despite the low frequencies of recombination, cRSS2-4 reporters give rise to distinct 
populations of GFP-positive cells (Figure 3B), in contrast to SCL(12) and SCL(23) cRSSs. 
Moreover, the efficiencies of recombination of PTEN cRSS1-4 differed significantly from the 
those of SCL(12) or SCL(23) cRSSs (Figure 3C). These results strongly support the involvement 
of predicted cRSS1-4 in PTEN microdeletions in illegitimate RAG-mediated recombination 
events. Additionally, the recombination potential of these cRSSs are in line with the observed 
frequencies of type I microdeletions (cRSS3-cRSS1) versus type II (cRSS4-cRSS1) and type III 
(cRSS1-cRSS2) microdeletions in T-ALL patients (Figure 2B). 
 
PTEN microdeletions in xenografted human T-ALL cells  
 57 
Subclonal microdeletions in PTEN, even in patients that already had undergone clonal 
inactivating events affecting one allele, strongly imply that acquisition of microdeletions is an 
ongoing phenomenon in T-ALL leading to clonal diversity.34 To test this, we performed primary 
and secondary xenotransplantation experiments into NSG mice (Figure 4A) using TAL1-
rearranged T-ALL blasts from patient (#24) at diagnosis that had a subclonal microdeletion 
(Figure 4B). Several months post-transplantation, mice developed overt leukemia. Primary (X1) 
and secondary (X2) xenotransplanted material was then analyzed for the presence of PTEN 
microdeletions in bone marrow, thymus, spleen and liver biopsies. Using MLPA analysis, no 
PTEN microdeletions were detected (data not shown), indicating that the subclonal PTEN 
microdeletion in the diagnostic patient material had not been clonally selected following 
xenotransplantation. Three distinct, subclonal PTEN microdeletions were detected by PCR in 
thymocyte and liver biopsies: One (X1-24 thymus-1) was identical to the microdeletion as 
originally identified in this patient (Figure 4B), whereas 2 novel microdeletions were detected 
suggesting that these had occurred upon serial retransplantation. 
 
PTEN deletions are associated with TALLMO T-ALL patients 
PTEN aberrations have been associated with a low incidence of NOTCH1-activating mutations, 
but with a high incidence of rearrangements in TAL1- and/or LMO2-related oncogenes.18 We 
now extend these findings, totaling 26 out of 146 T-ALL patients (18%) that have PTEN 
aberrations including point, missense or nonsense mutations, entire locus deletions and/or 
microdeletions at the clonal or subclonal level as summarized in Table 1. Twelve patients had 
clonally inactivated PTEN on both alleles and 10 patients on one allele. Evidence for subclonal 
PTEN aberrations was found in 11 patients, seven of whom also had clonally inactivated PTEN 
at least in one allele. The other four patients had either a subclonal missense mutation (patient 
#23) or subclonal microdeletions (3 patients) only. Still, for 8 T-ALL patients for whom protein 
data were available, absence of PTEN protein could not be solely explained by the genetic 
aberrations found, suggesting that additional PTEN inactivating mechanisms await identification. 
Overall, our previously observed association with TAL or LMO-rearranged leukemia18 became 
considerably more significant (p=0.003; Table S6). Also, the significance levels for absence of 
these mutations in TLX3-rearranged T-ALL (p=0.002; Table S6) and reduced overlap with 
NOTCH1-activating mutations were further strengthened (p=0.001, Table S6).  
 
PTEN aberrations and outcome 
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Our results do not support observations by others34 that PTEN-inactivated T-ALL subclones 
become selected during disease progression giving rise to relapse. Therefore, we regarded T-
ALL patients with subclonal PTEN aberrations as wild type patients in outcome analyses. 
PTEN/AKT aberrant T-ALL patients, including patients lacking PTEN protein expression, were 
not significantly associated with poor outcome in both treatment cohorts (5yrs RFS for 
PTEN/AKT mutant patients is 64±15% versus 70±6% for wild type patients on DCOG protocols 
and 57±15% versus 76±6% for patients on COALL protocols). This is due to the fact that 
PTEN/AKT mutations and NOTCH-activating mutations predominantly behave as mutually 
exclusive mutations. In addition, NOTCH-activating mutations have a strong trend towards poor 
outcome (5yrs RFS for NOTCH-activated patients is 62±8% versus 82±8% for wild type patients 
on DCOG protocols and 68±8% versus 80±9% for patients on COALL protocols, (p=0.06 
(stratified for protocol); and supplementary Table S7).35 However, if NOTCH-activated and 
PTEN/AKT mutated T-ALL patients are being compared to wild type patients, wild type patients 
demonstrate significantly fewer relapses (stratified p=0.04; Figure 5), albeit having more 
frequent events including toxic deaths and secondary malignancies.18 Using the Cox regression 
proportional hazard method, NOTCH-activating and PTEN/AKT mutations were investigated 
along with male gender and the presence of TLX3 rearrangements that both negatively relate 
with poor outcome (Supplementary Table S7 and Table 2). NOTCH1-activating mutations and 
PTEN/AKT mutations did not significantly predict for increased risk for relapse in univariate 
analyses, but both were identified as strong, independent risk factors along with male gender in 
multivariate analysis (Table 2). 
 
PTEN microdeletions in healthy human thymocytes  
The presence of recombination-prone cRSSs in PTEN intron sequences led us to speculate that 
microdeletions may occur in healthy thymocytes. Screening DNAs that were isolated from 
thymocytes of non-leukemic children for the presence of PTEN microdeletions by PCR revealed 
evidence for subclonal type I deletions in 3 out of 11 (27%) thymocyte biopsies. Two of those 
microdeletions had unique random nucleotide sequences inserted in between the breakpoints 
(Figure 4C), ruling out false PCR positivity due to contamination. Thus, RAG-mediated PTEN 
microdeletions are not exclusive to T-ALL, but also occur during normal T-cell development. 
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Discussion 
PTEN has been identified as a haploinsufficient tumor suppressor gene,21-23 for which gene 
mutations and/or deletions have been associated with poor outcome in T-ALL in various17,18,36,37 
but not all studies.16,38 For T-ALL patients treated on DCOG ALL-7/8/9 or COALL97/03 treatment 
protocols, we demonstrate that clonal PTEN inactivating aberrations or loss of PTEN protein is 
an independent factor that predicts for relapse just like NOTCH-activating mutations and male 
gender. About half of the T-ALL patients that retained one wild type allele do not express PTEN 
protein. This indicates that additional genetic, epigenetic or post-translational inactivating events 
are expected. We have identified recurrent inactivating PTEN microdeletions in T-ALL patients 
due to illegitimate RAG-mediated recombination events, mediated through cryptic RSSs 
(cRSSs). Taking into account all point, missense or nonsense mutations as well as deletions 
including microdeletions, 18% of T-ALL patients in our patient cohort harbor PTEN inactivating 
aberrations.  
Increasing evidence suggests that cRSSs can participate in oncogenic mechanisms, 
including chromosomal translocations in lymphoma, B-ALL39,40 and T-ALL4,41,42, such as SIL-
TAL1 gene fusions and HPRT deletions. Different chromosomal translocation mechanisms have 
been described as a consequence of erroneous rearrangements between cRSS that flank 
oncogenes with RSS-sequences of T-cell receptor gene segments. Alternatively, broken DNA 
strands near oncogenes become mistakenly fused through a non-cRSS mechanism to T-cell 
receptor gene during V(D)J-assembly (reviewed in Radich and Sala43). Other illegitimate, cRSS-
driven coding-joint recombination events may cause intrachromosomal deletions such as 
described for IKZF1,44,45 ERG1,46 BTG1,47 and CDKN2A/B48-50 in humans and Notch151,52 and 
Bcl11b53 in mice.  
PTEN microdeletions occur as a consequence of aberrant RAG-mediated recombination 
events, and breakpoints are flanked by cRSSs containing heptamer and nonamer sequences 
separated by 12 or 23 nucleotide spacers. These cRSSs facilitate recombinations in in vitro 
recombination assays54 with efficiencies that match the frequencies of different types of 
microdeletions in T-ALL patients. Approximately, one third of all signal joint-related type I and II 
microdeletions have perfect heptamer-to-heptamer fusions that lack incorporation of random 
nucleotides just like IgH or TCR excision circle signal-joints. Two third of microdeletion signal 
junctions represent atypical joints that incorporated GC-rich N-nucleotides, phenomena which is 
also observed in V(D)J-associated signal junctions in mouse lymphocytes.55 The T-cell receptor-
mediated translocation in T-ALL line SUP-T1 is a comparable atypical signal junction.56 Some of 
these microdeletion atypical signal joints (patient #12, #26 and #11) had undergone exonuclease 
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processing of signal ends (Figure 2B). Non-canonic heptamer sequence variations may 
destabilize the RAG complex, allowing alternative joining mechanisms of coding-ends and 
signal-ends.57 This may include open-and-shut joint recombinations,58,59 resulting from a single 
RAG cleavage adjacent to cRSS heptamers, exonuclease processing and insertion of random 
nucleotides before re-ligation of the DNA ends. This may explain one rare T-ALL case24 with a 
mutation that replaces 13 nucleotides including the start codon by 15 random nucleotides. This 
mutation is flanked by a 12-spacer cRSS with a strong RIC score of -45.48 that allows RAG-
mediated recombinations equal to the efficiency (2.5±0.13%) of the mouse IgH locus VH/87 RSS 
(L.M.S., unpublished data and Davila et al60). However, no other T-ALL patient in our current 
series had an equivalent mutation at this position, indicating that these events are rare.  
The identification of subclonal PTEN microdeletions—as well as entire PTEN locus 
deletions18—indicates that RAG activity may be ongoing in (at least part of) the leukemic cell 
population. This may explain clonal diversity and selection that results in disease progression 
and relapse. This latter is also supported by in-vitro recombination assays using T-ALL cell lines, 
and demonstrate that about one percent of leukemic cells or less will undergo recombinations of 
the reporter construct within a one week time-frame.30 Since intraclonal heterogeneity at 
diagnosis and clonal evolution at relapse are known to occur in ALL,46,61-64 we checked whether 
PTEN microdeletions in minor leukemic clones at presentation of disease become clonally 
selected following xenograft transplantation just like lentiviral PTEN-silenced T-ALL blasts.34 
However, we did not observe preferential selection of leukemic cells with PTEN microdeletions 
to near clonal levels following xenotransplantation. This could be explained by preferential 
outgrowth of leukemic subclones having other mutations that were advantageous for 
engraftment in mice over subclones having PTEN microdeletions. Furthermore, additional and 
new illegitimate RAG-mediated PTEN microdeletions possibly as consequence of ongoing RAG 
activity were detected that were not found in primary leukemic cells. We cannot formally rule out 
that subclonal selection of a leukemic subpopulation with a novel PTEN microdeletion occurred 
from a PCR-undetectable subclone that was already present at diagnosis. In addition, one 
patient had a subclonal missense mutation, indicating that there is an ongoing pressure on 
TALLMO-dysregulated leukemic cells to inactivate remaining wild-type PTEN alleles. RAG 
activity also results in PTEN microdeletions in developing thymocytes of healthy individuals. 
These rearrangements may facilitate a pre-malignant condition from which leukemia can 
develop. Likewise, Marlunescu et al5 described two mechanisms of illegitimate V(D)J 
chromosomal rearrangement that were found in healthy children, i.e. the Dδ2/LMO2 
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recombination in the t(11;14)(p13;q11) and the TAL2/TCRβ translocation t(7;9)(q34;q32),65 
known as driving oncogenic lesions in T-ALL.  
Overall, our discovery of PTEN microdeletions has reinforced the fact that PTEN 
aberrations are especially abundant in TAL- or LMO-rearranged leukemia but not in TLX3-
rearranged patients,18 as also observed in adult T-ALL patient series37. PTEN abnormalities 
seem to be associated with a reduced incidence of NOTCH1-activating mutations. The TALLMO 
subtype represents an immunophenotypically mature subtype of arrested leukemic cells in T-
ALL, in which ongoing RAG-activity creates an opportunistic and extended time window for 
cRSS-mediated illegitimate recombination events. These may provoke disease progression and 
relapse in leukemia patients, adding a new level of complexity that should be addressed in the 
development of future antileukemic strategies for ALL. Taking into account all currently known 
PTEN inactivation mechanisms —PTEN mutations, entire locus deletions and PTEN 
microdeletions—, some seemingly wild type T-ALL patients still lack PTEN protein expression 
indicating that other PTEN inactivation mechanisms await identification. 
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Legends of Figures   
 
Figure 1. Identification of PTEN microdeletions in T-ALL patients. (A) MLPA 
electropherograms of normal reference DNA and representative examples of T-ALL patients 
with heterozygous or homozygous PTEN microdeletions affecting exons 2-3 or a 
heterozygous deletion of exons 4-5. Fluorescence intensities of amplified PCR products for 
specific PTEN exons are shown. PCR product sizes are shown at the top. Each arrow points 
to a homo- or heterozygously deleted exon. (B) Array-CGH plot exhibiting the homozygous 
PTEN exon 2-3 microdeletion in one T-ALL patient sample. 
 
Figure 2. Breakpoints of PTEN microdeletions. (A) Schematic representation of the PTEN 
gene. Missense mutations are represented by open triangles above the exons, whereas a 
silent mutation is presented as a filled grey triangle as shown before18. Nonsense 
insertion/deletion mutations are indicated by a filled black triangle. Left or right-pointing open 
triangles in introns 1, 3 and 5 represent cRSSs. (B) Sequences of cloned intron 1-3 type I 
and type II breakpoints and the intron 3-5 type III breakpoint for T-ALL patients with PTEN 
microdeletions. Cryptic recombination signal sequences (cRSS) are indicated by a box with 
the canonic CAC trinucleotide sequences or the corresponding GTG nucleotides in 
heptamer sequences indicated in bold and underlined. Insertion of non-template, random 
nucleotides are shown in bold. (C) Examples of sequence traces of cDNA resulting from type 
I, II and IIImicrodeletions. (D) Involvement of specific cRSSs in illegitimate RAG-mediated 
recombination events resulting in types I and II microdeletions (signal joint) and aberrant 
PTEN splice variant or the type III with the aberrant exon 4-5 microdeletion PTEN transcript 
(coding joint). 
 
Figure 3. Intronic PTEN cryptic RSS mediate RAG recombination events. (A) Upper panel: 
Linear representation of the GFPi reporter construct that results in the inversion of GFP 
coding sequence during RAG-mediated recombination, and consequent GFP expression. 
The inverted GFP sequence (light green box) is flanked by a proximal 12-spacer RSS (light 
grey triangle) and a distal 23-spacer RSS (dark grey triangle) followed by the IRES-RFP as 
transfection control reporter (red box). GFP positivity is a measure for recombination 
potential. Lower panel: Control in vitro RAG recombination assay; flow cytometry analysis of 
HEK293T cells transiently transfected with either an irrelevant, mock vector (in the absence 
of RAG1/2 expression vectors; negative control) or the GFPi-reporter construct containing 
the consensus 12- and 23-RSS in the presence of RAG1/2 expression vectors.30 The flow 
cytometry plots show the expression of GFP and RFP within gated live cells defined by FSC 
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and SSC parameters (not shown) and the values represent the percentage of each cell 
population in the quadrants. The gate used to discriminate RFP-positive from RFP-negative 
cells is depicted by a red square and used for the contour plot analysis. The efficiency of 
recombination is indicated as the percentage of GFP-positive (recombination positive) cells 
within the RFP-positive (transfected) population. (B) Flow cytometry analysis of HEK293T 
cells transiently transfected with the GFPi variant constructs containing specific 12-spacer 
cRSS (LMO2, SCL/TAL1, PTEN-cRRS1 or the Jβ2.2-RSS) site combined with the 
consensus 23-spacer RSS (left panel). The GFPi variant constructs containing the 
consensus 12-RSS30 was combined with 23-spacer PTEN cRSS2, cRSS3, cRSS4 or the 
control SCL/TAL1 23-spacer cRSS version (right panel). The human LMO2 12-spacer cRSS 
and the mouse Jβ2-2 bona fide RSS were used to establish the range of recombination 
activitites for low-efficiency RSSs as measured by the GFPi reporter assay. The 12- and 23-
spacer versions of the human SCL/TAL1 cRSS were used to define the lower limit of 
detection of cRSS function in this reporter assay. Average percentage ±SD of GFP+ cells in 
the RFP+ population are derived from 4-5 independent experiments. (C) Recombination 
index was determined by normalizing the recombination efficiencies of each indicated 
reporter to that of GFPi Con12/23 and recombination efficiencies were calculated subtracting 
the GFP background of each respective unrecombined control. Values represent the 
mean±SEM of 3 independent experiments with 3 replicates per condition; * p < 0.05; ** p < 
0.01 and *** p < 0.0001. 
 
 
Figure 4. PTEN microdeletions in xenotransplants of a T-ALL primary patient sample and in 
human thymocytes from healthy individuals. (A) Schematic representation of the 
xenotransplantation strategy. Several months post-transplant of the patient’s (#24) leukemic 
cells into immunodeficient NSG mice (n=9), we collected cells from bone marrow (BM), 
thymus (Thy), spleen (Spl) and liver. Primary (X1) and secondary (X2) xenotransplanted 
material was then analyzed for the presence of any of the three different PTEN 
microdeletions. (B) Breakpoint sequences of PTEN microdeletions as detected in samples 
from primary (X1) and secondary (X2) xenotransplanted mice. Canonic CAC trinucleotide 
sequences or the corresponding GTG nucleotides in heptamer sequences are indicated in 
bold and underlined. (C) Sequences of the breakpoints for PTEN type I microdeletions as 
identified in thymocytes of healthy individuals (H-Thy1 – H-Thy3).  
 
Figure 5. T-ALL patients lacking PTEN/AKT mutations and NOTCH-activating mutations 
have a good outcome. Relapse free survival curves (RFS) for T-ALL patients treated on (A) 
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Dutch DCOG ALL7/8 or 9 protocols or (B) German COALL-97/03 protocols. Green line; 
NOTCH-activating mutations including mutations in NOTCH and FBXW7, red line; PTEN-
inactivating or AKT-activating mutations, blue line; NOTCH-activating mutations and PTEN-
inactivating or AKT-activating mutations combined, black line; wild type for NOTCH/FBXW7 
and PTEN/AKT. Tick-marks in figures refer to patients that are lost from further follow-up. 
The numbers of patients included at various time points in these studies have been shown. 
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Table 1. PTEN genetics of T-ALL patients 
Patient PTEN mutation PTEN Deletion PTEN Deletion Genomic  Aberrant  PTEN  Cytogenetic NOTCH/FBXW7  
  Allele A Allele B (FISH/Array-CGH) (MLPA) breakpoint PCR transcript protein aberration mutation 
  
Clonal inactivation of 2 alleles 
  
1 R129G T231fsX24  
- 
- - ND Mutant LMO3 - 
2 F144fsX37 R232fsX23 Subcl Del - - ND Absent LMO2 PEST 
3 P246fsX11 - Het Del Het Del exons 2-9 - ND Absent SIL-TAL1 - 
4 D235fsX9 P245fsX12 ND ND - ND Absent CALM-AF10 PEST 
5 R232fsX13 Q244fsX8 - - - ND Absent Unknown - 
6 R233fsX10 P245fsX9 - - - ND ND Unknown FBXW7 
7 R232fsX10 P243fsX18 - - - ND ND TLX1 - 
8 R232fsX10 P245fsX14 - - - ND Absent LMO2 FBXW7 
9 L180fsX2 I305fsX7 - - Intron 1-3 Del (type II; Subcl) ND Absent NKX2-5 HD 
10 C104fsX2 K236fsX5 - - - ND Absent SIL-TAL1 - 
11 P245fsX3 - ND Het Del exons 2-3 Intron 1-3 Del (type II, Clonal) in1/2-ex4  ND MYC - 
12 - - Hom Del/FISH negative Hom Del exons 2-3 2 Intron 1-3 Del variants (type I, Clonal) in1/2-ex4  Absent SIL-TAL1 - 
  
Clonal inactivation of 1 allele 
  
13 R129fsX4/P245fsX3 - Subcl Del Het Del exons 1-9 - ND ND Unknown - 
14 R232(STOP) - - - - - ND SIL-TAL1 - 
15 C249fsX10 - - - Intron 1-3 Del (type I; Subcl) - Absent Unknown - 
16 T231fsX14 - - - - - Absent NKX2-1 HD/FBXW7 
17 T276A - - - Intron 1-3 Del (type I; Subcl) - Absent Unknown - 
18 - - Het Del Het Del exons 1-9 - WT Absent Unknown PEST 
19 - - Het Del Het Del exons 3-9 Intron 1-3 Del (type I; Subcl) Altered Absent SIL-TAL1 - 
20 - - - Het Del exons 4-5 Intron 3-5 Del (type III, Clonal) / Intron 1-3 Del (type I; Subcl) ex3-ex6 splice Absent SIL-TAL1 - 
21 - - ND Het Del exons 1-3 Intron 1-3 Del (type I, Clonal) in1/2-ex4  ND SIL-TAL1 HD 
22 - - Het Del Het Del exons 2-9 - ND ND Unknown - 
  
Subclonal inactivating event only 
  
23 R232fsX (Subcl) - - - - - ND SIL-TAL1 - 
24 - - - - Intron 1-3 Del (type I; Subcl) ND ND SIL-TAL1 HD/PEST 
25 - - ND - Intron 1-3 Del (type I; Subcl) ND ND SIL-TAL1 - 
26 - - - - Intron 1-3 Del (type I; Subcl) ND ND Unknown - 
Others 
27 - - - - - - Absent TAL2 FBXW7 
28 - - - - - - Absent TAL1 HD 
PTEN frameshift mutations are indicated with the number of encoded amino acids in the alternative reading frame. PTEN deletion status was determined by 
fluorescent in situ hybridization (FISH), array-comparative genomic hybridization (array-CGH) and/or multiplex ligation-dependent probe amplification (MLPA). 
Introns harboring the genomic breakpoints of PTEN deletions and/or microdeletions have been indicated. Exons for alternative spliced PTEN transcripts are 
indicated. Abbreviations: Del, deletion; FS, frameshift; HD, NOTCH1 heterodimerization domain mutation; Het, heterozygous; Hom, homozygous; PEST, 
NOTCH1 mutation in the proline, glutamine, serine and threonine-rich C-terminal region; Subcl, subclonal.
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Table 2. NOTCH1-activating and PTEN/AKT mutations predict for poor outcome in pediatric T-ALL 
treated on DCOG ALL7/8/9 or COALL-97/03 protocols. 
  Univariate analyses using Cox regression model 
  n Hazard ratio 95% confidence interval P 
Male gender 146 3.278 1.267-8.486 0.014 
TLX3 146 2.044 1- 4.175 0.05 
NOTCH1/FBXW7 141 2.077 0.946-4.560 0.068 
§PTEN/AKT aberrations 142 1.675 0.787-3.567 0.18 
  Multivariate analyses using Cox regression model 
  n Hazard ratio 95% confidence interval P 
 Male gender 141 2.910 1.117 – 7.577 0.029 
TLX3 141 2.018 0.921 – 4.424 0.079 
NOTCH-activating 141 2.588 1.083 – 6.183 0.032 
§PTEN/AKT aberrations 141 3.407 1.254-7.400 0.014 
 
Univariate and multivariate Cox regression analyses stratified for DCOG or COALL treatment 
protocols using relapse-free survival for various parameters that were significantly associated 
with poor relapse-free survival (see supplementary table S7). §Includes T-ALL patients that do 
not express PTEN protein while lacking PTEN aberrations, but does not include patient 
samples with PTEN aberrations only on the subclonal level.   
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Abstract 
Contemporary biomedical research increasingly depends on techniques to induce or to inhibit 
expression of genes in hematopoietic stem cells (HSCs) or other primary cells to assess their 
roles on cellular processes including differentiation, apoptosis, and migration. Surprisingly little 
information is available to optimize lentiviral transduction of HSCs. We have therefore carefully 
optimized transduction of murine and human HSCs by optimizing vector design, serum-free virus 
production, and virus quantitation. We conclude that the viral RNA length, even in relatively 
small vectors, is an important factor affecting the lentiviral gene transfer on the level of both the 
virus production and the cellular transduction efficiency. Efficient transfer of large gene 
sequences into difficult-to-transduce primary cells will benefit from reducing the lentiviral 
construct size. 
 
Introduction 
Human immunodeficiency virus-based lentiviral gene transfer has been embraced in 
contemporary laboratory practice as an efficient procedure to shuttle gene-encoding RNA 
molecules into target cells, where they are reverse-transcribed and integrated into the host 
genome. Third-generation lentiviral vector systems have proven to be safe methods in gene 
therapy with very low risks of ongoing integrations in the host genome or generation of 
replication-competent viral particles.[1, 2] Lentiviruses infect both dividing and non-dividing cells, 
making them ideally suited to transduce human and murine hematopoietic stem cells (HSCs).[3-
6] Many fields of research often require lentiviral constructs that drive gene expression from a 
promoter as well as a fluorescent reporter expressed from an internal ribosomal entry site or 
secondary promoter. The virus production (tested for vectors that encode viral RNA ranging from 
4-7.5 kb in length)[7] and efficiency to transduce adherent cell lines seems dependent on the 
size of the lentiviral vector that encodes for the viral RNA. Vectors with viral RNA ranging from 5-
9 kb generally tested decent, whereas those ranging from 10-18 kb transduced very poorly.[8] 
However, the nature of the target cell (cell line or primary cells) is crucial and most of the studies 
published to date have not addressed the transduction efficiency of primary cells. Additionally, it 
is important to control the production process of lentiviral particles (in HEK293T cells), and the 
quantitation method to determine the number of competent viral particles produced. Since little 
information is available regarding these variables and their effects on lentiviral transduction, we 
carefully optimized lentiviral transfer by optimizing vector design, serum-free virus production 
and quantitation, as well as by optimizing transduction of murine and human HSCs.  
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Methods 
 
Cloning 
For fast, highly flexible and reliable cloning purposes, we have adapted the third-generation self-
inactivating lentiviral LeGO-iC2 vector[9] into a Gateway compatible destination vector (LeGO-
DEST) by replacing the ApaI/PciI 2kb insert with the Gateway ccdB cassette (Life Technologies). 
We assembled lentiviral expression constructs in which we cloned a promoter, a gene, a Thosea 
asigna virus 2A (T2A) element,[10] and the blue fluorescent protein reporter (mTagBFP). These, 
in combination with other lentiviral elements, are flanked by long terminal repeats and encode 
for the viral RNA. Upon translation, the gene and BFP moieties are efficiently separated by T2A 
cleavage in target cells (Figure 1). 
 
Cell line 
The human T-cell leukemia cell line JURKAT (DSMZ, #ACC-282) identity was confirmed by DNA 
fingerprinting and cells were regularly tested for mycoplasma contamination. 
 
Virus production, concentration and quantification 
We optimized HEK293T transfection in DMEM supplemented with 10% serum using X-
tremeGENE HP DNA Transfection Reagent (Roche, #06 366 236 001) to produce vesicular 
stomatitis virus-G pseudotyped virus particles without the addition of serum (low-serum Opti-
MEM I with Glutamax: Life Technologies, #51985-026), in batches of 40 ml (harvest twice, with 
24-hour intervals, from two confluent 14-cm dishes starting two days after transfection, see 
Supplementary Protocols). Low serum levels minimize the risk of premature differentiation of 
HSCs that are subjected to lentiviral transduction. Furthermore, fetal bovine serum can influence 
transduction,[11] and we found that increasing amounts of serum (ranging from 0% to 10%) 
negatively affects transduction rates of human HSCs, perhaps due to the aggregation of virus 
particles in the presence of serum proteins (data not shown). In relation to the quantitation of 
intact viral particles, the commonly used p24 protein ELISA method overestimates the number of 
functional viruses by the detection of incomplete, transduction-deficient viral particles as well as 
soluble p24 protein in the production medium.[12] Quantitative RT-PCR of encapsulated viral 
RNA particles is a valuable alternative. We therefore calculate the number of viral particles that 
we produce by quantification of viral RNA copies using RT-qPCR (two RNA copies per viral 
particle, see Supplementary Protocols). RT-qPCR is performed using primers flanking the cPPT 
region: 5’-AGGTGGAGAGAGAGACAGAGAC-3’ and 5’-CTCTGCTGTCCCTGTAATAAAC-3’ 
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Human CD34+ HSC transduction 
Human CD34+ HSCs were positively selected from umbilical cordblood (Miltenyi Biotec, #130-
100-453) and stimulated for 16-20 hours at a concentration of 1x106 cells/ml in X-VIVO 10 
(Lonza, #BE04-743Q) supplemented with 50 ng/ml rhSCF (R&D, #255-SC), 20 ng/ml rhTPO 
(R&D, #288-TP/CF) and 50 ng/ml rhFlt3L (Miltenyi Biotec, #130-093-855). Prior to transduction, 
add protamine sulfate (Sigma, #P4020-1G) to the cells to a final concentration of 4 µg/ml and 
pipet the concentrated virus (IVSS VIVASPIN 20 centrifugation concentration columns, Sartorius 
AG, Sigma-Aldrich, #Z614653-48EA) into a 50 µg/ml retronectin (r-Fibronectin CH-296: TaKaRa, 
#T100A)-coated 96-well plate (Falcon, #351172). Add HSCs on top of the virus to a final volume 
of 200 µl/well and mix by gently tapping the plate. Spinoculation: centrifuge the cells in the virus-
containing medium at 1800 rpm, 32ºC for 1 hour. Incubate the transduced cells at 37ºC, 5%CO2 
for 24 hours before further use. 
 
Results 
We set out to relate the length of the viral RNA to the efficiency of virus production as well as to 
the potency of these viral batches to transduce the T-cell acute lymphoblastic leukemia line 
JURKAT. Our optimized lentiviral particle production consistently leads to near equal yields for 
consecutive batches produced from the same lentiviral construct (average variation of 4.3 fold 
(range 1.3-12 fold) for repetitive viral batches from 10 different constructs). We observed an 
inverse exponential correlation between the length of the viral RNA encoded by the construct 
and the number of viral particles produced by HEK293T cells (Figure 2). RT-qPCR in 
combination with functional titration experiments on a cell line reliably determines the number of 
viral particles required to efficiently transduce target cells. We investigated transduction 
efficiencies for virus batches of three different viral RNA lengths: 4215, 5190 and 5750 bases. 
For each construct, three independent viral batches were produced. Transduction experiments 
using serial dilutions of each viral batch were performed on JURKAT cells. Four to six days after 
transduction, the percentage of BFP-positive (transduced) cells was determined (Figure 3A, 
representative curves for three independently produced virus batches of each construct). While 
the intensity of BFP signal was highest for the virus with the shortest viral RNA and lower for 
longer constructs, in each case the transduced population was easily distinguished from non-
transduced cells (inset in Figure 3A). The gene of interest encodes a protein with the C-terminal 
T2A that separates it from the BFP (Figure 3B). The percentage of transduced JURKAT cells 
remained unchanged for over three weeks of culture (not shown), reflecting stable integration of 
the viral genome in the host DNA. All independently produced batches from the same lentiviral 
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construct were virtually equally efficient to transduce JURKAT cells, indicating that the optimized 
production, quantitation and transduction procedures are very robust and reproducible. The 
transduction efficiency was highest for viruses with the shortest viral RNA sequence, and 
became progressively lower with increasing length. This is also true for all other virus batches 
produced with viral RNA lengths varying from 4 to 9 kb. In general, more viral particles with 
longer viral RNAs seem to be required to achieve equal transduction percentages in target cells 
compared to viruses with shorter viral RNAs. 
 
We then tested the efficiency of these viral batches to transduce primary human CD34+ HSCs 
and murine ‘lineage-negative’ bone marrow (Lin- BM) cells. To achieve comparable transduction 
rates for JURKAT, human HSCs and mouse Lin- BM, a thousand-fold more virus particles of the 
4215 bp vector are required for the primary cells than JURKAT (Figure 3C). This difference 
becomes even higher (up to 104) for viruses with larger viral RNAs (5190 and 5750 bases). 
Thus, the viral RNA size moderately, albeit significantly, affects the transduction rate of a cell 
line such as JURKAT, but greatly influences transduction efficiencies of freshly isolated human 
HSCs and murine Lin- BM cells. Transduced human HSCs cultured on stromal support cells 
retained an equal percentage of BFP-positive cells over the course of three weeks, indicating 
stable integration (data not shown). To investigate whether specific sequences can influence 
transduction efficiency, we generated new vectors harboring double or triple BFP sequences 
(5105 and 5995 bp, respectively; Figure 1). These vectors only differ in size from the single BFP 
construct, but contain the same sequence. Also for these viruses, the transduction efficiency in 
JURKAT was highest for the shortest vector and reduced with increased length (Figure 4). 
 
Discussion 
We conclude that while larger viral RNA size negatively affects both virus production and 
transduction of target cells, other factors can also influence the transduction efficiency (e.g. 
sequence). This is evident from the observation that the 5750 bp vector (containing the 1535 bp 
gene) revealed lower transduction efficiency than the slightly larger triple BFP vector (5995 bp). 
The transduction efficiency of human or mouse stem cells decreases tremendously for viruses 
with viral RNAs approaching 6 kb or larger. Lentiviral vectors encoding smaller viral RNA 
sequences perform better and even a reduction of merely 600 bp (5750 versus 5190 bp) already 
improves transduction efficiency by more than three-fold (Figure 3). To produce more efficient 
lentiviruses, reducing the viral RNA backbone size by removal of non-essential sequences may 
be effective. Codon optimization alters the gene sequence without affecting the protein 
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sequence and may also increase transduction efficiency. Additionally, the development of 
smaller reporter genes or complete removal of the reporter may further enhance the transduction 
efficiency. In the absence of a fluorescent reporter, integrated lentiviral constructs into the host 
genome or expression of lentiviral transgene mRNA can be quantified by qPCR[13, 14] or RT-
qPCR,[15] respectively. In conclusion, size reduction of lentiviral constructs will facilitate efficient 
transfer of large gene sequences into difficult-to-transduce primary cells, and will be most helpful 
in many fields of (basic) research.  
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Figure legends 
Figure 1. Schematic representation of the elements cloned into our Gateway compatible LeGO-
DEST vector. The different elements and their sizes (bp) that were cloned into our Gateway 
compatible LeGO-DEST vector to generate lentiviral expression vectors of different sizes 
between SIN-LTRs: 4215, 5190, and 5750 bp. SFFV: Spleen Focus Forming Virus promoter, 
T2A: Thosea asigna virus 2A element, BFP: blue fluorescent protein. Grey boxes indicate 
lentiviral elements in LeGO-DEST. 
 
Figure 2. Relationship between the viral RNA length and production of lentiviral particles. The 
quantity of lentiviral particles that are produced (calculated using RT-qPCR) plotted as a function 
of the viral RNA length (kb). Each point in the plot represents an individual virus batch, each time 
produced using the pLEGO-DEST backbone and the same transfection method and producer 
cell line (see S1 Protocol). The viral RNA length is the length of the sequence flanked by the 5’ 
and 3’ SIN-LTRs in the lentiviral expression vector (see Figure 1). 
 
Figure 3. Transduction efficiency of JURKAT, CD34+ human HSCs, and murine Lin- BM with 
lentiviral vectors of varying sizes. Transduction efficiency of different cell types as a function of 
the amount of virus particles, measured 4-6 days after transduction and expressed as the BFP+ 
percentage of the viable cells. Lentiviruses with three different viral RNA sizes (length between 
SIN-LTRs) are compared: 4215 (solid black lines), 5190 (dark-grey dashed lines), and 5750 bp 
(light-grey dashed lines). A. Triplicate transductions ±SD of JURKAT cells using serial dilutions 
of each lentivirus, representative of one of three individually produced virus batches. Inset: 
example flow cytometry plot displaying the BFP+ transduced fraction. B. Western blot probed 
with anti-2A antibody. Total lysates expressing the T2A-tagged proteins of the 4215 bp (BFP 
only, no T2A), 5190 and 5750 bp constructs, separated from BFP. *: non-specific signals. C. 
Triplicate transductions ±SD of human CD34+ HSCs (solid triangles) and murine Lin- BM (solid 
circles) with the three lentiviruses. 
 
Figure 4. Transduction efficiency of JURKAT with independently generated and different 
lentiviral vectors of varying sizes. A. Transduction efficiency of JURKAT cells as a function of the 
amount of virus particles, measured 4-6 days after transduction and expressed as the BFP+ 
percentage of the viable cells. Lentiviruses with three different viral RNA sizes (length between 
SIN-LTRs) are compared: 4215 (1xBFP; black), 5105 (2xBFP; blue), and 5995 bp (3xBFP; red). 
Triplicate transductions ±SD using serial dilutions of each lentivirus, representative of one of 
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three individually produced virus batches. B. Average transduction percentage of the different 
viruses, measured at the number of virus particles that yielded 75% in the ‘1xBFP’ (4215 bp) 
vector (indicated by dashed vertical lines in Figure 3 and 4A) 
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Abstract 
Human T-cell development is less well studied than its murine counterpart due to the lack of 
genetic tools and the difficulty of obtaining cells and tissues. Here we report the transcriptional 
landscape of 11 immature, consecutive human T-cell developmental stages. The changes in 
gene expression of cultured stem cells on OP9-DL1 match those of ex vivo isolated human 
thymocytes. These analyses led us to define evolutionary conserved gene signatures that 
represent pre- and post- αβ T-cell commitment stages. We found that loss of CD44 marks 
human T-cell commitment in early CD7+CD5+CD45dim cells, before the acquisition of CD1a 
surface expression. The CD44-CD1a- post-committed thymocytes have initiated in frame TCR 
rearrangements and have completely lost the capacity to develop into myeloid, B- and NK-cells, 
unlike uncommitted CD44+CD1a- thymocytes. Therefore, loss of CD44 represents a previously 
unrecognized stage that defines the earliest committed T-cell population in the human thymus. 
 
Introduction 
T-cell development in the thymus is a complex process that depends on sequential 
transcriptional and epigenetic changes leading to T-cell lineage commitment while suppressing 
alternative cell fates.(Rothenberg et al., 2008; Zhang et al., 2012) T-cell development has been 
extensively studied in mice, while human T-cell development is less well defined due to limited 
availability of human thymus material and inherent genetic diversity. Research has focused on 
mimicking the thymus environment using in vitro differentiation cultures starting with 
hematopoietic stem cells (HSCs) derived from human cord blood or bone marrow. Historically, 
human-mouse hybrid fetal thymic organ cultures (FTOC) have been used to functionally define 
the various stages of human T-cell development.(Plum et al., 1994) Later, OP9-DL1 co-cultures 
have been proven more useful to study T-cell differentiation.(Schmitt and Zuniga-Pflucker, 2002) 
The expression of the Delta-like 1 ligand on bone marrow-derived stromal cells from op/op M-
CSF deficient mice(Yoshida et al., 1990) induces NOTCH signaling in target cells of the 
hematopoietic lineage. NOTCH signaling promotes T-cell differentiation while inhibiting B-cell 
differentiation.(Radtke et al., 2004) The differentiation of HSCs in this co-culture recapitulates 
human in vivo T-cell development as measured by the successive acquisition of CD7, CD5, 
CD1a, and CD4+CD8 surface markers.(Awong et al., 2009; La Motte-Mohs et al., 2005) 
During development in the thymus, early T-cell precursors migrate within the cortex from 
which the positively selected CD4 and CD8 double positive (DP) thymocytes migrate to the 
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medulla. As a result, developing thymocytes encounter specific signals at specific locations in 
the thymus.(Halkias et al., 2014) The OP9-DL1 in vitro co-culture lacks the proper thymus 
architecture required for T-cell development. Hence, it supports the development of early T-cell 
development until the DP stage, with few cells reaching the CD8 single-positive (SP) stage. 
These few CD8SP cells have most likely been subject to positive selection based on MHC class 
I expression on OP9-DL1 cells.(Dervovic and Zuniga-Pflucker, 2010) Despite the presence of 
these rare SP cells it is generally believed that the absence of proper antigen-presenting cells 
and a thymus environment impair complete positive and negative selection processes in OP9-
DL1 co-cultures. 
Early T-cell progenitors (ETPs) are pre-committed, multi-potent thymocytes that retain 
the ability to develop into hematopoietic cells other than the T-cell lineage including NK-cells, B-
cells, and cells of the myeloid and erythroid lineages.(Bell and Bhandoola, 2008; Bhandoola et 
al., 2007; Weerkamp et al., 2006) Fully-committed thymocytes have lost multi-potency and have 
undergone RAG1/2-mediated T-cell receptor (TCR) alpha and beta chain rearrangements. 
Human CD4/8 double-negative (DN) thymocytes acquire CD1a at the proliferation stage when 
cells are committed to the T-cell fate.(Dik et al., 2005) The human hematopoietic stem cell 
marker CD34 is gradually lost throughout development but it is a poor marker for ‘stemness’ of 
pre-committed thymocytes as it remains expressed (albeit dimly) on most CD1a+ T-cell 
committed thymocytes.(Dik et al., 2005; Weerkamp et al., 2006; Weerkamp et al., 2005) Until 
now, upregulation of CD1a has been used to define human T-lineage commitment,(Weerkamp 
et al., 2006) but the human DN thymocyte maturation stages and the exact T-cell commitment 
point had not been clearly defined. 
In this study, we have generated gene expression profiles of sequential human T-cell 
differentiation stages, derived from umbilical cord blood stem/progenitor cells that have full multi-
lineage differentiation potential and that were cultured on OP9-DL1 stromal cells. Comparison 
between these in vitro-derived signatures and the gene signatures from normal murine and 
human early T-cell development stages in the thymus reveals strong conservation of pre- and 
post-T-cell commitment transcriptional profiles. From this analysis, we found that loss of human 
CD44 expression at the surface membrane of early DN thymocytes marks the loss of alternative 
cell fate decisions, initiation of TCRB recombination, and T-cell commitment. 
 
Results 
Consecutive stages of human in vitro T-cell differentiation represent two major gene 
signatures 
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CD34+ HSCs isolated from human umbilical cord blood were cultured on OP9-DL1 stromal cells. 
At various time points during a 27-day co-culture (performed in biological triplicate), we sorted 
seven distinct T-cell populations as progeny from pooled CD34+ HSCs from multiple cord blood 
donors (Fig. 1A). We performed microarray gene expression analysis on a total of 26 OP9-DL1-
generated T-cell populations and three CD34+ HSC starting pools. Principal component analysis 
(PCA) revealed three distinct clusters, one of which consists of the CD34+ stem/progenitor 
starting populations (Fig. S1A). After filtering for probes with high variance (top 5%) and high 
log2 expression (>8), the expression profile was trimmed to 1387 genes (2179 probesets) that 
retain the three PCA clusters (Fig. 1B, Table S1). One cluster represents the gene expression 
profile of CD34+ cells. The other two developmental clusters characterize ‘early’ T-cell progenitor 
(ETP) populations  (including the CD7+ and the day 7 and day 12 CD7+CD5+ sorted populations) 
and ‘late’ T-cell differentiation populations (including the day 18 CD7+CD5+, CD7+CD5+CD1a+, 
CD4/8 DP, and SP sorted populations). The ‘early’ and ‘late’ clusters represent a major change 
in transcriptional programs  (Fig. 1B,C). Of note, the CD7+CD5+ population (in orange) is divided 
over both clusters (Fig. 1B); those fractions that were sorted on day 7 and day 12 of the co-
culture cluster with the early CD7+ population, whereas those sorted on day 18 fall in the ‘late’ 
cluster. Therefore, this CD7+CD5+CD1a- population is not homogeneous and represents two 
distinct differentiation stages that dramatically differ in their transcriptional programs. 
The 1387 genes of our expression profile harbor 16 different gene signatures of co-
expressed genes (Fig. 1C,D, Table S1). Based on gene set enrichment analysis (GSEA) we 
identified five signatures that are differentially expressed between the early and late T-cell 
differentiation populations (Figure 1E). Signatures #7 and #8 are enriched for genes that are 
highly expressed in the early T-cell progenitor stages, and downregulated at later T-cell 
differentiation stages. Signatures #2, #15 and #16 are enriched for genes that become 
expressed at later T-cell differentiation stages. These five gene signatures—comprising 547 
genes in total—faithfully distinguish the early and late T-cell differentiation populations (Fig. 2A, 
Fig. S1B, Table S1). Early T-cell differentiation signatures #7 and #8 include transcription 
(co)factors that are important for HSC/ETP maintenance and/or lineage determination, such as 
MEIS1, LMO2, MEF2C, LYL1, and HHEX.(Goodings et al., 2015; Yui and Rothenberg, 2014; 
Zohren et al., 2012) Genes encoding transcription factors that are responsible for T-cell identity 
(including GATA3, TCF7, BCL11B) and TCR rearrangements (RAG1/2) are present in late 
signatures #2, #15 or #16. Therefore, these five signatures contain essential genes that are 
associated with transcriptional programs required for stem/progenitor identity, T-cell specification 
and lineage commitment. 
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The in vitro gene expression signatures recapitulate in vivo signatures of pre- and post- 
T-cell committed thymocytes 
We then compared our gene expression signatures to those from murine and human ex vivo 
sorted thymocyte subsets.(Dik et al., 2005; Mingueneau et al., 2013; Yui and Rothenberg, 2014) 
We performed GSEA to determine the enrichment of our five gene signatures in the dataset of 
consecutive T-cell development populations from murine thymi, generated by the Immunological 
Genome Consortium.(Mingueneau et al., 2013) As a result, we demonstrate that our “early” 
signatures #7 and #8 are significantly enriched for genes expressed in pre-committed murine 
subsets ranging from long-term HSCs to DN1-DN2a stages (Fig. 2B; false discovery rate (FDR)-
corrected p-value is q<0.001). Known pre-commitment genes such as HHEX, KIT, MEF2C, 
LYL1 are among the top-10 genes in our early signatures (Fig. 2B: left panel, Table S2). Our 
“late” T-cell development gene signatures #2, #15, and #16 are significantly enriched for genes 
expressed in post-committed murine thymocyte subsets (DN2b and later subsets) and include 
BCL11B, TCF7, LEF1, GATA3 and various molecules associated with TCR signaling (FDR 
q=0.028, Fig. 2B: right panel, Table S2). Next, we applied our in vitro gene signatures onto the 
gene expression data of human ex vivo sorted thymocyte populations.(Dik et al., 2005) 
Interestingly, similar maturation stages of in vitro and ex vivo populations group together in 
hierarchical clustering (not shown) and our gene signatures that discriminate pre- and post-
commitment also divide the ex vivo sorted human thymocytes into pre-committed (the CD1a- 
populations(Dik et al., 2005)) and post-committed populations (CD1a+ and beyond; Fig. 2C and 
Table S3).(Dik et al., 2005) These results show that the pre- and post-commitment programs of 
murine and human in vivo T-cell development are highly conserved in T-cells cultured from 
HSCs on OP9-DL1 stromal support.  
 
Loss of CD44 surface expression marks T-cell commitment in early human thymocytes  
Further examination of the genes expressed in the ex vivo CD34+CD1a- human thymocyte 
sorted populations(Dik et al., 2005) revealed that certain post-commitment genes (including 
PTCRA, RAG1, RAG2 and DNTT (known as TDT)) are already expressed, suggesting that 
thymocytes prior to their expression of CD1a have initiated TCRB rearrangement and committed 
to the αβ T-lineage  (Fig. 2C, Table S3). From our pre- and post-commitment gene signatures, 
we searched for surface antigens that are differentially expressed between pre and post 
commitment. In doing so, we observed that expression of CD44, CD33, CD34, CD63, CD69, 
and CD300LF were reduced before the CD1a+ stage (Fig. 1D). In order to investigate whether 
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loss of CD44 protein marks human T-cell commitment, we examined CD44 surface expression 
on differentiating T-cells in the OP9-DL1 system and observed that CD44 is lost from CD5+ T-
cells before they express CD1a (Fig. 3A). We sorted subsets at days 12 and 18 from two 
independent OP9-DL1 co-cultures with the inclusion of CD44 as an additional sorting marker, 
and were able to discriminate CD5+CD44+CD1a- (E1), CD5+CD44-CD1a- (E2) and CD5+CD44-
CD1a+ (F) populations (Fig. 3A). Microfluidic cards-based RT-qPCR analysis of 47 pre- or post- 
commitment genes strongly supported a pre-commitment profile in sorted populations A through 
E1, and a T-lineage commitment profile in populations E2 and F (Fig. 3B). Therefore, T-cell 
commitment of differentiating T-cells cultured on OP9-DL1 is associated with loss of CD44 
before the acquisition of CD1a surface expression. 
Next, we asked whether CD44 represents a pre-commitment marker in ex vivo human 
thymocytes. Thymi from four independent immunologically healthy donors were used to sort 
CD7+CD5+CD45dim immature thymocytes (following depletion of CD3, CD4, CD8, and CD19 
cells). Within the CD7+CD5+CD45dim cells, we sorted three populations: CD44+CD1a- (population 
I, equivalent to the OP9-DL1 co-cultured population E1), CD44-CD1a- (II, equivalent to E2), and 
CD44-CD1a+ (III, equivalent to F) (Fig. 3C). CD44 becomes highly re-expressed on mature 
thymocytes, requiring depletion of the large bulk of mature cells that constitutes approximately 
99% of all thymocytes. CD44 expression on early, pre-committed thymocytes is dim in 
comparison to CD44 expression on mature T-cells,(Marquez et al., 1995) and correlates with 
CD45 expression levels (Fig. S2A). CD45dim thymocytes predominantly consist of 
developmentally early cells including CD4/8 DN, CD4 immature single positive (ISP) and some 
CD3- DP cells, whereas CD45bright thymocytes mostly consist of CD3+ DP, CD4 SP and CD8 SP 
cells (Fig. S2A). Mature B-, myeloid, and NK-cells are present in very low numbers in the 
thymus,(Weerkamp et al., 2005) and these mature CD3/4/8 triple-negative cells are also 
CD45brightCD44bright (Fig. S2B). Therefore, immature (CD34+)CD7+CD5+ thymocytes were sorted 
from the CD45dim population, and further sorted into sub-populations I-III based on CD44 and 
CD1a expression. Hierarchical cluster analysis of the gene expression levels of the panel of 47 
pre- and post commitment genes identifies population I (CD44+) as pre-committed thymocytes, 
whereas populations II and III (CD44-) represent post-committed thymocytes (Fig. 3D). 
Therefore, loss of CD44 marks the transition to human T-cell commitment in vivo, consistent with 
our in vitro data. Of note, expression of the stem-cell marker CD34 gradually decreased in 
populations I-III but was still present on CD1a+ thymocytes (population III, Fig. 3C), in line with 
previous observations.(Dik et al., 2005; Weerkamp et al., 2006) Therefore, loss of CD34 
expression is not directly associated with T-cell commitment. 
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Loss of CD44 functionally marks human T-cell commitment 
αβ T-cell committed thymocytes have initiated or completed TCRB gene rearrangements. To 
further validate commitment in human thymocyte populations II and III, we analyzed Dβ-Jβ and 
Vβ-Jβ recombination events using GeneScan analysis(van Dongen et al., 2003). Analysis of 
sorted CD44+ uncommitted thymocytes (population I) did not reveal detectable rearrangements 
(Fig. 4A). In contrast, incomplete Dβ-Jβ and Vβ-Jβ recombination events were identified in the 
earliest population of post-committed CD44-CD1a- thymocytes (II) with a more complete 
spectrum of full recombinations present in CD44-CD1a+ thymocytes (III) (Fig. 4A). To provide 
functional evidence that loss of CD44 marks T-cell commitment, we investigated the intrinsic 
potential of alternative cell fate decisions in the three sorted human thymocyte populations I-III. 
We co-cultured thymocyte populations I (pre-committed), II and III (post-committed) on OP9-
DL1, OP9-GFP (control), and a mixture of OP9-DL1/OP9-GFP stromal cells. These cultures 
were performed in the presence of cytokines that support differentiation into various 
hematopoietic lineages. After seven days of co-culture, microscopic inspection already revealed 
the inability of committed thymocyte populations II and III to proliferate in co-cultures with OP9-
GFP stromal cells that do not support T-cell differentiation (Fig. S3). After ten days of co-culture 
under various stromal support conditions we determined the total numbers of T-, NK-, B-, and 
myeloid cells based on lineage markers CD5 and CD1a (T), CD56 and CD94 (NK), CD19 (B), 
and CD33 (myeloid) (Fig. 4B, C). The pre-committed thymocytes (population I) proliferated well 
and differentiated into cells of all four lineages on OP9-DL1 support. This pre-commitment 
population also differentiated into B-, myeloid and NK-cells—but not T-cells—when cultured on 
OP9 control cells. In contrast, committed thymocyte populations II and III gave rise to 
CD5+CD1a+ T-cells only, indicating that these populations have lost the potential for alternative 
cell fates (Fig. 4C). The fact that both populations II (CD44-CD1a+) and III (CD44-CD1a-) fully 
adopted the T-cell fate illustrates that loss of CD44—rather than the acquisition of CD1a—is the 
first surface marker that identifies post-committed human thymocytes. 
 
Discussion 
The early stages of human T-cell development have been investigated(Spits, 2002) without or 
with gene expression profiling,(Dik et al., 2005) using FTOC cultures,(Pike-Overzet et al., 2007; 
Plum et al., 1994; Res et al., 1996) and more recently co-cultures on OP9-DL1.(Van Coppernolle 
et al., 2009) During the last decade, the OP9-DL1 in vitro co-culture system has been used 
widely to study T-cell development.(de Pooter and Zuniga-Pflucker, 2007) The use of human 
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hematopoietic progenitors in this culture system offers a relatively easy and efficient tool to 
translate studies from in vivo mouse models to the human situation.(Van Coppernolle et al., 
2009) Sequential acquisition of T-cell specific surface markers recapitulates T-cell development 
from bone marrow or cord blood hematopoietic progenitors to the DP stage.(Awong et al., 2009) 
Here, we have sorted subsets at different stages during early T-cell differentiation and 
demonstrated conservation of early T-cell transcriptional profiles including pre- and post-T-cell 
commitment programs. We identified loss of CD44 expression in immature thymocytes as a 
marker for T-cell commitment that precedes acquisition of CD1a. Our results demonstrate that 
population II (CD44-CD1a-) has initiated TCR Dβ-Jβ and Vβ-Jβ rearrangements and is already 
completely T-lineage restricted. These results explain why the CD34+CD1a- thymocyte 
population from previous studies—considered to be uncommitted thymocytes—is in fact 
heterogeneous with mixed CD44 expression.(Awong et al., 2009; Dik et al., 2005) The multi-
lineage potential of CD34+CD44+ human thymocytes has been suggested,(Marquez et al., 1995) 
but this study places CD44 expression in the context of other T-cell development markers, and 
more importantly provides the first functional evidence that loss of CD44 marks human T-cell 
commitment in vivo. 
Similar to human early T-cell development, the predominant transcriptional change in 
murine T-cell development—well before the DP stage—is from pre- to post- αβ T-cell 
commitment.(Mingueneau et al., 2013; Zhang et al., 2012) In murine thymocytes, this well-
characterized transition occurs in the second CD4/8 double-negative stage (DN2; CD44+CD25+), 
before the TCR checkpoint in DN3 (CD44-CD25+).(Bhandoola et al., 2007; Godfrey et al., 1994) 
T-cell commitment is defined by the transition from DN2a to DN2b that is marked by the initial 
reduction of CD44 surface expression.(Mingueneau et al., 2013; Zhang et al., 2012) The fact 
that the initial reduction of CD44 in the transition from DN2a to DN2b thymocytes also marks T-
cell commitment in mice suggests a functional role for CD44 in pre-committed thymocytes that is 
conserved in humans. 
CD44 is an glycosylated adhesion and migration molecule with several isoforms due to 
alternatively spliced exons in the extracellular domain.(Zoller, 2015) The standard CD44 isoform 
(CD44s) is expressed on hematopoietic (stem) cells (as well as many other cell types) and is 
required for HSC niche formation and quiescence during early hematopoietic development. 
CD44 has gained clinical interest because CD44s and variant isoforms (CD44v) feature 
‘stemness’ potential of many cancer types, including leukemia. Currently, multiple anti-CD44-
based therapeutic approaches are investigated for their ability to target leukemia- or cancer-
initiating cells (LIC/CIC) with this ‘stemness’ potential.(Zoller, 2015) In addition to its expression 
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on hematopoietic stem/progenitor and ETP cells, CD44 is highly re-expressed on mature 
lymphocytes (Fig. 5) and functions in the homing to secondary lymphoid organs. In the thymus, 
CD44 and its cleavage by metalloproteinases also direct the migration of mature thymocytes 
within the medulla as well as the exit from the medulla.(Vivinus-Nebot et al., 2004) The rare 
population of uncommitted CD44+ ETPs is present in subcapsular clusters in the cortex of the 
thymus, suggesting that CD44 also directs thymocyte precursors from the bone marrow to the 
thymus, entry into the thymus, and potentially intrathymic migration during early T-cell 
development.(de la Hera et al., 1989; Horst et al., 1990)  
 By adding CD44, we have expanded the immunophenotypes of the different phases of 
early T-cell development in the human thymus (Fig. 5). CD44dimCD45dim human thymocytes 
reflect pre-committed ETP cells that are mainly characterized by the expression of transcription 
factors from alternative blood lineages, multi-lineage potential, and the absence of TCRB 
rearrangements. Loss of CD44 marks T-cell commitment that coincides with the upregulation of 
T-cell specific transcription factors (e.g. GATA3, BCL11B, TCF7), loss of alternative cell fate 
potential, and the initiation of TCRB rearrangements. Next, the thymocytes acquire CD1a and 
complete their TCRB rearrangements. Therefore, combining CD44 and CD1a surface markers in 
CD45dim thymocytes (in addition to other markers) is important in the characterization of pre- and 
post-committed human thymocytes and will help to better understand human T-cell development 
and T-cell commitment.  
 
Materials and Methods 
Human umbilical cord blood and thymus samples 
Human umbilical cord blood (UCB) samples were obtained from consenting mothers after 
delivery at local hospitals. Mononuclear cells (MNCs) were isolated by Ficoll-Paque density 
centrifugation, washed and frozen in 10% dimethyl sulfoxide (DMSO) and 90% fetal bovine 
serum (FBS) for later use. Thymi were obtained as surgical tissue discards from infants 2-9 
months of age undergoing cardiac surgery at Erasmus MC Rotterdam, after informed consent 
from the parents or legal guardians. The children did not have immunological abnormalities. 
Thymocytes were isolated by cutting the thymic lobes into small pieces and squeezing them 
through a metal mesh, and stored at -80oC until further analyses. Informed consents were in 
accordance with the Institutional Review Board of the Erasmus MC Rotterdam and in 
accordance with the Declaration of Helsinki.  
 
Isolation of CD34+ cells from umbilical cord blood   
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Frozen MNCs were thawed, washed and labeled with MicroBeads conjugated to the monoclonal 
mouse anti-human CD34 antibody according to the manufacturer’s procedure (Miltenyi Biotec). 
The magnetic separation was performed twice using two MACS Columns (Miltenyi Biotec), 
consistently reaching a CD34+ purity of approximately 95%.  
 
Antibodies 
Antibodies (with clone identification) used for flow cytometry: CD1a (HI149), CD3 (UCHT1), CD7 
(M-T701), CD10 (HI10a), CD11b (ICRF44), CD13 (WM15), CD14 (MΦP9), CD20 (L27), CD22 
(HIB22), CD33 (WM53), CD34 (8G12) (BD Biosciences), CD3 (BW264/56), CD4 (VIT4), CD5 
(UCHT2), CD8 (BW135/80), CD19 (LT19), CD33 (AC104.3E3), CD34 (AC136), CD44 (DB105), 
CD45 (5B1), CD56 (REA196), CD94 (REA113) (Miltenyi Biotec). 
 
OP9-DL1 co-cultures 
OP9-DL1 co-cultures were performed according to the original protocol.(Holmes and Zuniga-
Pflucker, 2009) Briefly, CD34+ human HSC isolated from UCB were plated into 100mm or 
145mm culture dishes (Greiner Bio-One B.V.), which were seeded with a monolayer of OP9-DL1 
cells beforehand. The α-minimal essential medium (α-MEM) (Life Technologies) used for culture 
was supplemented with 20% fetal bovine serum (FBS) (Integro B.V.) plus 10 U/mL Penicillin, 10 
µg/mL of streptomycin, and 0.025 µg/mL fungizone (PSF) (Life Technologies). Recombinant 
human stem cell factor (SCF) (10 ng/mL) (R&D systems), FLT3L (5 ng/mL) (Miltenyi Biotec), and 
interleukin-7 (IL7) (2 ng/mL) (Miltenyi Biotec) were added at the initiation of coculture and every 
2-3 days during transfer of HSC-derived cells onto new OP9-DL1 plated cells. Co-cultures were 
disaggregated by vigorous pipetting and passaged through a 40-µm filter to reduce stromal cell 
line aggregates and eliminate contaminating OP9-DL1 cells. 
Multi-lineage differentiation experiments were performed with the following modifications: 
recombinant human SCF (10 ng/ml), FLT3L (5 ng/ml), IL7 (5 ng/ml), and IL15 (10 ng/ml) were 
added every 3-4 days to half of the medium that was refreshed without disturbing the cells. A 
continuous 10-day OP9- co-culture was initiated with 1000 OP9 (-DL1, -GFP, or 1:1 mix) 
cells/well plated in 96-well plates one day before adding 4000/well of the sorted thymocytes. 
OP9-GFP and OP9-DL1 cell lines were kindly given to us by Dr. Zúñiga-Pflücker; the 
identity of the cell lines was confirmed by DNA fingerprinting and cells were regularly tested for 
mycoplasma contamination. 
 
TCRB rearrangements 
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In-frame Dβ-Jβ and Vβ-Jβ gene rearrangements were determined using the BIOMED-2 
multiplex PCR and visualized using GeneScan.(van Dongen et al., 2003) Primers for the Jβ1 
cluster were hexachloro-6-carboxy-fluorescein (HEX)-labeled (blue traces), and primers for the 
Jβ2 cluster were 6-carboxy-fluorescein (FAM)-labeled (green traces). 
 
Cell sorting and RNA preparation  
Throughout the differentiation of HSC towards the T-cell lineage, we sorted T-cell fractions at 
various time points (days 0, 7, 12, 18, and 27) based on the expression of cell surface markers 
including CD45, CD34, CD7, CD5, CD1a, CD4 and CD8. Cell sorting was performed using the 
FACSAria II (BD Biosciences), flow-cytometry was performed using the MACS Quant (Miltenyi 
Biotec), and data analysis was performed using the FlowJo software (TreeStar Inc.). Sorted 
populations were collected, washed twice in PBS, lysed in buffer RLT (Qiagen) plus 1/100 β-
mercaptoethanol and stored at -80oC. RNA was isolated using RNeasy Micro Kit according to 
the manufacturer’s protocol (Qiagen). 
 
Affymetrix gene expression arrays   
The quality control, RNA labeling, hybridization and data extraction were performed at 
ServiceXS B.V. (Leiden, the Netherlands). RNA concentration was measured using the 
Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies). The RNA quality and integrity 
was determined using Lab-on-Chip analysis on the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Inc.) and/or on the Shimadzu MultiNA RNA analysis chips (Shimadzu 
Corporation). Biotinylated cRNA was prepared using the Affymetrix 3’ IVT Express Kit 
(Affymetrix) according to the manufacturer’s specifications with an input of 100ng total RNA. The 
quality of the cRNA was assessed using the Shimadzu MultiNA in order to confirm if the average 
fragment size was according to Affymetrix’ specifications. Per sample, 7.5μg cRNA of the 
obtained biotinylated cRNA samples was fragmented and hybridized in a final concentration of 
0.0375 μg/μl on the Affymetrix HT HG U133+ PM (Affymetrix). After an automated process of 
washing and staining by the GeneTitan machine (Affymetrix) using the Affymetrix HWS Kit for 
GeneTitan (part nr. 901530), absolute values of expression were calculated from the scanned 
array using the Affymetrix Command Console v3.2 software. 
The data discussed in this publication have been deposited in NCBI's Gene Expression 
Omnibus(Edgar et al., 2002) and are accessible through GEO Series accession number 
GSE79379 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79379). 
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Taqman array microfluidic cards 
Reverse-transcriptase (RT) reactions (Promega) were performed to convert mRNA into cDNA. 
The real-time PCR (qPCR) reactions were performed by Taqman Custom arrays that were pre-
designed according to the manufacturer instructions (Applied Biosystems). TaqMan gene 
expression assay targets were based on selected primers that were pre-loaded into each of the 
wells of a 384-well Taqman array card. TaqMan Gene Expression Assays consist of a pair of 
unlabeled PCR primers and a TaqMan probe with a FAM or VIC dye label on the 5’ end and 
minor groove binder (MGB) and nonfluorescent quencher (NFQ) on the 3’ end. For the reaction, 
cDNA samples were diluted and mixed in 1:1 ratio with Taqman Fast Universal PCR Master Mix 
(Applied Biosystems). Relative levels of gene expression are determined from the fluorescence 
data generated during PCR using the 7900HT Fast Real-Time PCR System Relative 
Quantitation software (Applied Biosystems).  
 
Bioinformatics 
Affymetrix gene expression CEL files were processed using Partek® Genomics Suite® 6.6. 
Robust Multi-array Average (RMA) (Irizarry et al., 2003) was applied prior to further analysis. In 
brief, the intensity levels were quantile normalized after background correction. Probeset-level 
expression values were summarized by median polish approach and eventually log2 
transformed. Probesets were filtered for high variance (top 5%) and log2 expression values (>8), 
which resulted in 2179 probesets. Using the annotation file of the array, these probesets were 
then summarized into 1387 genes by taking the median of all probesets across a gene. Principle 
component analysis (PCA) and hierarchical clustering were done using Partek® Genomics 
Suite® 6.6. Log2 expression values were standardized into z-scores prior to the clustering 
analysis. Pearson dissimilarity and Euclidean distance were used as distance metric. Gene set 
enrichment analysis (GSEA) (Subramanian et al., 2005) was performed using GSEA software 
downloaded from Broad Institute (http://www.broadinstitute.org/gsea). For the OP9-DL1 in vitro 
dataset, the GSEA input gene list consisted of 1387 genes that were grouped into the 16 gene 
signatures identified by the clustering analysis. The T-cell populations were denoted as early or 
late T-cell program according to their gene expression profile similarities during T-cell 
differentiation. Gene sets with FDR q≤0.25 were considered significantly correlated to the class 
distinction.(Subramanian et al., 2005) The murine in vivo microarray data was obtained through 
access to the Immunological Genome Project data, GEO accession code: 
GSE15907.(Mingueneau et al., 2013) For analysis of this in vivo dataset, the GSEA input gene 
list consisted of 547 genes enclosed in the 5 signatures that form the T-cell development gene 
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expression signature. The human in vivo microarray data was obtained at 
http://www.ebi.ac.uk/miamexpress, MIAME accession no. E-MEXP-337. Hierarchical clustering 
on the human thymocyte populations was performed using only 399 out of 547 genes from the 
T-cell development gene signature as the remaining 148 genes were not profiled in the human 
dataset. 
Relative levels of gene expression data generated by the Taqman array microfluidic 
cards were processed using Partek® Genomics Suite® 6.6. The sorted in vitro populations (A-F) 
were subject to ANOVA analysis to remove day and pool effects prior to the hierarchical 
clustering. Standardized z-scores of the expression values in 47 selected T-cell development 
genes were clustered using Pearson dissimilarity measure and average linkage. These 47 
genes are a subset of the 1387 genes with high variation and expression levels in our in vitro T-
cell differentiation dataset. The same genes and clustering method were used for the human 
thymocyte populations (I-III) dataset. For this dataset, the expression values obtained by the 
microfluidic cards were subject to quantile normalization before further analysis. 
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Figure Legends 
Figure 1. Consecutive stages of human early in vitro T-cell differentiation represent two major 
gene signatures. (A) Schematic representation of the OP9-DL1 co-culture with the sorting 
strategy of consecutive T-cell differentiation stages. The table displays the sorted populations 
(and the replicates) based on surface markers (CD45, CD34, CD7, CD5, CD1a, CD4, CD8) and 
number of days in co-culture. All populations were also gated for CD45+GFP- to exclude OP9-
DL1 cells that are GFP positive. (B) Principle component analysis of 29 samples based on the 
2179 probesets with high variance (top 5%) and log2 expression values (>8). These probesets 
were summarized into 1387 genes by taking the median of all probesets across a gene. (C) 
Hierarchical clustering analysis using 1387 genes. Pearson dissimilarity measure and average 
linkage were applied to cluster the samples, and Euclidean distance and Ward’s method were 
applied to define 16 distinct gene signatures with similar expression patterns. (D) Average 
expression pattern of genes in the 16 gene signatures. z-scores are on the y-axis and 29 
populations on the x-axis, ordered according to Fig. 1C. The grey area represents 1 SD. (E) 
Gene set enrichment analysis (GSEA) on the in vitro T-cell differentiation dataset to select gene 
signatures that are significantly enriched in the early or late T-cell program (marked in green and 
bold). The Normalized Enrichment Score (NES) and False Discovery Rate (FDR) q-value for 
each gene signature are given on top of each sub-figure. Populations belonging to the early/late 
T-cell program were determined according to Fig. 1C. Gene sets with FDR q≤0.25 were 
considered significantly correlated to the class distinction.(Subramanian et al., 2005) 
 
Figure 2. The in vitro gene expression signatures recapitulate in vivo signatures of pre- and post- 
T-cell committed thymocytes. (A) Hierarchical clustering analysis (Pearson average method) of 
the different sorted populations based on the 547 genes that discriminate early (characterized by 
gene signatures #7 and #8) from late (characterized by gene signatures #15, #16 and #2) T-cell 
programs. The clustering obtained is similar to Fig.1C where 1387 genes were used. (B) Gene 
set enrichment analysis of our in vitro gene signature on the gene expression dataset of 
consecutive T-cell development populations from murine thymi. The first and second sub-figures 
from the left are the analysis results using gene signatures #7 and #8. The Normalized 
Enrichment Score (NES), Nominal (NOM) p-value, and False Discovery Rate (FDR) q-value 
indicate that these two gene signatures correlate with the pre-commitment stages. Also shown in 
the first sub-figure is the list of top 10 input genes with the highest signal-to-noise ratios in this 
dataset. The third and fourth sub-figures are the same analysis for gene signatures #2, #15, and 
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#16, which correlate with the post-commitment stages. (C) Hierarchical clustering (Euclidean 
distance and Ward’s method) on human thymocyte populations using 399 out of the 547 in vitro 
pre-/post-commitment signature genes (the remaining 148 genes were not profiled because they 
were not on the HG-U133A array used in the dataset by Dik et al., 2005). The dendrogram on 
the left shows the clustering of different sorted human thymocytes, separating the pre- and post-
committed populations. 
 
Figure 3. Loss of CD44 surface expression marks T-cell commitment in early human 
thymocytes. (A) Sorting strategy for isolating T-cell differentiation stages A-F from duplicate 
(n=2) 12- and 18-day co-cultures started with pooled CD34+ HSCs, based on surface markers 
CD45, CD34, CD7, CD5, CD1a, and CD44. (B) Hierarchical clustering (Pearson average) of 
sorted populations A-F using 47 selected T-cell development genes. Expression values were 
obtained by Taqman array microfluidic cards, followed by ANOVA to remove day and pool 
effects. (C) Sorting strategy for isolating T-cell developmental stages I-III from four independent 
donors (n=4), based on CD45, CD7, CD5, CD1a, and CD44 after pre-depletion of CD3-, CD4-, 
CD8-, and CD19-expressing thymocytes. (D) Hierarchical clustering (Pearson average) of sorted 
populations I-III using 47 selected T-cell development genes. Expression values were obtained 
by Taqman array microfluidic cards, followed by quantile normalization. 
 
Figure 4. Loss of CD44 functionally marks human T-cell commitment. (A) GeneScan 
visualization of in-frame Dβ-Jβ (left column) and Vβ-Jβ (middle and right columns) gene 
rearrangements, determined using the BIOMED-2 multiplex PCR.(van Dongen et al., 2003) One 
representative example of three independent donors is shown. Healthy peripheral blood 
mononuclear cells were used as a positive, polyclonal control (top row); populations I-III are 
indicated (rows 2-4). Primers for the Jβ1 cluster were hexachloro-6-carboxy-fluorescein (HEX)-
labeled (blue traces), and primers for the Jβ2 cluster were 6-carboxy-fluorescein (FAM)-labeled 
(green traces). Red traces: internal size markers. (B) Flow cytometry analysis of sorted human 
thymocyte populations I-III after 10 days of co-culture on OP9-DL1:GFP mixed cells. 
Differentiation into various hematopoietic lineages is defined as follows: T-lineage (blue): 
CD5+CD1a+, NK-lineage (red): CD56+CD94+, B-lineage (yellow): CD19+, myeloid lineage 
(green): CD33+. During differentiation, all populations remain CD45+ and CD7+. (C) Absolute cell 
numbers ±SD of each differentiated and proliferated hematopoietic lineage from a representative 
of three experiments, after 10 days of co-culture on a layer of OP9-DL1, a 1:1 mix, or OP9-GFP 
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(ctrl.) cells. The number of cells from populations I-III used to initiate the co-cultures on day 0 
was 4,000 cells/well, indicated by the dashed horizontal line. 
 
Figure 5. Schematic comparison of human and mouse early T-cell development in the thymus. 
Bone marrow-derived lymphoid progenitors enter the thymus (depicted as a blue oval) and 
exhibit dim CD44 expression. T-cell commitment is marked by the downregulation of CD44. As 
cells mature, they regain CD44 expression. 
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Abstract 
Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is a cancer of developing T-cells in the 
thymus. The T-ALL subtypes are characterized by specific chromosomal rearrangements driving 
the ectopic expression of oncogenes that result in arrest of leukemic cells at specific T-cell 
developmental stages. Here, we show that T-ALL subtypes are strongly associated with the 
expression of particular T-cell developmental programs. Immature/early T-cell precursor (ETP)-
ALL and TLX subtypes of T-ALL express a pre-commitment program whereas the proliferative 
and TALLMO subtypes express a post-commitment program. This suggests that T-ALL 
oncogenes require the expression of particular T-cell transcriptional programs to exert an 
oncogenic function, and therefore may hijack T-cell developmental programs by facilitating a 
developmental arrest. That is further supported by functional in vitro studies where we 
investigate the impact of typical ETP-ALL (proto-)oncogenes, including MEF2C, LYL1 or LMO2 
on early T-cell development. Umbilical cord blood stem cells transduced with lentiviral 
expression constructs that constitutively drive MEF2C, LYL1 or LMO2 were cultured on OP9-
DL1 cells for differentiation towards the T-cell lineage. Expression of MEF2C or its putative co-
factors (LYL1 or LMO2) blocks T-cell development at ETP-stages, in line with their roles in 
immature T-ALL. Contrarily, expression of the oncogenes in T-cells beyond the ETP-stages 
does not lead to T-cell development arrest, indicating that their leukemogenic potential is 
dependent on ETP-stage and expression of pre-commitment transcriptional networks. Thus, we 
conclude that the specific interaction of an aberrant oncogenic transcription factor with specific 
transcriptional network in a developing T-cell is an important requirement for oncogenesis.    
 
Introduction 
T-cell development in the thymus is a complex process that depends on sequential 
transcriptional and epigenetic events that promote T-cell lineage commitment while 
simultaneously suppressing alternative cell fates.[1, 2] During this process, inappropriate 
activation of specific oncogenic transcription factors arrest thymocytes at specific T-cell 
developmental stages.[3] The ectopic expression of these oncogenes results from specific 
chromosomal rearrangements that place T-ALL oncogenes under the control of regulatory 
elements, such as enhancers of T-cell receptor or BCL11B genes, promoters from other genes, 
or occasionally result in oncogenic fusion proteins. Based on unsupervised gene cluster analysis 
we previously identified four T-ALL subtypes with specific gene expression signatures that are 
denoted as immature, TLX, proliferative or TALLMO clusters.[4]   
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 Gene expression signature and clustering analysis of the immature T-ALL cluster highly 
overlap with the previously described high-risk early T-cell precursor (ETP)-ALL,[5] and 
represent the same disease entity.[6] The immature/ETP-ALL subtype is characterized by the 
overexpression of stem cell associated transcription factors that are normally extinguished 
during early T-cell development. These include the high expression of the MEF2C transcription 
factor,[4] and the expression of LMO2 and LYL1 [7, 8] that form a macromolecular transcriptional 
complex.[9] We have previously demonstrated that the immature/ETP-ALL subtype exhibits 
rearrangements of MEF2C and translocations involving transcription factors that target MEF2C 
(e.g. NKX2.5, SPI1) or MEF2C-associated cofactors (e.g. NCOA2),[4] and we showed that 
MEF2C regulates transcriptions factors as LYL1, LMO2 and HHEX.[4] This implies that those 
genes may be involved in MEF2C-deregulated T-ALL. The ectopic expression of LMO2 and 
HHEX are associated with a hematopoietic stem cell (HSC)-specific transcriptional program that 
is responsible for an arrest and self-renewal of preleukemic thymocytes, which impedes the new 
entry of seeding T-cell precursors in the thymus.[10, 11] Recently, this disruption in the turnover 
of cells in thymus was described to promote T-ALL.[12] However, these transcription factors are 
expressed in normal T-cell precursors that continuously seed the thymus, demonstrating that 
their expression is not exclusive for T-ALL.[13, 14] Normally, these transcription factors can 
exert roles in proliferation, survival and self-renewal of hematopoietic cells, and their expression 
is retained at the early phases of T-cell development until T-cell lineage commitment. [13] (R.D. 
Mendes and K. Cante-Barrett et al. unpublished data)  
 In our previous study, we used the OP9-DL1 in vitro culture system[15] to investigate the 
transcriptional landscape of differentiating human T-cells from umbilical cord-blood isolated 
HSCs. (Chapter 5, R.D. Mendes and K. Cante-Barrett et al. unpublished data) The changes in 
gene expression of five subsequent development stages revealed important early and late T-cell 
programs that are conserved in mouse and human T-cell development in vivo, and represent 
pre-commitment and post-commitment programs, respectively. Importantly, we found that loss of 
CD44 functionally defines human T-cell lineage commitment in ETP cells, before the acquisition 
of CD1a surface expression. 
In the present study, we have investigated the effect of ectopic expression of MEF2C, 
LYL1 or LMO2 transcription factors in T-cell development to better understand how aberrant 
expression of these (proto-)oncogenes can contribute to differentiation arrest during early T-cell 
development. Thus, we ectopically expressed MEF2C, LYL1 or LMO2 in HSCs and then 
cultured these cells in the OP9-DL1 in vitro system. These proteins each result in the 
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developmental arrest within the ETP-stage and may therefore play an important role in the 
pathogenesis of ETP-ALL. 
 
Materials and methods 
 
Patients and gene expression profiles   
A total of 117 primary pediatric T-ALL patient samples enrolled in the Dutch Childhood Oncology 
Group (DCOG) protocols or the German Cooperative Study Group for Childhood Acute 
Lymphoblastic Leukemia study (COALL) were included in this study.  Informed consents were in 
accordance with the institutional review boards of the Erasmus MC, Rotterdam, and the 
Declaration of Helsinki. The microarray datasets are available at 
http://www.ncbi.nlm.nih.gov/geo/ under accession number GSE26713. 
 
Lentiviral expression vectors  
The third-generation self-inactivating lentiviral LeGO-iC2 vector[16] was adapted into a Gateway 
compatible destination vector (LeGO-DEST) by replacing the ApaI/PciI 2kb insert with the 
Gateway ccdB cassette (Life Technologies, Bleiswijk, the Netherlands). The lentiviral expression 
constructs were assembled by cloning the Spleen Focus Forming Virus (SFFV) promoter, the 
MEF2C, LYL1 or LMO2 oncogenes flanked by a Thosea asigna virus 2A (T2A) element [17] and 
the blue fluorescent protein reporter (mTagBFP). These components in combination with other 
lentiviral elements are flanked by long terminal repeats, encoding for the proviral RNA. The 3 
lentiviral expression constructs encoding the oncogenes LMO2, LYL1 or MEF2C exhibit proviral 
RNA lengths of 4830 bp, 5190 bp and 5750 bp, respectively. The control vector is solely 
composed of the SFFV promoter followed by the BFP reporter and contains 4215 bp.   
 
Virus Production  
Virus productions were performed according to the protocol described in Chapter 4. Briefly, the 
different virus batches were produced in serum-free Opti-MEM I with Glutamax (Life 
Technologies) and were concentrated using VIVASPIN 20 centrifugation concentration columns 
(Sartorius, Goettingen, Germany). The number of viral particles was measured by quantification 
of proviral RNA copies using RT-qPCR. 
 
Western-blot 
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Lentiviral vectors were functionally tested by western-blot (WB), using transduced Jurkat and 
Loucy T-ALL cell lines. Transduced cells were propagated and monitored for the expression of 
BFP protein. Cells were lysed in RIPA buffer and 40 µg of total protein was loaded in lanes of 
Any kD Mini-PROTEAN TGX Precast Protein Gels (Biorad, Veenendaal, the Netherlands). The 
primary antibodies (abs) with reactivity against the human proteins were used according to the 
manufacturer’s protocol; and include the anti-2A Peptide (ABS31) polyclonal Rabbit Ab (Millipore 
BV, Amsterdam-Zuidoost, the Netherlands), the anti-LMO2 polyclonal Goat Ab (R&D systems), 
the anti-LYL1 polyclonal Rabbit Ab (Thermo Fisher Scientific, Waltham, MA, USA), and the anti-
MEF2C (D80C1) XP monoclonal Rabbit Ab (Cell Signaling, Danvers, MA, USA). Incubations 
with the primary antibodies were followed by incubations with secondary IRDye 680RD goat 
anti-rabbit or 680LT donkey anti-goat antibodies (LI-COR Biosciences, Lincoln, NE, USA), and 
detected with the Odyssey imaging system (LI-COR). 
 
Human umbilical cord blood  
Human umbilical cord blood (UCB) samples were obtained by syringe extraction and collected in 
a blood-pack unit containing citrate phosphate dextrose anticoagulant from mothers after 
delivery in local hospitals. Mononuclear cells (MNCs) were isolated by Ficoll-Paque density 
centrifugation, washed and frozen in 10% dimethyl sulfoxide (DMSO) and 90% fetal bovine 
serum (FBS) for later use. Informed consents were in accordance with the Institutional Review 
Boards of the Erasmus MC (Rotterdam, the Netherlands) and the Declaration of Helsinki.  
 
Isolation of CD34+cells from umbilical cord blood   
Frozen MNCs from UCB samples were thawed, washed and labeled with MicroBeads 
conjugated to the monoclonal mouse anti-human CD34 antibody according to the 
manufacturer’s protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). Magnetic separation 
was performed twice using two MACS Columns (Miltenyi Biotec), consistently reaching a CD34+ 
purity of approximately 95%.  CD34+ HSCs were resuspended to concentration of 0.5x106 
cell/ml in pre-stimulation medium consisting of serum-free X-VIVO 10 medium (Lonza, Verviers, 
Belgium) supplemented with 50 ng/ml rhSCF (R&D systems, Abingdon, UK), 20 ng/ml rhTPO 
(R&D systems) and 50 ng/ml rhFlt3L (Miltenyi Biotec). Cells were incubated for 16-20 hours at 
37ºC and 5% CO2.  
 
Transduction of Human CD34+ cells 
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Cells were transduced immediately after 16-20 hours of pre-stimulation. Transduction of cells 
was performed according to the protocol described in Chapter 4. Briefly, 96-well nontreated 
surface plates (BD Biosciences, Breda, The Netherlands) were coated with retronectin (Takara, 
Saint-Germain-en-Laye, France), and 1.0x105 cells were mixed with 109 -1010 virus particles in a 
final volume of 200 µl/well, followed by spinoculation. Transduced cells were incubated for 24 
hours at 37ºC, 5%CO2.  
 
OP9-DL1 co-cultures 
OP9-DL1 co-cultures were performed according to the original protocol.[18] Briefly, transduced 
HSC were plated into 6-well cell culture plates (Greiner Bio-One B.V., Alphen aan den Rijn, 
Netherlands), which were seeded the day before with 7x104 OP9-DL1 cells to reach 70-80% 
confluence. The α-minimal essential medium (α-MEM) (Life Technologies) used for culture was 
supplemented with 20% fetal bovine serum (FBS) (Integro b.v., Dieren, the Netherlands) plus 10 
U/mL Penicillin, 10 µg/mL of streptomycin, and 0.025 µg/mL fungizone (PSF) (Life technologies). 
Recombinant human stem cell factor (SCF) (10 ng/mL) (R&D systems, Abingdon, UK), FLT3L (5 
ng/mL) (Miltenyi Biotec), and interleukin-7 (IL7) (2 ng/mL) (Miltenyi Biotec) were added at the 
initiation of coculture and every 2-3 days during transfer of HSC-derived cells onto fresh plates 
that had been seeded with OP9-DL1 cells beforehand. Cocultures were disaggregated by 
vigorous pipetting and passaged through a 40-µm filter to reduce stromal cell line aggregates. 
 
Flow-cytometry 
T-cell differentiation was followed-up by flow-cytometry using the MACS Quant (Miltenyi Biotec). 
The different stages of differentiation were based on the expression of cell surface markers 
including the following antibodies (with clone identification): CD1a (HI149), CD7 (M-T701), CD13 
(WM15), CD33 (WM53), CD34 (8G12) (BD Biosciences), CD4 (VIT4), CD5 (UCHT2), CD8 
(BW135/80), CD19 (LT19), CD33 (AC104.3E3), CD34 (AC136), CD44 (DB105), CD45 (5B1) 
(Miltenyi Biotec). The data analysis was performed using the FlowJo software (TreeStar Inc., 
Ashland, OR).  
 
Results 
T-ALL subtypes are associated with pre-/post- commitment developmental programs  
In our previous study, we performed gene expression arrays of consecutive T-cell 
developmental stages from early thymus progenitors (ETP) to CD4+CD8+ double-positive (DP) 
T-cells (Supplemental Figure S1a). Using bioinformatics tools we obtained a gene signature of 
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547 genes, which is composed of differentially expressed genes across T-cell differentiation 
(Supplemental Figure S1b). Importantly, the changes in gene expression of the subsequent 
stages matched those of human and murine in vivo thymocyte subsets, and consequently two 
distinct T-cell differentiation programs named “early” and “late” were correlated with in vivo pre- 
and post- αβ T-cell commitment profiles, respectively (Supplemental Figure S1b).  
Following that work, here we examine whether this gene signature can distinguish T-ALL 
patient subtypes, since different T-ALL subtypes exhibit a specific developmental arrest that is 
driven by the ectopic expression of specific oncogenic rearrangements. Thus, the gene 
signature of 547 genes was applied to the gene expression data obtained from 117 pediatric T-
ALL samples. Interestingly, the PCA mapping showed clustering of the 117 samples into four 
main clusters that closely resembled the four clusters as previously obtained by unsupervised 
cluster analysis,[4] i.e. the immature/ETP-ALL, TLX, proliferative and TALLMO clusters (Figure 
1a). In addition, analysing T-ALL samples together with the T-cell sorted fractions obtained using 
the OP9-DL1 in vitro system, revealed that UCB-CD34+ stem cells co-cluster with 
immature/ETP-ALL samples. Furthermore, immature/ETP-ALL and TLX cases, which frequently 
exhibit an immature or γδ-lineage associated phenotype,[8] both express a pre-commitment 
gene signature as they co-cluster with “early”/pre-commitment T-cell stages. Proliferative and 
TALLMO cases express a post-committed gene signature and co-cluster with “late”/post-
commitment T-cell stages (Figure 1b). Yet, a few samples are apparently misclustered (arrows), 
fact that can be possibly explained by the translocation partners observed on their 
rearrangements. For instance, translocations or fusions with Bcl11b, which is a haplo-insufficient 
tumor suppressor, could impair TALLMO rearranged leukemic cells to pass beyond the T-cell 
commitment point, whereas TLX3 translocations with TCR-β or TCR-δ loci among normal, 
unrearranged Bcl11b loci may allow cells to pass T-cell commitment and αβ-lineage 
development. (work in progress)  
 Instead of the 547 genes signature, which is purely based on differentially expressed 
genes during normal T-cell development, PCA mapping was also performed using the 435 
probeset (398 genes) gene signature (Figure 1c), which previously separated T-ALL patient 
samples into the 4 T-ALL clusters by using an unsupervised approach.[4] As expected, the 
samples could be separated into the 4 T-ALL clusters (immature/ETP-ALL,TLX, proliferative and 
the TALLMO), showing a close overlap with the clustering that distinguished pre- and post-
commitment T-cell programs (Figure 1a). This suggests that the 398-gene signature could 
already contain differentially expressed T-cell developmental genes among the T-ALL clusters. 
We then examined the coinciding genes between the 547 T-cell development gene signature 
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and the 398 gene set (435 probes) from our previous unsupervised T-ALL cluster analysis, and 
identified 107 overlapping genes that are differentially expressed during T-cell development as 
well as among the 4 clusters of T-ALL. Hierarchical clustering of the T-ALL samples based on 
these 107 genes revealed four main gene groups (I-IV) that are closely related to the four T-ALL 
clusters (Figure 1d and Supplemental Table S1). For instance, immature/ETP-ALL is associated 
with high expression of genes known to be expressed during the ETP-stage, such as LMO2 and 
HHEX (Group I); the TLX cluster that comprises HOXA-activated and TLX3-rearranged T-ALL 
cases expresses NOTCH3, a relevant gene for gamma-delta T cell differentiation (Group II)[19]; 
the proliferative cluster exhibits genes as DNTT (also known as TDT) that may reflect the 
initiation of T-cell receptor recombination events, and CD1A, which is a hallmark of this cluster 
(Group III), and finally the TALLMO group contained genes of more mature T-cells such as LEF1 
and CD8 (Group IV). Thus, the gene signature of 435 probesets that we established to cluster 
different T-ALL samples is highly enriched with genes from the T-cell developmental signature 
(Supplemental Figure S1c), indicating that T-ALL oncogenes cooperate with T-cell 
developmental programs for leukemogenesis. This may imply that oncogenes can only exert 
their leukemogenic potential and promote differentiation arrest when ectopically expressed 
during specific T-cell developmental programs (Figure 1e).  
 
Validation of lentiviral vectors expressing MEF2C, LYL1, or LMO2 in Jurkat cells. 
We further studied this in OP9-DL1 co-cultures analyzing the effect of various genes that are 
highly expressed in immature/ETP-ALL patients (LYL, LMO2 and MEF2C) on normal T-cell 
development. For this, we designed and produced lentiviral vectors that allow the 
overexpression of MEF2C, LYL1 or LMO2 in differentiating HSCs in vitro (Figure 2a). Following 
virus production and titration of the lentiviral oncogene vectors or BFP-control vector we checked 
expression of oncogenes upon transduction of T-ALL cell lines, Jurkat (Figure 2b) and Loucy 
cells (Supplemental Figure S2). The oncogenes and BFP moieties are efficiently expressed in 
target cells and therefore transduction efficiencies can be measured by the percentage of BFP-
positive cells (Figure 2b, upper panel). The percentage of transduced Jurkat cells (BFP-positive) 
remained unchanged (>95%) for over three weeks of culture, reflecting stable integration of the 
viral genome in the host DNA (data not shown). The only exception occurred to cells transduced 
with the MEF2C lentiviral vector as the percentage of BFP-positive cells gradually decreased, 
possibly reflecting toxic effects of MEF2C overexpression. To confirm the ectopic expression of 
the oncogenes on transduced cells, MEF2C, LYL1 and LMO2 were identified by western-blot 
analysis using T2A or specific antibodies (Figure 2b and Supplemental Figure S2). 
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Constitutive Expression of MEF2C, LYL1, or LMO2 impairs T-cell development 
To study the effect of MEF2C, LYL1 or LMO2 on normal T-cell development, we transduced 
umbilical cord blood-derived HSCs with each lentiviral construct, in at least 3 independent 
experiments. All lentiviral batches transduced UCB-HSCs with 40-60% transduction efficiencies, 
as measured by the percentage of BFP-positive cells (data not shown). The MEF2C construct 
provided low transduction efficiency that barely exceeded 10% transduction rates. The effect of 
constitutive expression of each of these genes in differentiating HSCs was analyzed upon 
culture of transduced HSCs on the OP9-DL1 in vitro system (Figure 3a).  
 The dynamics of the co-cultures was evaluated by detection of CD34 and CD7 
expression (Figure 3b and Figure 3c). HSCs are CD34+CD7-, CD34-CD7- are non T-cell 
populations (including myeloid-, B- and NK-cells), and CD34+CD7+ and CD34-CD7+ cells 
represent T-cell populations (Figure 3b). The BFP reporter allows for flow-cytometry gating and 
analysis of transduced HSCs (Figure 3c, two right graphs with blue dots), whereas BFP-negative 
cells from non-transduced HSCs can be monitored as a control in the same culture (two left 
graphs with pink dots). BFP-negative cells from the transduction experiments with each 
expression construct and the BFP-positive cells transduced with the BFP control vector normally 
differentiate into the T-cell lineage (top graphs). However, expression of each of the three ETP 
genes LMO2, LYL1 or MEF2C results in a reduced number of T-cells. This was not due to a 
defective T-cell development caused by a culture defect, as untransduced HSCs (BFP-) in the 
same experiment efficiently generated T-cells.  
 MEF2C not only blocked T-cell development, but also blocked differentiation of HSCs 
into alternative B-, myeloid or NK- lineages. (Figure 3c) Also, expression of LYL1 or LMO2 
reduced the T-cell differentiation potential of HSCs, while the potential to develop into alternative 
cell fates remains unchanged. As a consequence, the number of untransduced (BFP-) T-cells 
and other cell lineages is higher compared to the BFP control due to the extra availability of 
space and cytokines in the absence of surviving transduced cells.  
 Notably, ectopic expression of MEF2C, LYL1 or LMO2 in HSCs arrested developing cells 
at early T-cell development (Figure 3d). The expression of MEF2C leads to an immediate block 
in T-cell differentiation and cells fail to acquire CD7 as the first T-cell marker (Day 5). Instead, 
with increased passage cells gradually lose CD34 expression and eventually disappear from the 
co-culture due to apoptosis. Overexpression of LYL1 or LMO2 allows the cells to acquire CD7, 
although fewer BFP+, CD7+ cells are obtained compared to the control (Day 9 and 12, 
respectively), and there is also a lower percentage of CD7+ cells losing CD34 as a parameter of 
122 
 
 
 
 
T-cell maturation. Thus, constitutive expression of MEF2C, LYL1, or LMO2 impairs early T-cell 
development in vitro, comparable to what is seen in ETP-ALL patients.   
  
Constitutive expression of MEF2C, LYL1, or LMO2 is dependent on ETP-transcriptional 
programs to promote differentiation block before T-cell commitment     
To distinguish and characterize the differentiation arrest caused by each oncogene, we 
measured five immunophenotype markers (CD34, CD44, CD7, CD5, CD1a) that can 
discriminate consecutive T-cell developmental stages (A-F), from HSC till the CD1+ stage 
(Figure 4a). Those populations together with the non T-cell (M) population represent >85% of 
the total of cells detected in each well by flow-cytometry, while <15% of cells remain un-
characterized as these fall outside the defined flow-cytometry gates. The T-cell lineage 
commitment occurs in the CD7+CD5+ stage when cells lose the expression of the CD44 surface 
marker (Chapter 5). Figure 4b shows the total number of BFP-positive cells per fraction, 
representing the emergence of consecutive T-cell developmental stages over different days of 
co-culture. Cells transduced with the BFP control vector at day 2 of co-culture remain mostly as 
hematopoietic progenitors (CD34+CD44+CD7-), while at days 5 and 8 a substantial number of 
early T-cells are observed based on the expression of CD7 and CD5 (fractions B and C, 
respectively). Besides the presence of early T-cell populations, day 12 is characterized by 
further differentiated T-cell subsets that have lost CD34 expression (D-E2), including cells that 
have undergone T-cell commitment (E2) as characterized by loss of CD44. Populations 
expressing CD1a appear at day 18 of co-culture. Importantly, the dynamics of the populations 
(A-F) during the co-culture is identical between HSCs that are transduced with the BFP control 
vector (BFP-positive) in comparison to cells that have not been transduced (BFP-negative) 
(Supplemental Figure S3a).  
 The expression of MEF2C leads to an immediate differentiation block of the transduced 
(BFP+) HSCs, as practically there are no cells that have differentiated in either the T-cell or non-
T-cell lineages (Figure 4b). The expression of LYL1 facilitates a partial differentiation block at the 
most immature CD7+ ETP stage that impairs further differentiation into CD7+CD5+ cells (fraction 
C). Ectopic expression of LMO2 facilitates T-cell development up till the CD7+CD5+ ETP-stage, 
where cells are partially blocked. Few cells may escape this block and further lose CD34 and 
CD44, and acquire CD1a (D-F). Overall, each of these oncogenes facilitate a T-cell 
developmental arrest of differentiating T-cells before the T-cell commitment checkpoint, 
consistent with the early T-cell development block of leukemic ETP-ALL cells (Figure 4c). This 
indicates that the oncogenes may only exert their ability to block differentiation in the context of 
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appropriate T-cell development. In order to prove this point, we investigated whether MEF2C, 
LYL1, or LMO2 might block T-cell differentiation in further differentiated T-cells. We therefore 
transduced early CD7+ T-cells, and studied their differentiation potential on OP9-DL1 stromal 
cells. Remarkably, when CD7+-sorted cells were transduced (day 6 of co-culture) with the 
MEF2C or LYL1 lentiviral vector, those cells were able to differentiate normally into the various 
T-cell stages (Supplemental Figure S3b). This indicates that the differentiation block caused by 
overexpression of MEF2C or LYL1 is dependent on the presence of a very premature T-cell 
developmental program, before the expression of CD7. In contrast, sorted CD7+ cells transduced 
with LMO2 lentiviral vector still exhibited a partial block at the CD7+CD5+ ETP-stage 
(Supplemental Figure S3b). Overall, constitutive expression of MEF2C, LYL1 or LMO2 in vitro 
results in a premature differentiation arrest of developing T-cells, but at different ETP-stages. 
Further, we also demonstrate that MEF2C, LYL1 or LMO2 are dependent on those early T-cell 
developmental programs to exert their leukemogenic effect. 
 
Discussion 
In this study we reveal that T-cell development gene signatures provide a similar rearrangement-
associated clustering of T-ALL subtypes as previously obtained by unsupervised cluster 
analysis. We further demonstrate that T-ALL oncogenes are only able to exert an oncogenic 
function in the context of expression of particular T-cell transcriptional programs. In addition, the 
observation that the previously described T-ALL signature was highly enriched for important T-
cell development regulators indicated that the T-ALL oncogenes highly cooperate with T-cell 
developmental programs for leukemogenesis. This was further supported by the OP9-DL1 in 
vitro studies, where MEF2C, LYL1 or LMO2 were dependent on the transcriptional networks 
from the initial stages of T-cell development to induce a differentiation arrest characteristic of 
ETP-ALL. In addition, we showed that the TLX subtype that is mostly associated with γδ-lineage 
express a pre-commitment transcriptional program of T-cell development. This is in line with our 
own patient data, as most TLX3-rearranged cases have translocations where BCL11B is 
involved, and are therefore haploinsufficient for the essential role of BCL11B in T-cell lineage 
commitment and maintenance of T-cell identity.[20, 21] Of note, the OP9-DL1 system clearly 
favors the differentiation of αβ-T cells, thus to specifically comprehend the transcriptional 
program of γδ-lineage a similar in vitro system needs to be established that will support γδ-T-cell 
lineage development.  
 The transcription factors MEF2C, LYL1 and LMO2 play central roles in normal early T-
cell development and consequently abnormal regulation of MEF2C can promote 
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leukemogenesis, resulting in ETP-ALL. We have previously demonstrated that LYL1 and LMO2 
are regulated by MEF2C, and showed that MEF2C can directly bind to the promoter regions of 
LMO2. These observations support the oncogenic roles of LYL1 and LMO2 in MEF2C-
deregulated ETP-ALL.[4] Thus, it is crucial to understand both the oncogenic function of each 
protein individually and their involvement in major transcriptional complexes by identification of 
protein-protein interactions. ETP-ALL cells usually express myeloid surface markers (CD13 
and/or CD33) and have lower expression of T-cell specific genes compared to other types of T-
ALL.[22] This may be derived from the fact that the expression of MEF2C is higher in myeloid 
and B-cells compared to T-cells and may therefore favor the differentiation of other non T-cell 
lineages, and also ectopic expression of MEF2C has been linked to MLL-rearranged acute 
myeloid leukemia.[14] Consequently, MEF2C-transduced HSCs in the OP9-DL1 in vitro system 
blocks T-cell development at very early stage when cells are still CD34+, and exhibit high 
expression of CD13 and CD33 in cells that attempt to differentiate into non T-cell lineages (such 
as B-, myeloid or NK-cells). Possibly, T-cells arrested at this immature/ETP-ALL stage do not 
survive in vitro, as these cells may not be sustained with enough proliferation and survival 
signals, which may be supported by IL7R[23] or RAS mutations in ETP-ALL. (Y. Li and J.G. 
Buijs-Gladdines et al. unpublished data). Importantly, the MEF2C-driven oncogenic mechanism 
that leads to differentiation block in ETP-cells is dependent on a very early T-cell developmental 
stage, as MEF2C overexpression at later stages did not provoke developmental arrest in vitro.  
 Furthermore, constitutive expression of LYL1 or LMO2 in HSC is also incompatible with 
development into and beyond the T-cell commitment checkpoint and these proteins could 
therefore play important roles in the pathogenesis of ETP-ALL. The partial block observed at the 
constitutive expression of LYL1 or LMO2 may be related to “escaper cells” that have a lower 
expression of those oncogenes or due to continuous NOTCH1-activation promoted by the DL1-
ligand expressed on the membrane of OP9-DL1 cells that enforces T-cell differentiation. 
Similarly, a study using fetal thymus organ cultures showed that human CD34+ cells with ectopic 
expression of LMO2 result in an incomplete developmental block, exhibiting a lower percentage 
of CD1+ cells compared to untransduced cells.[24] However, LMO2 is an oncogene for TALLMO 
patients that have arrested at more advanced αβ-lineage T-cells, therefore ectopic expression of 
LMO2 may facilitate multiple stages of T-cell developmental arrest. In line with this, a recent 
study with humanized NSG mice transplanted with human CD34+ stem/progenitor cells that 
were genetically modified to overexpress LMO2, caused 3 aberrant effects on human T-cell 
development in vivo.[25] Specifically, it was observed a block at the DN/ ISP stage, an 
accumulation of CD4+CD8+ DP CD3- cells, and an altered CD8/CD4 ratio with enhanced 
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peripheral T lymphocytes. These results highlight the limitations of the OP9-DL1 in vitro system 
in developing T-cells into more mature stages, and demonstrate the strength of complementing 
this kind of studies with humanized mouse model. Furthermore, CD2-LMO2 mice give rise to 
highly penetrant T-ALL by two distinct patterns of gene expression: with ETP-ALL features such 
as high expression of HHEX, LYL1 and MEF2C [10] or alternatively, with Notch1 target gene 
activation. [26] These mice studies point to a synergy between co-expression of LMO2, LYL1 or 
HHEX with ectopic expression of MEF2C in ETP-ALL. For instance, HHEX and LYL1 seem to 
tightly collaborate with MEF2C as the incidence of T-ALLs in those mice is strongly reduced in 
the absence of each transcription factor. [9, 26] Therefore, we hypothesize that MEF2C 
synergizes with LMO2 and LYL1 in the dysregulation of important signaling pathways, resulting 
in ETP-ALL.    
 Overall, we conclude that T-ALL oncogenes can only promote leukemogenesis if they 
are activated at specific developmental stages where they can perturb normal T-cell 
development. This hypothesis is supported by cytogenetic analysis of T-ALL patients, as specific 
translocations (e.g. Bcl11b or TCR rearrangements) only occur at developmental contexts when 
the chromatin of those loci is open. The developmental arrest allows the rapid acquisition of 
additional genetic mutations, so called type-B mutations that will give proliferative advantage to 
those pre-leukemic cells and ultimately lead to T-ALL. The in vitro system approach is a valuable 
tool to investigate the mechanisms that promote cellular arrest and it may help to understand 
how specific oncogenes and genetic lesions cooperate during T-cell leukemogenesis and 
disease progression.  
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Figure legends 
 
Figure 1. T-ALL subtypes are associated with pre-/post- commitment developmental programs 
(a) Co-clustering of 117 T-ALL patient samples and in vitro T-cell sorted fractions (Chapter 5). 
The PCA analysis is based on the 547 genes that are differentially expressed across T-cell 
differentiation. The T-ALL subtypes are divided into the four T-ALL unsupervised clusters: 
Immature/ETP-ALL, TLX, Proliferative and TALLMO; and the T-cell sorted fractions are divided 
into CD34+ UCB-derived stem/progenitor cells, pre-commitment and post-commitment stages. 
(b) Hierarchical clustering analysis using the Kendall average method for 236 genes (547-
Var50Val50). The dendogram at the left represents the similarity between the 117 T-ALL 
patients divided into 4 T-ALL clusters. The dendogram at the top indicates how related is the 
expression of the 547 genes throughout the different T-ALL samples. The dashed line 
represents the T-cell lineage commitment and the two arrows identify two T-ALL samples that 
are misclustered due to translocation partners (c) PCA mapping of 117 T-ALL patient samples 
using a gene signature of 435 probesets (398 genes) that was used to distinguish the 4 gene 
expression-based clusters of T-ALL in Homminga et al. Cancer Cell 2011. (d) Hierarchical 
clustering analysis (PearsonWards method) using 107 genes that overlap between the 547-gene 
signature and the T-ALL signature of 435 genes probesets. The dendogram at the left 
represents the similarity of expression of 107 genes across the 117 T-ALL patient samples. The 
dendogram at the top indicates how related are the 117 T-ALL patients samples and the 
respective cluster is indicated. (e) Schematic representation of the different subtypes of T-ALL 
with the corresponding developmental arrest stages provoked by the ectopic expression of the 
oncogenes. The four T-ALL clusters are also separated into pre-commitment and post-
commitment T-cell developmental programs.   
 
Figure 2. Constitutive Expression of MEF2C, LYL1, or LMO2 impairs T-cell development (a) 
Schematic representation of the elements cloned into our Gateway compatible LeGO-DEST 
vector. The 3 lentiviral expression constructs coding the oncogenes LMO2, LYL1 or MEF2C 
exhibit 4830 bp, 5190 bp and 5750 bp of proviral RNA lengths, respectively. The BFP control 
vector composed by the SFFV promoter followed by the BFP reporter contains 4215 bp. SFFV: 
Spleen Focus Forming Virus promoter, T2A: Thosea asigna virus 2A element, BFP: blue 
fluorescent protein. Grey boxes indicate lentiviral elements in LeGO-DEST. (b) Top panel: flow-
cytometry image demonstrating BFP- and BFP+ (transduced) Jurkat cells; bottom panel: 
Western-blot of lysates from Jurkat cells transduced with MEF2C, LYL1, or LMO2 lentiviral 
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constructs and the SFFV-BFP control. After cleavage of the proteins, the MEF2C, LYL1, or 
LMO2 retain the majority of the T2A peptide that can serve as an epitope tag and can be 
recognized by the anti-2A antibody (left blot). The BFP reporter that folllows the T2A sequence is 
separated and not recognized by anti-2A. Direct antibodies against MEF2C, LYL1, or LMO2 
were used to detect the expression of those proteins in transduced Jurkat cells.  
 
Figure 3. Constitutive Expression of MEF2C, LYL1, or LMO2 impairs T-cell development (a) 
Schematic representation of the OP9-DL1 co-cultures used to differentiate transduced HSCs 
into consecutive T-cell differentiation stages. Briefly, HSC were transduced with the different 
lentivirus constructs and cultured on top of OP9-DL1 cells for 18 days until the cells reached the 
CD1a+ stage. (b) Schematic representation of the flow-cytometry analysis used to distinguish the 
different populations present in the co-cultures. The use of CD34 and CD7 antibodies allows the 
detection of 4 different populations: HSCs (CD34+CD7-), non-T-cell populations (CD34-CD7-), 
ETPs (CD34+CD7+) and T-cells (CD34-CD7+). (c) Transduced cells are illustrated as BFP-
positive cells in flow-cytometry analysis. Analysis of transduced cells is depicted as blue dots on 
the right graphs and analysis of non-transduced cells is depicted as pink dots on the left graphs. 
The two top-graphs correspond to the number of T-cells (CD7+CD34+/-) and the two bottom 
graphs correspond to the number of non T-lineage cells (CD7-CD34-) in 3 independent single 
well experiments for each construct over 18 days of co-culture (n=3). (d) Flow-cytometry plots 
illustrating distinct T-cell differentiation stages based on the expression of CD34 and CD7 
markers at days 5, 9 and 12. Cells transduced with the control vector are on top and cells 
transduced with lentiviral constructs expressing oncogenes are at the bottom. All populations 
were also gated for CD45+GFP- to exclude OP9-DL1 cells that are GFP positive. 
 
Figure 4. Constitutive expression of MEF2C, LYL1, or LMO2 is dependent on ETP-
transcriptional programs to promote differentiation block before T-cell commitment (a) 
Immunophenotype of 7 T-cell subsets (A-F) measured over time in OP9-DL1 co-cultures based 
on surface markers CD45, CD34, CD7, CD5, CD1a, and CD44. (b) Total cell numbers of distinct 
T-cell subsets (A-F, all BFP+ gated) upon transduction of HSCs with control-, MEF2C-, LYL1-, or 
LMO2-lentiviral vectors and differentiation in OP9-DL1 during 18 days. All subsets were also 
gated on CD45+ and GFP- to exclude OP9-DL1 cells. (c) Schematic representation of the 
differentiation block caused by constitutive expression of MEF2C, LYL1, or LMO2 before T-cell 
commitment. 
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General discussion and future perspectives 
 
Over the last decades, diverse genomic aberrations were identified and characterized in T-ALL 
patient samples, resulting in the activation of specific oncogenes or the inactivation of tumor 
suppressor genes. The overexpression of rearranged oncogenic transcription factors classify 
distinct genetic T-ALL subgroups that harbor specific gene expression profiles. These 
aberrations (type-A) are considered the driving oncogenic events, which are associated with 
arrest at specific stages of T-cell differentiation. In addition, recurrent genetic aberrations that 
affect cell viability and/or proliferation are denoted as type B hits, and are found in nearly all T-
ALL genetic subgroups. Despite the extensive identification of genetic defects driving human T-
ALL, multi-agent chemotherapy sometimes combined with stem cell transplantation is the 
standard treatment for pediatric T-ALL patients. Besides the risk for severe acute toxicities and 
long-term side effects that are associated with this intensive treatment, still 15% of the patients 
relapse and die due to therapy resistance. The current challenge is therefore to search for 
alternative patient-tailored treatment regimens that may reduce toxicity or enhance the cellular 
response to chemotherapeutic agents. To achieve this we need to understand how those 
genetic aberrations occur, which oncogenic mechanisms are being activated, and how these 
events contribute to leukemogenesis, disease progression or relapse. This thesis clearly shows 
the benefits of using in vitro methodologies to understand the impact of oncogenic mechanisms 
and their contribution to leukemogenesis. These data may therefore contribute to the 
development of novel targeted therapies. 
 
The impact of type B mutations in T-ALL heterogeneity and clonal evolution  
Clonal genetic diversity is a common feature of cancer and is probably, from a Darwinian natural 
selection perspective, the essential substrate for clonal evolution, disease progression and 
relapse. T-ALL is a genetically complex type of leukemia, exhibiting a mixture of leukemic 
subclones carrying different combinations of genetic lesions at diagnosis that are under constant 
selection pressure during chemotherapeutic treatment. In contrast to type-A mutations, which 
are considered the driving genetic events present in all cells of the leukemia, type-B mutations 
may not be clonal and are frequently acquired or lost during disease progression as result of 
clonal evolution. Studies on clonal evolution are possible nowadays due to advances in Next-
generation sequencing (NGS) techniques and the development of bioinformatic tools that can 
distinguish these mutations at the clonal and subclonal levels. Identifying the full complexity of 
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subclonal architecture and genetic diversity in T-ALL can be done through deep sequencing of 
entire tumor cell populations. This approach allows to discriminate subclonal passenger 
mutations from the oncogenic driver mutations that most likely contribute to disease progression 
and therapy resistance.1 Targeted therapy directed against mutant molecules may have limited 
efficacy if the targets themselves are not initiating lesions, but reflect secondary mutations 
occuring in leukemia subclones. Because genetic variation may represent a significant obstacle 
to effective therapy, WGS will certainly support personalized targeted therapy, namely the 
combination of specific signaling inhibitors. For instance, NOTCH1-activated leukemias should 
be screened for the presence of subclonal PTEN aberrations – such as PTEN microdeletions 
described in Chapter 3 – since newly acquired PTEN mutations may drive resistance to 
NOTCH1-targeting therapies as discussed in Chapter 2. In this case, combined NOTCH and 
AKT-directed therapies may prove an effective treatment relapse of T-ALL blasts (Chapter 2). 
Different lines of research are currently focusing on the understanding of molecular mechanisms 
that are associated with chemotherapy resistance, as the biological basis for disease relapse in 
T-ALL is still poorly understood. Recently, whole-exome sequencing of matched diagnosis, 
remission and relapse DNA samples, identified recurrent mutations that are acquired in relapse 
samples after chemoterapy, indicating that relapse is not only mediated by minor leukemic 
subclones that are already present at diagnosis. Specifically, activating mutations in  the 
cytosolic 5′-nucleotidase II gene (NT5C2) were found in about 20% of relapsed T-ALL patients 
and are associated with the outgrowth of 6-mercaptopurine (6-MP)- or 6-thioguanine (6-TG)- 
resistant clones.2,3 NT5C2 encodes a 5′-nucleotidase enzyme that is responsible for the 
inactivation of nucleoside-analog chemotherapy drugs routinely used in T-ALL maintenance 
therapy, including 6-MP and 6-TG.4,5 Accordingly, expression of NT5C2 mutant in ALL 
lymphoblasts resulted in increased nucleotidase activity in vitro confering resistance to 6-MP and 
6-TG.2,3 These results demonstrated the impact of increased nucleoside-analog metabolism in 
disease progression and chemotherapy resistance. Furthermore, increasing evidence is 
demonstrating the role of leukemic stem cells (LSC),6-8 epigenetic changes9,10 and metabolism 
alterations9 in the evolution of resistant leukemic clones. Overall, the identification and 
comprehension of molecular mechanisms involved in disease progression and therapy-
resistance is critical for the development of new strategies that may prevent the acquisition or 
outgrowth of treatment resistant subclones.   
 
Genetic abnormalities in normal healthy tissues  
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In our studies in Chapter 3 we reveal that PTEN microdeletions can also occur in the thymus of 
normal healthy thymocytes. This observation together with other studies11,12 show that healthy 
human thymocytes are also prone to illegitimate RAG-mediated recombination events as 
observed in T-ALL blasts, resulting in the inactivation of tumor suppressor genes or activation of 
oncogenes. However, in healthy thymocytes, those mutations may occur as single events or in 
cells that lack essential collaborating mutations to become a pre-leukemic cell. As proposed by 
Mel Greaves13 this phenomena corroborates the vulnerability of human tissues to oncogenic 
processes, which is supported by the high prevalence of “hidden” malignant cancers or pre-
malignant carcinomas identified in organs of individuals dying of non-cancer causes. In line with 
this, the author defends that the process of tumorigenesis is a lottery, since most tumors never 
emerge all the bottlenecks. As an example, the screening of mutations in archived neonatal 
blood spots or Guthrie cards showed that many healthy babies carry pre-leukemic translocations 
such as TEL/AML gene fusion, but never develop leukemias as the secondary hits never 
occur.14,15 Hence, cancer is commonly or ubiquitously initiated but promotion to full malignancy is 
rare as the emergence of a cancer clone is a relatively inneficient evolutionary process. 
Accordingly, despite the frequent acquisition of PTEN microdeletions in thymocytes, this event 
by itself is not sufficient to enable increased cell survival or proliferation that leads to 
development of T-ALL. To become malignant, developing thymocytes with PTEN inactivation 
may require the collaboration with specific oncogenes (type A aberrations), such as TAL or LMO 
genes, that promote a late developmental arrest and allow the acquisition of additional genetic 
hits. Late T-cell development stages (post-commitment  program) are especially prone to such 
oncogenic chromosomal translocations, because the “recombination machinery” that is 
responsible for TCR recombinations (i.e. V(D)J rearrangements) and for these leukemogenic 
events is especially expressed after T-cell commitment.  
   
Normal T-cell development as a reference to elucidate the role of T-ALL oncogenes in 
leukemogenesis  
In this thesis we have used two different approaches to understand the role of oncogenic 
transcription factors (Type-A aberrations) in T-ALL. First, we determined the expression of those 
oncogenes in normal T-cell development (Chapter 5); second, we examined the associations of 
these oncogenes with particular T-cell developmental programs that may be required for 
leukemogenesis and accordingly, we tested the enforced expression of ETP-ALL oncogenes 
during early T-cell development (Chapter 4 and 6). In the first approach (Chapter 5), supervised 
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cluster analysis of consecutive human T-cell differentiation stages in the OP9-DL1 system 
demonstrated that in vitro development closely resembles the in vivo situation both in human 
and mice. It therefore validates the OP9-DL1 culture system using umbilical cord blood-derived 
HSCs to study human T-cell development. Gene expression analysis exhibits the pattern of 
expression of the proto-oncogenes and other transcription factors throughout normal T-cell 
development, and helps to comprehend the function of expressed oncogenes in the different 
stages of the developmental process. Although some oncogenes as TLX1, TLX3, NKX2.1 and 
fusion proteins are not expressed during normal T-cell development, their ectopic expression in 
malignant thymocytes may interfere with important T-cell development regulators that are 
expressed during normal T-cell development. For instance, it has been described that TLX1 and 
TLX3 can interact with ETS1, which is a critical component of the complex that binds and 
activates the TCR enhancer element (Eα), resulting in an enrichment of repressive histone 
modifications and lack of TCRα gene expression that ultimately leads to a differentiation arrest.16 
Accordingly, in order to distinguish the activation of particular oncogenic mechanisms upon 
ectopic expression of the oncogenes and to understand how their abnormal regulation can 
promote leukemogenesis, it is crucial to fully understand normal T-cell development.  
 Remarkably, we identified the T-cell lineage commitment point in humans to occur during 
the CD7+CD5+stage, precisely when cells downregulate the expression of CD44 at the surface 
membrane. This exactly resembles the DN2a-DN2b transition that has been revealed as T-cell 
commitment point in mice. Despite a previous study that described a differential expression of 
CD44 earlier than CD1a expression in human T-cell development,17 here we place CD44 
expression in the context of other T-cell development markers, which allows to distinguish 
consecutive T-cell developmental stages. More importantly, we functionally demonstrated that 
loss of CD44 marks human T-cell lineage commitment. This contributed to define pre- and post-
commitment programs of T-cell development and helps understanding the association of 
different oncogenes with these particular programs. Defining the consecutive stages of normal 
T-cell development is also particularly useful when testing the leukemogenic effects of 
oncogenic transcription factors in vitro, as shown by the developmental arrest at the ETP-stage 
upon ectopic expression of MEF2C, LYL1 or LMO2. Overall, these results can be potentially 
interesting for the field of normal human T-cell development and accompanying T-cell 
(developmental) malignancies.  
 
The oncogenic effect of T-ALL oncogenes depends on specific developmental programs  
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Furthermore, gene expression analysis of the consecutive T-cell stages obtained with the OP9-
DL1 in vitro system allowed us to identify a gene expression signature of 1387 genes that cluster 
human T-ALL samples in four T-cell developmental clusters. Importantly, these clusters are 
nearly identical to the 4 genetic subgroups (ETP-ALL, TLX, proliferative and TALLMO) that we 
previously identified using unsupervised hierarchical clustering analysis of 117 pediatric T-ALL 
samples.18 Particularly, samples that are classified as ETP-ALL or TLX are characterized by the 
expression of a pre-commitment profile, while proliferative and TALLMO patient samples 
exhibited a post-commitment profile. This was expected for ETP-ALL, since it is the most 
immature T-ALL entity, but more importantly it supports our hypothesis that γδ-lineage cells – 
characteristic of the TLX phenotype – diverge from αβ-development before T-cell commitment. 
This hypothesis is supported by genetic analysis of T-ALL patient samples: TLX and ETP-ALL 
patients are frequently characterized by BCL11B enhancer-driven translocations to TLX3 or 
other genes (NKX2.5, SPI1, LMO2). In contrast, TALLMO and proliferative subtypes frequently 
have TCR-driven rearrangements, supporting a pathogenic role of RAG1/2 proteins in pre-
leukemic T-cells that have passed T-cell commitment.   
Remarkably, about half of the genes represented in the gene signatures obtained from in 
vitro T-cell development data overlapped with the T-ALL gene signature composed of 435 
probesets that previously led to the identification of the four T-ALL genetic subgroups.18 T-ALL 
oncogenic aberrations are therefore closely associated with pre- or post-commitment 
developmental programs. This supports our hypothesis that oncogenes need to cooperate with 
those programs for leukemogenesis, and actually may only exert their leukemogenic role in the 
context of specific T-cell developmental programs. This may help to understand how the 
oncogenes can block T-cell differentiation, and to what extent they are responsible for driving 
the expression of genes in these programs.  Regarding this, we have physiologically tested the 
leukemogenic potential of MEF2C, LYL1 or LMO2 using the OP9-DL1 system, providing 
evidence that all three are able to block T-cell development within the ETP-stage. Contrarily, 
ectopic expression of these genes in thymocytes that already passed the ETP-stage revealed 
that these oncogenes did no longer affect the developmental process as cells could normally 
differentiate into the T-cell lineage. Accordingly, we conclude that solely the ectopic expression 
of the oncogene is not sufficient for leukemogenesis, but instead it requires a specific 
transcriptional program characteristic of distinctive T-cell developmental stages to cause a 
differentiation arrest. Moreover, although MEF2C overexpression was capable of arresting the 
cells at a very immature stage, those cells eventually disappeared from culture. Probably, those 
cells require extra signals for survival and proliferation that are usually derived from type B 
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mutations in T-ALL, such as the IL7R or RAS mutations found in ETP-ALL. Importantly, if we 
understand the oncogenic mechanisms of type A mutations, we could alleviate the 
developmental block of leukemic cells by targeting critical downstream molecules that are 
responsible for differentiation arrest. This may not only impair the acquisition of additional 
genetic hits, but also prevent the uncontrolled proliferation of cells at that stage. 
Moreover, it would be interesting to further investigate the genes that are contained in the 
T-ALL gene signature (435 probesets), especially after filtering out all genes that are associated 
with T-cell development. Studying the resultant genes could provide new insights into important 
oncogenic mechanisms that are specific for each T-ALL subgroup, such as the activation of 
critical proliferation or survival signaling molecules, e.g. MYC and TP53. This would indicate that 
there are alternative pathways apart from pre- or post-commitment networks that are prone to 
become mutated in each T-ALL subtype to promote proliferation and/or survival mechanisms. 
Overall, this could give a better rationale for the use of specific inhibitors to different T-ALL 
entities.    
 
Current methodologies to unravel the leukemogenic mechanisms of ETP-ALL  
Despite the important insights obtained on the leukemogenic potential of ETP-ALL oncogenes 
using the OP9-DL1 in vitro system, some questions remain to be investigated. First, we would 
like to examine the combinations of oncogene and type B aberrations that are essential do drive 
leukemogenesis, and investigate the downstream activation of oncogenic signaling 
mechanisms. Second, it is important to develop models to test the efficacy of specific pathway 
inhibitors in T-ALL.  
 We are currently using in vitro techniques in T-ALL cell lines to characterize the 
transcriptional complex that comprises MEF2C, to investigate molecular interactions between 
MEF2C and other proteins that participate in an oncogenic transcription complex (e.g. LYL1 and 
LMO2). This may help to identify new therapeutic targets that could dismantle such a complex. 
Furthermore, it may lead to a better understanding on how MEF2C drives particular genes at the 
ETP-stage, which can be additional targets for therapy. In addition, we are working with in vivo 
mouse models that contain conditional deletion (KO) and overexpression (KI) of MEF2C to 
understand the role of this oncogene in normal and malignant in vivo T-cell development, 
respectively. Gene expression analysis of leukemic or pre-leukemic (potentially arrested) 
thymocytes (KI) will determine the effects of enforced expression of MEF2C transcriptional 
complex components or critical downstream targets on T-cell proliferation and differentiation. 
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Thus, MEF2C-driven leukemias in these mice will form a relevant model to investigate and 
characterize oncogenic MEF2C transcriptional complexes and its downstream target genes. It 
can also represent an important in vivo model to test the effects of compounds against relevant 
MEF2C-driven oncogenic pathways. 
 In addition, we can further explore the OP9-DL1 in vitro to test the expression of ETP-
ALL oncogenes in combination with frequent ETP-ALL type-B aberrations, such as IL7R or RAS 
activating mutations. Although, we have shown that MEF2C-, LYL1- or LMO2- overexpression at 
the very early stages of T-cell development was capable of promoting a differentiation arrest, it 
would be interesting to transduce arrested cells with other collaborative events such as IL7R or 
RAS activating mutations to promote cell proliferation and survival. This system could provide 
new insights into the downstream molecular pathways that are activated to promote 
leukemogenesis and it may be a useful tool for testing drugs that target (pre-)leukemic cells. 
Alternatively, cells expressing the combination of oncogenes and type-B mutations could be 
xenotransplanted into sublethally irradiated mice to further examine the oncogenic potential of 
different mutations and the resulting malignancies at a cellular and molecular level.  
  
Future research in T-ALL  
Despite a detailed understanding of the genetic defects that drive T-ALL, we face a number of 
interesting challenges. First, we need to better understand how specific T-ALL oncogenes and 
tumor suppressors cooperate to drive full leukemic transformation. We still lack detailed 
information whether the co-occurrence of certain mutations may be synergistic in the activation 
of molecular oncogenic mechanisms that transform normal developing T-cells into (pre)-
leukemic blasts. Secondly, the potential contribution of the exact order in which genetic lesions 
are acquired during disease initiation, progression, and/or maintenance, which underlie disease 
subclonality and evolutionaly selection before and after therapy, should also be further 
investigated. Moreover, the existence of leukemic initiating cells (LICs) in the context of T-ALL is 
still under debate, and the molecular mechanism that could regulate LIC activity remains poorly 
characterized. Furthermore, deregulated expression of microRNAs, long non-coding RNAs, 
enhancer activities, aberrant chromatin remodeling, and/or epigenetic changes in the context of 
malignant T-cell transformation need to be further investigated. 
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Summary 
 
This thesis aimed to: 1) identify additional PTEN-inactivating events as novel type-B mutations 
that may provide survival and proliferation advantage to (pre)-leukemic cells, and understand 
their clinical impact in T-ALL;  2) to establish an in vitro co-culture system (OP9-DL1) that 
supports T-cell development from human umbilical cord blood-derived hematopoietic stem cells 
(HSCs), with the intention of defining distinct human T-cell development stages in relation to the 
underlying transcriptional programs and expression of cell surface markers;  3) to optimize a 
lentivirus system that supports transduction and stable expression of oncogenes in human and 
mouse HSCs and  4) to study the impact of ETP-ALL expressed oncogenes (such as MEF2C, 
LYL1 or LMO2) on human T-cell development using the OP9-DL1 in vitro system.  
 
Chapter 2. The tumor suppressor PTEN negatively regulates PI3K-AKT signaling and is often 
inactivated by mutations (including deletions) in a variety of cancer types, including T-ALL. In 
chapter 2, we review mutation-associated mechanisms that inactivate PTEN together with other 
molecular mechanisms that activate AKT and contribute to T-cell leukemogenesis. In addition, 
we discuss how Pten mutations in mouse models affect the efficacy of gamma-secretase 
inhibitors (GSI) to block NOTCH1 signaling through activation of AKT. Based on these models 
and on observations in primary diagnostic T-ALL patient samples, we propose that PTEN-
deficient cells employ a compensatory mechanism in which PI3K-AKT signaling is dampened 
over time. As a result of this reduced PI3K-AKT signaling, the level of AKT activation is 
insufficient to compensate for NOTCH1 inhibition, resulting in responsiveness to GSI. On the 
other hand, de novo acquired PTEN inactivating events in a NOTCH1-dependent T-ALL result in 
immediate, strong activation of PI3K-AKT signaling, increased glycolysis and glutaminolysis, and 
consequently GSI resistance. Due to the central role of PTEN-AKT signaling in T-ALL and in 
resistance to NOTCH1 inhibition, AKT inhibitors may be a promising addition to current 
treatment protocols for T-ALL. 
 
Chapter 3. Phosphatase and tensin homolog (PTEN)-inactivating mutations and/or deletions are 
an independent risk factor for relapse of T-cell acute lymphoblastic leukemia (T-ALL) patients 
treated on Dutch Childhood Oncology Group or German Cooperative Study Group for Childhood 
Acute Lymphoblastic Leukemia protocols. Some monoallelic mutated or PTEN wild-type patients 
lack PTEN protein, implying that additional PTEN inactivation mechanisms exist. We show that 
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PTEN is inactivated by small deletions affecting only a few exons in 8% of pediatric T-ALL 
patients. These so-called microdeletions were clonal in 3% and subclonal in 5% of patients. 
Conserved deletion breakpoints were identified that are flanked by cryptic recombination signal 
sequences (cRSSs) and frequently have non-template-derived nucleotides inserted in between 
breakpoints, pointing to an illegitimate RAG recombination activity. Identified cRSSs drive RAG-
dependent recombination in a reporter system as efficient as bona fide RSSs elements that flank 
T-cell receptor locus gene segments. Microdeletions strongly associate with the TALLMO 
subtype that is characterized by TAL1 or LMO2 rearrangements, in line with the  previous 
association of PTEN non-sense mutations or entire locus deletions. Primary and secondary 
xenotransplantation of TAL1- rearranged T-ALL allowed development of leukemic subclones 
that acquired new PTEN microdeletions, indicating that PTEN aberrations may be continuously 
acquired and a mechanism for subclonal diversity. Remarkably, equivalent microdeletions were 
also detected in thymocytes of healthy individuals indicating that ongoing RAG activity may 
actively contribute to the acquisition of preleukemic hits in normal thymocytes that will be 
effectively eradicated by the immune system. 
 
Chapter 4. Leukemia research increasingly depends on techniques to induce or to inhibit 
expression of oncogenes or tumor-suppressors in HSCs or primary leukemic cells. Surprisingly 
little information is available to optimize lentiviral transduction of primary leukemic cells or HSCs. 
We have therefore carefully optimized transduction of murine and human HSCs using an 
optimized lentiviral vector design, serum-free virus production of recombinant viruses and 
quantitation, and optimized delivery (transduction) into primary human or mouse HSCs. We 
developed a quantitative RT-PCR-method to quantify the encapsulated proviral RNA particles. 
We have observed an inverse exponential relation between the length of the proviral RNA 
encoded by the construct and the number of viral particles that are being produced in HEK293T-
cells.The length of the proviral RNA also determines the transduction efficiency of target cells. 
Increased concentrations of serum (ranging from 0% to 10%) during transduction negatively 
affect the transduction rate of human HSCs. In conclusion, we provide an optimized serum-free 
lentiviral gene transfer into human and murine hematopoietic stem cells, where the reduction of 
lentiviral constructs size will facilitate efficient transfer of large oncogene sequences into human 
or mouse HSCs or primary leukemic cells. 
 
Chapter 5. Human T cell development is less well studied than its murine counterpart due to the 
lack of genetic tools and the difficulty of obtaining cells and tissues. However, recent 
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technological advances allow identification of the transcriptional landscape of differentiating 
human thymocytes. Here we report the gene expression profiles of 11 immature, consecutive T-
cell developmental stages that were obtained using the OP9-DL1 in vitro culture system. The 
changes in gene expression of cultured stem cells on OP9-DL1 match those of ex vivo isolated 
human thymi. These analyses let us to define a gene signature that distinguishes pre- and post- 
αβ T-cell commitment. We found that loss of CD44 marks T-cell commitment in early 
CD7+CD5+ cells, before the acquisition of CD1a surface expression. The CD44-CD1a- post-
committed thymocytes have initiated in frame TCR rearrangements and have completely lost the 
capacity to develop into myeloid, B- and NK-cells, unlike uncommitted CD44+CD1a- 
thymocytes. Therefore, loss of CD44 represents a previously unrecognized stage that defines 
the earliest committed T-cell population in the human thymus. 
 
Chapter 6. Pediatric T-ALL is a cancer of developing T-cells in the thymus. The T-ALL subtypes 
are characterized by specific chromosomal rearrangements driving the ectopic expression of 
oncogenes that result in arrest of leukemic cells at specific T-cell developmental stages. Here, 
we show that T-ALL subtypes are strongly associated with the expression of particular T-cell 
developmental programs. Immature/ETP-ALL and TLX subtypes of T-ALL express a pre-
commitment program whereas the proliferative and TALLMO subtypes express a post-
commitment program. This suggests that T-ALL oncogenes require the expression of particular 
T-cell transcriptional programs to be able to exert an oncogenic function, and therefore may 
hijack T-cell developmental programs by facilitating a developmental arrest. That is further 
supported by functional in vitro studies where we investigate the impact of typical ETP-ALL 
(proto-)oncogenes, including MEF2C, LYL1 or LMO2 on early T-cell development. Umbilical 
cord blood stem cells transduced with lentiviral expression constructs that constitutively drive 
MEF2C, LYL1 or LMO2 were cultured on OP9-DL1 cells for differentiation towards the T-cell 
lineage. Expression of MEF2C or its putative co-factors (LYL1 or LMO2) blocks T-cell 
development at ETP-stages, in line with their roles in immature T-ALL. Contrarily, expression of 
the oncogenes in T-cells beyond the ETP-stages does no longer support T-cell development 
arrest, indicating that their leukemogenic potential is dependent on ETP, pre-commitment 
transcriptional networks. Thus, we conclude that the specific interaction of an aberrant 
oncogenic transcription factor with specific transcriptional network in a developing T-cell is an 
important requirement for oncogenesis.    
 
Chapter 7.  The findings described in the thesis are discussed and put into perspective.  
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Nederlandse samenvatting 
 
Dit proefschrift heeft de volgende doelstellingen gehad: 1) Het identificeren van bepaalde 
afwijkingen in het PTEN gen, in toevoeging van de al bekende genetische afwijkingen, die als 
nieuwe type-B mutaties een overlevings- of groeivoordeel zouden kunnen bieden voor (pre-) 
leukemische cellen. Ook het begrijpen en beschrijven van de klinische impact van PTEN 
afwijkingen in T-cel acute leukemie (T-ALL) patiënten behoorde tot deze doelstelling. 2) Het 
opzetten van een kweeksysteem (OP9-DL1) waarin bloedstamcellen verkregen uit 
navelstrengbloed in een petrischaal gedurende enkele weken kunnen uitgroeien tot T-cellen. 
Het bepalen van genexpressieprofielen van de verschillende T-cel ontwikkelingsstadia aan de 
hand van specifieke oppervlakte markers heeft het functioneren van het systeem gevalideerd en 
ook geleid tot de identificatie van een extra oppervlakte marker. 3) De optimalisatie van een 
methode waarmee met behulp van lenti-virussen bepaalde oncogenen ingebracht en 
geactiveerd kunnen worden in bloedstamcellen van menselijke en muizen oorsprong. 4) Het 
bestuderen van het effect van de activatie van oncogenen die specifiek voorkomen in een 
vroege vorm van T-ALL (genaamd ETP-ALL) op de menselijke T-cel ontwikkeling in het OP9-
DL1 kweeksysteem.  
 
Hoofdstuk 2. De functie van het zogenaamde ‘tumor suppressor gen’ PTEN is het remmen van 
een belangrijk signalerings-pad PI3K-AKT dat na activatie de overleving en groei van cellen 
stimuleert. In T-ALL, net als in verscheidene andere kanker soorten, komen afwijkingen voor die 
leiden tot het inactief of afwezig zijn van PTEN, en daardoor tot verminderde remming van het 
PI3K-AKT pad. In hoofdstuk 2 hebben we de literatuur samengevat rondom PTEN, PI3K-AKT en 
een ander belangrijk signalerings-pad dat begint bij de NOTCH1 receptor. We behandelen hoe 
bepaalde mutaties en andere afwijkingen in deze verschillende paden samen kunnen leiden tot 
de ontwikkeling van T-ALL, en hoe verschillende remmers aangrijpen op deze mechanismes en 
dus mogelijk klinisch relevant zijn. We concluderen dat AKT remmers veelbelovend kunnen zijn 
als toevoeging aan de huidige behandelingsprotocollen voor T-ALL. 
 
Hoofdstuk 3. T-ALL patiënten met PTEN afwijkingen die in Nederland en Duitsland zijn 
behandeld hebben een verhoogd risico op terugval. Hoewel veel van deze afwijkingen verklaard 
kunnen worden door genetische mutaties of deleties van het PTEN gen die resulteren in het 
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niet-functioneren of afwezig zijn van het PTEN eiwit, zijn er ook cellen van patiënten zonder een 
dergelijke verklaring voor de afwezigheid van PTEN. We hebben in deze cellen hele kleine, 
gedeeltelijke deleties in het PTEN gen gevonden die ook leiden tot de afwezigheid van PTEN. 
Deze zogenaamde ‘micro-deleties’ werden met de eerdere technieken over het hoofd gezien, en 
komen voor in 8% van kinderen met T-ALL. We hebben laten zien dat deze micro-deleties 
worden veroorzaakt door een herschikkings-proces wat normaliter de herschikking van T- en B-
cel receptor genen verzorgt en dus een normaal actief proces is in rijpende T-cellen. 
Opmerkelijk genoeg hebben we deze PTEN-microdeleties ook gevonden in sommige rijpende T-
cellen van enkele gezonde kinderen, wat aangeeft dat er meerdere mutaties moeten optreden 
voordat deze microdeleties een risico kunnen worden. 
 
Hoofdstuk 4. Ten behoeve van ons T-ALL onderzoek naar het effect van de activatie van 
bepaalde oncogenen introduceren (‘transductie’) we grote DNA moleculen in normale 
bloedstamcellen met behulp van specifieke lenti-virussen. Omdat deze techniek uiterst inefficiënt 
is in stamcellen, hebben we het door meerdere aanpassingen verbeterd. We hebben de 
volgende facetten geoptimaliseerd: ontwerp lenti-virale DNA vector, virus productie, 
nauwkeurige bepaling hoeveelheid virus, transductie in bloedstamcellen. We hebben gezien dat 
met toenemende lengte van de vector zowel de virus productie alsook de transductie efficiëntie 
afneemt. Om toch grote oncogenen te kunnen bestuderen in bloedstamcellen, zullen andere 
elementen uit de DNA vector verkleind of verwijderd moeten worden om een betere transductie 
efficiëntie te realiseren. 
 
Hoofdstuk 5. T-cel ontwikkeling/rijping in mensen vindt plaats in de thymus, voornamelijk 
gedurende de eerste 10 levensjaren. Vergeleken met het onderzoek naar T-cel ontwikkeling in 
de muis is de menselijke T-cel ontwikkeling weinig bestudeerd, gedeeltelijk omdat primair 
materiaal van kinderen weinig beschikbaar is. Met de opkomst van geavanceerde 
kweeksystemen (OP9-DL1) kan ook de menselijke T-cel ontwikkeling nagebootst en bestudeerd 
worden in een petrischaal. We hebben dit systeem opgezet en gebruikt om 
genexpressieprofielen van meerdere opeenvolgende menselijke T-cel ontwikkelingsstadia (aan 
de hand van oppervlakte markers) te bepalen. Uit de analyse van deze profielen blijkt dat ook op 
het niveau van de genexpressie het kweeksysteem de werkelijke ontwikkeling goed weergeeft. 
Bovendien heeft de analyse geleid tot een extra oppervlakte marker CD44 die onze 
genexpressieprofielen van voor en na een belangrijk checkpunt in T-cel ontwikkeling, de 
zogenaamde ‘T-cel commitment’, scheidt. We hebben getest dat de vroegste cellen in de 
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thymus die nog CD44 hebben, ook nog kunnen uitrijpen naar andere bloedceltypes; de iets 
latere ‘gecommitteerde’ T-cellen hebben geen CD44 en kunnen alleen nog T-cellen worden. 
 
Hoofdstuk 6. T-ALL in kinderen kan, gebaseerd op genexpressieprofielen, grofweg in vier 
subgroepen worden verdeeld: de meest vroege ETP-ALL, TLX groep, proliferatieve groep, en de 
TALLMO groep. De TLX en TALLMO groep zijn genoemd naar de belangrijkste oncogenen die 
de T-ALL veroorzaken: TLX3, TAL1 en LMO2. De proliferatieve groep wordt gekenmerkt door de 
oncogenen TLX1 en NKX2.1 terwijl de meest vroege ETP-ALL groep gekenmerkt wordt door 
MEF2C, LYL1 en ook LMO2. We hebben de genexpressieprofielen van voor en na normale T-
cel commitment (hoofdstuk 5) gebruikt om de T-ALL patiënten opnieuw te klusteren en vonden 
grofweg dezelfde vier groepen terug. De ‘vroege’ ETP-ALL en TLX groepen overlappen met het 
profiel ‘voor-commitment’, terwijl de ‘latere’ proliferatieve en TALLMO groepen overlappen met 
het ‘na-commitment’ profiel. Dit suggereert dat de T-ALL oncogenen functioneren in de context 
van normale T-cel ontwikkelingsgenen die ook actief zijn, en dat T-ALL oncogenen het normale 
ontwikkelingsprogramma blokkeren in specifieke stadia. Gebruikmakend van de expertise 
ontwikkeld in hoofdstukken 4 en 6, hebben we dit nagebootst voor ETP-ALL, waarin de 
oncogenen MEF2C, LYL1 en LMO2 actief zijn. We hebben deze oncogenen ingebracht in 
normale bloedstamcellen middels virale transductie, en vervolgens de ontwikkeling gevolgd in 
het OP9-DL1 kweeksysteem. Deze oncogenen leiden alle drie tot een blokkade vroeg in de 
ontwikkeling, terwijl ze geen effect hebben als ze pas in latere (na ‘commitment’) cellen 
aangezet worden. Deze observatie ondersteunt de hypothese dat de normale T-cel ontwikkeling 
alleen geblokkeerd wordt door specifieke oncogenen in dát specifieke stadium waarin het 
normale ontwikkelingsprogramma actief is en het de functie van het oncogen en de leukemie 
ontwikkeling ondersteunt. 
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Supplementary Data  
 
Chapter 3 
Supplementary Materials and Methods  
 
Multiplex ligation-dependent probe amplification (MLPA) reaction  
For MLPA analysis, the SALSA MLPA kit (MRC-Holland, Amsterdam, the Netherlands) was used in 
combination with the P200-A1 Human DNA reference-1 probemix kit (MRC-Holland). Two synthetic left 
and right hybridization probe oligonucleotide (LPO and RPO) pairs were designed per exon for all 9 exons 
of PTEN. Probe pairs were designed according to the manufacturer guidelines, and obtained from IDT 
(Coralville, USA). Probe pairs were combined into a probe-mix with a concentration of 4nM per 
oligonucleotide (Table S1). Reactions were carried out in a model 2320 thermocycler (Applied 
Biosystems, Bleiswijk, the Netherlands). MLPA fragment analysis was performed using GeneMarker 
V1.85 (Softgenetics, State College, PA, USA). 
    
Breakpoint Mapping and PCR-based screening  
To map breakpoints for PTEN exons 2-3 and 4-5 deletions, multiple forward or reverse primers were 
designed for PTEN introns 1, 3 and 5 (Table S2 and S3). Specific primers (Table S4) were selected for 
PTEN exon 2-3 and 4-5 breakpoint screening. Positive reactions were directly sequenced for both strands 
or following cloning into the TOPO TA vector (Life Technologies). Sequence reactions were run on the 
3130x capillary sequencer (Applied Biosystems) and analyzed using CLC Main Workbench software 
(Aarhus, Denmark). 
 
Computational detection of putative RAG recombination signal sequences 
The human PTEN gene (ENSG00000171862) was screened for the presence of cryptic RAG 
recombination signal sequences (cRSS) using the PERL software algorithms developed by Cowell et al.28 
Mouse 12- and 23-RSSs (n=356) from all TCR and Ig loci were used for modeling. Both the program and 
12-/23-RSSs were available at http://www.duke.edu/~lgcowell/. The program computes RSS information 
content (RIC) scores for 12-spacer RSSs (i.e. 28-bp sequences comprising the heptamer, a 12-bp spacer 
and the nonamer sequences: RIC12) or 23-spacer RSSs (i.e. 39-bp sequences comprising the heptamer, 
a 23-bp spacer and the nonamer sequences: RIC23) to predict cryptic RSSs (cRSS) based on a 
comparison to the RIC score for actual immunoglobulin and T-cell receptor RSS. RSSs that potentially 
function within the range of actual antigen receptor loci RSSs are predicted to score above the -38,81 as 
RIC12 and -58,45 as RIC23 thresholds. RSSs that potentially function within the range predicted for 
degenerated RSSs, i.e the so-called cryptic RSSs (cRSS), score below these thresholds but above the 
background (e.g. the mean of RIC scores determined for non-RSS DNA sequences: -60,07 for RIC12 and 
-77,76 for RIC23) as previously described.1  
 
Generation of GFPi-PTEN cRSS reporter constructs and recombination assay 
To measure efficiencies of predicted cRSSs in mediating recombination of GFPi-mRFP reporter 
constructs, PCR amplified PTEN cRSS1-4 or defined RSS control sequences were cloned into this 
reporter construct and recombination assays were carried out as described,2 with minor adaptations (see 
Supplementary Materials and Methods). Predicted PTEN cRSS1-4 or control RSSs were tested in 
combination with a consensus 12 or 23 RSS (Figure 3B). All RSS or cRSS used in the GFPi-mRFP 
constructs are summarized in Table S5.   
Briefly, HEK293T cells grown in standard culture conditions were seeded at 2x105 cells per well in 
12-well plates. After 24h, cells were transfected with a transfection mix that contains 5 µL of Lipofectamine 
2000 (Invitrogen, Carlsbad, CA, USA), 300 µL of Optimem (Gibco, Life Technologies, Paisley, UK), 0.8 µg 
of CMV-RAG1,2 0.7 µg of CMV-RAG2,2 and 2.5 µg of a GFPi-mRFP construct variant. Medium was 
replaced 16h after transfection. Cells were harvested at 48h following transfection, and analyzed by flow 
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cytometry for GFP and RFP fluorescence using a FACSAria III (BD Bioscience, Madrid, Spain). Data 
analysis was performed using the FlowJo software (TreeStar Inc., Ashland, OR). 
 
Xenotransplantation of primary T-ALL patient material 
NOD-SCID-IL2Rγnull (NSG) mice were bred and housed under specific pathogen free (SPF) conditions at 
the Experimental Animal Facility of ErasmusMC. All experiments have been approved by the committee 
on animal welfare of ErasmusMC and are in compliance with Dutch legislation. Sets of 6–10 week old 
mice were intravenously injected with 1-5x106 human bone marrow leukemic cells. Upon signs of illness, 
mice were euthanized and leukemic cells were collected from the different organs. Likewise, primary 
transplanted leukemic cells from bone marrow, thymus or spleen were retransplanted. 
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Chapter 4 
Supplementary Protocols: virus production and concentration, viral RNA isolation and RT-qPCR, 
and human CD34+ HSC transduction. 
 
Reagents 
X-tremeGENE HP DNA Transfection Reagent: Roche Cat. #06 366 236 001 
Opti-MEM I with Glutamax: Life Technologies Cat. #51985-026 
0.45 µm filter: Minisart Cat. #17598 or equivalent 
IVSS VIVASPIN 20 centrifugation concentration column: Sartorius AG, Sigma-Aldrich Cat. #Z614653-
48EA 
Retronectin: r-Fibronectin CH-296: TaKaRa Cat. #T100A 
Non-tissue culture treated plates: Falcon (96 wp) Cat. #351172 
X-VIVO 10 medium: Lonza Cat. #BE04-743Q 
Recombinant human stem cell factor (rhSCF): R&D Cat. #255-SC 
Recombinant human thrombopoietin (rhTPO): R&D Cat. #288-TP/CF 
Recombinant human FLT3 ligand (rhFlt3L): Miltenyi Biotec Cat. #130-093-855 
Protamine Sulfate salt from Salmon grade X: Sigma Cat. #P4020-1G 
 
Virus production and concentration (biosafety level 2) 
1) For a 14 cm dish, plate ~8x106 HEK293T cells in 15 ml DMEM + 10% FCS and grow O/N to near 
confluency 
2) Mix lentiviral vector DNA (25 µg), VSV-G (3.7 µg), RRE (GAG/POL; 5 µg), REV (3.1 µg) and serum-
free Opti-MEM (4 ml) 
3) Add X-tremeGENE HP DNA Transfection Reagent (37 µl) to the DNA mix 
4) Incubate at room temperature for 15 minutes 
5) In a drop-wise manner: add the transfection mixture to the cells 
6) Incubate cells at 37ºC, 5%CO2 for 16-20 hours 
7) Remove DMEM, wash cells once with pre-warmed PBS, and add 11 ml of pre-warmed serum-free 
Opti-MEM 
8) Incubate cells at 37ºC, 5%CO2 for 24 hours 
9) Collect the first batch of virus-containing medium and pass through a 0.45 µm filter 
10) Concentrate roughly 40-fold (for example: 2 plates: concentrate 20 ml to 0.5 ml) using a 
centrifugation concentration column according to the manufacturer’s recommendations and keep at 
4ºC 
11) Add 11 ml of fresh pre-warmed serum-free Opti-MEM to the cells and incubate at 37ºC, 5%CO2 for 
another 24 hours 
12) Collect the second batch of virus-medium and repeat steps 9 and 10 
13) Combine both batches and determine the concentration factor 
14) Take 2 µl of the concentrated virus for viral RNA isolation in step 17 
15) Aliquot virus and use fresh or store at -80ºC 
 
 
Viral RNA isolation and RT-qPCR 
16) To determine the number of viral particles by PCR quantification, make a serial dilution of a viral 
vector DNA plasmid with a known concentration 
17) Trizol isolation of viral RNA is performed according to the manufacturer’s procedure 
18) RT-qPCR is performed using primers flanking the cPPT region: 5’-
AGGTGGAGAGAGAGACAGAGAC-3’ and 5’-CTCTGCTGTCCCTGTAATAAAC-3’ 
 
Retronectin-coated plates 
19) Coat retronectin at a concentration of 50 µg/ml in PBS in non-tissue culture treated plates at 4ºC 
(overnight) 
20) Before using retronectin-coated plate: remove retronectin, add 2%BSA/PBS, incubate at 37ºC for 30 
minutes, and wash twice with PBS 
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Human CD34+ HSC O/N stimulation 
21) Resuspend HSCs to concentration of 0.5x106/ml in serum-free X-VIVO 10 supplemented with 50 
ng/ml rhSCF, 20 ng/ml rhTPO and 50 ng/ml rhFlt3L 
22) Incubate the cells at 37ºC, 5%CO2 for 16-20 hours 
 
Human CD34+ HSC transduction (96 well-plate) (biosafety level 2) 
23) Collect HSCs and centrifuge to adjust to a concentration of 1x106/ml, keeping them in the same 
medium with cytokines 
24) Add protamine sulfate to the cells to a final concentration of 4 µg/ml 
25) Pipet concentrated virus into retronectin-coated (96-well) plate 
26) Add HSCs on top of the virus to a final volume of 200 µl/well 
27) Mix by gently tapping the plate 
28) Spinoculation: centrifuge at 1800 rpm, 32ºC for 1 hour  
29) Incubate the transduced cells at 37ºC, 5%CO2 for 24 hours before further use  
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Chapter 5 
Supplementary Figures 
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Supplemental Tables 
Table S1: Gene Symbols in each of the 16 Gene Signatures from Figure 1C-E 
    Gene 
Signature Gene Symbol 
Gene 
Signature Gene Symbol 
1 JHDM1D 9 S100A8 
1 BTG2 9 S100A9 
1 NBEA 9 DEFA1///DEFA1B///DEFA3 
1 PFKFB2 9 TACSTD2 
1 HIST1H2AC 9 CHI3L1 
1 ARID5B 9 CD24 
1 PELI2 9 CSGALNACT1 
1 ERN1 9 MS4A3 
1 BTBD11 9 CSTA 
1 ZNF704 9 ACTN1 
1 RORA 9 PRG2 
1 MAFB 9 CLC 
1 LOC283070 9 RNASE3 
1 CAMK1D///LOC283070 9 S100P 
1 CAMK1D 9 RNASE2 
1 SPOCK2 9 CTSG 
1 DDIT4 9 ELANE 
1 TP53INP1 9 CEACAM6 
1 HIST2H2BE 9 CST7 
1 CREBRF 9 PRTN3 
1 AMY1A///AMY1B///AMY1C///AMY2A 9 AZU1 
1 LOC728392 9 CEACAM8 
1 DCHS1 9 BPI 
1 PCMTD1 9 DEFA4 
1 BRWD1 9 SLPI 
2 TRERF1 9 ANXA3 
2 DNTT 9 ETV5 
2 ITGB2-AS1 9 TNFRSF4 
2 LINC00340 9 TNFRSF18 
2 GAL3ST4 9 PRF1 
2 OTTHUMG00000166495///RP11-728F11.1 9 VPREB1 
2 MBD5 9 CTSW 
2 LBH 9 SVOPL 
2 SCN3A 9 GPA33 
2 IL10RA 9 PPIF 
2 FAIM3 9 ELOVL6 
2 CRIP1 9 CTHRC1 
2 OTTHUMG00000178878///RP11-214C8.5 9 CSRP2 
2 PCDH9 9 TNFSF4 
2 NEGR1 9 PRR5L 
2 ETS1 9 GCNT1 
2 BACH2 9 RAB27B 
2 PGM2L1 9 GZMA 
2 DUSP16 9 NKG7 
2 TANC1 9 DNMT3B 
2 ITGA6 9 TESC 
2 ARRDC4 9 ARRB1 
2 AGBL3 9 APOBEC3B 
2 PRSS2///PRSS3 9 IGLL1 
2 SCN7A 9 GUSBP11///IGLL1///IGLL3P 
2 PDE4D 9 COL5A2 
2 TUBB2A 9 SLC35F3 
2 ARHGAP29 9 CISH 
2 SIPA1L2 9 CFH///CFHR1 
2 ID2///ID2B 9 TFEC 
2 CDKN2D 9 SLC39A14 
2 S1PR1 9 NLN 
2 IKZF3 9 FKBP4 
2 RBMS3 9 TTLL12 
2 NSG1 9 PUS7 
2 NLGN4X 9 OSM 
2 LRRN3 9 H19///MIR675 
2 CD8A 9 LIN28B 
2 NINL 10 AGR2 
2 CD8B///LOC100996919 10 MS4A1 
2 EFNB2 10 KLRD1 
161 
 
 
 
 
2 VCAN 10 IL18RAP 
2 LOC100287598 10 GNLY 
2 ID1 10 XCL1 
2 RASSF6 10 ITGAM 
2 SEC31B 10 SAMD3 
2 COX6A1 10 KLRB1 
2 GBP1 10 KLRC4-KLRK1///KLRK1 
2 KANSL1-AS1 10 CRTAM 
2 GAS2 10 PTGDR 
2 PALLD 10 PDE7B 
2 HNRNPLL 10 EPHA4 
2 ANKRD36BP2///LOC101060554 10 KLRC3 
2 PLEKHG1 10 MAF 
2 NCALD 10 KLRC1///KLRC2 
2 SYNM 10 IL2RB 
2 GRK5 11 FCRL4 
2 RDH10 11 SIGLEC6 
2 ALOX5 11 UGCG 
2 FHIT 11 CTA-250D10.23///OTTHUMG00000172730 
2 TRERF1 11 C1orf186///LOC100505650 
2 DNTT 11 TBC1D9 
2 ITGB2-AS1 11 CDH1 
2 LINC00340 11 FGL2 
2 GAL3ST4 11 ENTPD1 
2 OTTHUMG00000166495///RP11-728F11.1 11 MPEG1 
2 MBD5 11 FGD2 
2 LBH 11 LGMN 
2 SCN3A 11 CACNA2D3 
2 IL10RA 11 SLAMF7 
2 FAIM3 11 LY9 
2 CRIP1 11 PTPRJ 
2 OTTHUMG00000178878///RP11-214C8.5 11 MCOLN2 
2 PCDH9 11 CCR2 
2 NEGR1 11 TGFBI 
2 ETS1 11 NAPSB 
2 BACH2 11 MYCL1 
2 PGM2L1 11 TLR10 
2 DUSP16 11 C5orf20///TIFAB 
2 TANC1 11 TIFAB 
2 ITGA6 11 LYZ 
2 ARRDC4 11 IL6R 
2 AGBL3 11 MRC1 
2 PRSS2///PRSS3 11 MNDA 
2 SCN7A 11 P2RY14 
2 PDE4D 11 TYROBP 
2 TUBB2A 11 FCER1G 
2 ARHGAP29 11 CCR1 
2 SIPA1L2 11 CD36 
2 ID2///ID2B 11 CTSZ 
2 CDKN2D 11 MS4A7 
2 S1PR1 11 CD86 
2 IKZF3 11 NCF2 
2 RBMS3 11 GSN 
2 NSG1 11 AMICA1 
2 NLGN4X 11 SLC41A2 
2 LRRN3 11 DNASE1L3 
2 CD8A 11 TICAM2///TMED7-TICAM2 
2 NINL 11 GAS2L3 
2 CD8B///LOC100996919 11 RGS18 
2 EFNB2 11 IDH3A 
2 VCAN 11 CD48 
2 LOC100287598 11 IGJ 
2 ID1 11 TRIB2 
2 RASSF6 11 SMIM14 
2 SEC31B 11 RNASE6 
2 COX6A1 11 CLCN5 
2 GBP1 11 GPR18 
2 KANSL1-AS1 11 LOC158402 
2 GAS2 11 FGR 
2 PALLD 11 EPHB1 
2 HNRNPLL 11 OTTHUMG00000175583///RP11-4O1.2 
2 ANKRD36BP2///LOC101060554 11 ARL4C 
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2 PLEKHG1 11 GPR183 
2 NCALD 11 CLECL1 
2 SYNM 11 FAM105A 
2 GRK5 11 SAMHD1 
2 RDH10 11 CLEC4A 
2 ALOX5 11 ITGB7 
2 FHIT 11 BLNK 
3 DENND1B 11 STX7 
3 PAPD4 11 IFI44L 
3 U2SURP 11 OAS1 
3 SF1 11 CRYBG3 
3 SREK1 11 ABHD6 
3 LOC100996467 11 KYNU 
3 MALAT1 11 CCR6 
3 CLK4 11 HCK 
3 OTTHUMG00000168768///RP11-463O12.5 11 GAS6 
3 KMT2A 11 IGK///IGKC 
3 CAPZA1 11 DAB2 
3 ZMYM2 11 MS4A4A 
3 CEP95 11 HDAC9 
3 B2M 11 CLEC12A 
3 IFNGR1 11 KMO 
3 EIF5///SNORA28 11 IRF8 
3 MORF4L2 11 CYBB 
3 NFAT5 11 DTX4 
3 C10orf118 11 ADRB2 
3 PCNX 11 THBD 
3 AC092620.2///OTTHUMG00000153633 11 RBM47 
3 TGFBR1 11 ATP10D 
3 INPP5D 11 CD180 
3 MIR612///NEAT1 11 GPR114 
3 WDR11 11 GAPT 
3 OTTHUMG00000168867///RP11-305O6.3 11 PAX5 
3 LRRFIP1 11 ARHGAP18 
3 CELF2 11 KIAA0930 
3 LONRF1 11 SUCNR1 
3 ANKRD28 11 LY86 
3 ZNF274 12 GZMB 
3 LOC100506312 12 NME8 
3 SEC61B 12 TCL1A 
3 NKTR 12 CMKLR1 
3 PIK3C2A 12 PTPRS 
3 RAB18 12 IL18R1 
3 GNAS 12 SOGA2 
3 PELI1 12 TPM2 
3 UBE2B 12 CYAT1///IGLC1///IGLV1-44 
3 TBRG1 12 IGLC1 
3 LINC00597 12 LAMP5 
3 SAMD4B 12 LOC285972 
3 DAPK1-IT1 12 SEL1L3 
3 PGAP1 12 IL3RA 
3 MLLT3 12 GNG7 
3 SPATA13 12 LHFPL2 
3 RGCC 12 ZDHHC14 
3 BCL6 12 BANK1 
3 KLF4 12 CCDC50 
3 RGS1 12 FZD3 
3 LOC100507577///LONP2 12 FCRLA 
3 ZBTB20 12 IFNLR1 
3 OTTHUMG00000175755///RP11-553L6.5 12 SPIB 
3 LOC100131564 12 IRF7 
3 PPP2R5C 12 FAM129C 
3 HECA 12 SULF2 
3 LOC100996653 12 LILRA4 
3 APBB1IP 12 CLEC4C 
3 TNFAIP3 12 PAPLN 
3 STK4 13 CDH17 
3 PRO2852 13 IL1R2 
3 ZFAND6 13 IGSF6 
3 ZNF638///ZNF638-IT1 13 CLEC10A 
3 RBM5 13 LGALS2 
3 RUNX1-IT1 13 HLA-DQB1 
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3 CCAR1 13 HLA-DQA1 
3 GGNBP2 13 AGPAT9 
3 PDCD6 13 CLIC2 
3 RPS27 13 CLEC7A 
3 RPS16P5 13 IL13RA1 
3 TLE4 13 CST3 
3 LOC100996866 13 AXL 
3 IKZF1 13 OTTHUMG00000173465///RP11-389C8.2 
3 GUSBP3///GUSBP9///LOC100653061///LOC101060519 13 MS4A6A 
3 MSI2 13 GEM 
3 RHOH 13 PKIB 
3 LOC100190986///LOC101060564 13 S100B 
3 LINC00342 13 TLR7 
3 FLJ31306 13 SERPINF1 
3 FLJ38379 13 CCR5 
3 TCF12 13 JAZF1 
3 RAB11FIP3 13 MARCH1 
3 ZNF124 13 CPVL 
4 C1orf54 13 IDO1 
4 GGTA1P 13 FCGR2B 
4 FCER1A 14 TASP1 
4 LGALS3 14 GXYLT2 
4 HLA-DRB1///HLA-DRB3///HLA-DRB4///HLA-DRB5///LOC100507709///LOC100507714 14 TRDC 
4 SERPINB2 14 YME1L1 
4 THEMIS2 14 CD3D 
4 SETBP1 14 TRAT1 
4 SERPINB9 14 GPR171 
4 EMP1 14 GPR65 
4 HLA-DPA1 14 LPXN 
4 CD74 14 CDK2AP2 
4 CSF2RB 14 VANGL1 
4 HLA-DOA 14 VASH2 
4 AHNAK 14 CD7 
4 HLA-DRB1///HLA-DRB3///HLA-DRB4///HLA-DRB5///LOC100507709///LOC100507714///LOC101060779 14 HES4 
4 DUSP1 14 ICOS 
4 RGS2 14 MYO1B 
4 KLF6 14 CEP41 
4 SIK1 14 SLC35B3 
4 ARRDC3 14 TMEM251 
4 ZBTB24 14 ATG4C 
4 PLK2 14 VPS41 
4 KLF2 14 ATP6V1D 
4 PPP1R15A 14 BPNT1 
4 DUSP4 14 KIAA1841 
4 ETNK1 14 PPHLN1 
4 EGR3 14 C17orf62 
4 PTGS2 14 PWWP2A 
4 NR4A2 14 CBR4 
4 FOSB 14 WDR67 
4 FOS 14 DCAF12 
4 VIM 14 LRIF1 
4 SGK1 14 ST8SIA4 
4 RASGEF1B 14 DNA2 
4 LOC284454 14 LOC389831 
4 ANXA1 14 HES1 
4 ITPKB 14 GIMAP7 
4 NASP 14 IL17RA 
4 EGR2 14 DPP4 
4 LAIR2 14 IFNAR1 
5 VWF 14 PAQR8 
5 EFEMP1 14 TRIM13 
5 MGP 14 ACSL3 
5 MAFIP 14 SHCBP1 
5 ELL2 14 UMODL1 
5 FN1 14 PHF20L1 
5 HBEGF 14 STK38L 
5 ABLIM1 14 CEP19 
5 NRIP1 14 C9orf64 
5 PIK3R1 14 HYLS1 
5 MYH10 14 ATP6V1C1 
5 OTTHUMG00000182869///RP11-420K14.2 14 ERCC4 
5 FLJ13197 14 ARL13B 
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5 ZBTB16 14 KBTBD7 
5 CDKN1C 14 HDHD1 
5 PXDN 14 FBXO5 
5 HIST3H2A 14 NCAPG2 
5 OCLN 14 SKA3 
5 HLA-DRB4 14 CCNF 
5 XIST 14 TROAP 
5 FOXO3///FOXO3B 14 AURKB 
5 MXI1 14 CASC5 
5 DGKE 14 NUSAP1 
5 PPP1R3B 14 TMPO 
5 ABCG1 14 CCDC15 
5 RBM38 14 SGOL2 
5 SHISA2 14 GTSE1 
5 GNL1 14 CDCA2 
5 BAG3 14 E2F7 
5 SPTBN1 14 E2F8 
5 CREM 14 KIF18B 
5 KBTBD2 14 MKI67 
5 IL6ST 14 KIF23 
5 SKIL 14 ECT2 
5 RIT1 14 CENPF 
5 HIST2H2AA3///HIST2H2AA4 14 NUF2 
5 PIK3IP1 14 FANCI 
5 ANKDD1A 14 KIF15 
5 CCNL1 14 KIF18A 
5 JUN 14 ESPL1 
5 MEX3C 14 KIFC1 
5 CSRNP1 14 BUB1B 
5 BCL10 14 STIL 
5 EPC1 14 KIF14 
5 BTG1 14 CENPE 
5 KRAS 14 DEPDC1 
5 CHMP3///RNF103///RNF103-CHMP3 14 KIF2C 
5 KLHL24 14 HJURP 
5 MIR4800///MXD4 14 CDCA8 
5 OTUD1 14 CCNB2 
5 CA2 14 CENPA 
5 RIN2 14 NEK2 
5 LILRB2 14 KIF11 
5 CPQ 14 KIF4A 
5 ADAM8 14 BUB1 
5 SQSTM1 14 RRM2 
5 IL8 14 TPX2 
5 TRIB1 14 RACGAP1 
5 CCL3///CCL3L1///CCL3L3///LOC101060267 14 MELK 
5 ZFP36 14 SPAG5 
5 TSC22D3 14 NCAPG 
5 METRNL 14 SRSF1 
5 ATF3 14 NDC80 
5 NAMPT 14 SPDL1 
5 RC3H2 14 CENPN 
5 MAFF 14 C9orf40 
5 POLB 14 CKAP2L 
5 CUL1 14 ARHGAP11A 
5 HEMGN 14 FOXM1 
5 PER1 14 NCAPH 
5 PCIF1 14 RAD54L 
5 CSNK1E///LOC100996460 14 BIRC5 
5 CUL4A 14 CCDC167 
5 STAT3 14 CCNE2 
5 FAM3C 14 ERCC6L 
5 RAPGEF2 14 PARPBP 
5 RNF130 14 C11orf82 
5 MECP2 14 KNSTRN 
5 SRSF11 14 CDCA5 
5 NLRP1 14 ASF1B 
5 MED23 14 AURKA 
5 ST3GAL1 14 CDKN3 
5 ZNF638 14 MND1 
5 IREB2 14 NIF3L1 
5 MIR22///MIR22HG 14 MTFR2 
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5 PPP1R16B 14 TCF19 
5 FLJ43663 14 HIRIP3 
5 ISG20 14 SPC24 
5 PIM2 14 RTP4 
5 PDE4B 14 RBL1 
5 SOCS3 14 TOP2A 
5 LPGAT1 14 FAM72A///FAM72B///FAM72C///LOC101060656 
5 HLA-E 14 UHRF1 
5 SMAD3 14 WDR76 
5 RNF144B 14 INTS7 
5 IDS 14 CDK1 
5 ERO1LB 14 DLGAP5 
5 ACVR2A 14 TTK 
5 TMEM200A 14 UBE2C 
5 IRAK2 14 CDCA3 
5 GABARAPL1 14 KIF20A 
5 SLC2A3 14 CEP55 
5 SYTL3 14 HMMR 
6 HAS1 14 ANLN 
6 CTSL1 14 BRIP1 
6 NINJ1 14 ERI2 
6 CXCL3 14 DIAPH3 
6 TM4SF1 14 C1orf112 
6 INHBA 14 SMC2 
6 CXCL1 14 DEPDC1B 
6 AQP9 14 UBE2T 
6 CCL2 14 CCNA2 
6 ICAM1 14 CDC20 
6 PHLDA1 14 CCNB1 
6 TNFRSF9 14 OIP5 
6 IL6 14 SPC25 
6 ZNF709 14 PKP4 
6 C10orf10 14 BRCC3 
6 RHOB 14 CDC25A 
6 IER3 14 FBXO22 
6 C15orf48 14 SLC25A19 
6 BCL2A1 14 POLR1B 
6 TLN1 14 IDH1 
6 HIST1H2BC 14 HK2 
6 TPP2 14 GIMAP6 
6 IL1RL1 14 GIMAP8 
6 CNST 14 GIMAP1 
6 USP36 14 NABP1 
6 MAX 14 NRARP 
6 FTH1 14 GAS1 
6 USP15 14 DCPS 
6 GFOD1 14 ARL11 
6 DOCK7 14 SGK223 
6 AREG///AREGB 14 STAMBPL1 
6 C7orf73///SLC13A4 14 OPN3 
6 SLC8A3 14 NLRP2 
6 TPM3 14 PSPH 
6 SOD2 14 FAM173B 
6 GABPB1 14 CHEK2 
6 STX11 14 ICMT 
6 CXCL2 14 POLR3K 
6 FAM198B 14 C2orf43 
6 CYLD 14 RAD51C 
6 RELB 14 GART 
6 BCL3 14 CSE1L 
6 NBL1 14 OTTHUMG00000159786///RP11-85F14.5 
6 SLCO3A1 14 TRMT1L 
6 SMURF1 14 METTL13 
6 SEMA6A 14 UBE2L3 
6 SDK2 14 EPDR1 
6 MINOS1-NBL1///NBL1 14 RPE 
6 SERAC1 14 BRI3BP 
6 EIF4G3 14 RMI1 
6 NFKB2 14 KIAA1524 
6 USP53 14 GINS1 
6 ERMN 14 ARFIP1 
6 TCF25 14 SHQ1 
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6 GNG4 14 TARP///TRGC2 
6 KSR1 14 RAD51 
6 SKI 14 DHFR 
6 MEG3 14 BRCA1 
6 AVP 14 MCM8 
6 THBS1 14 TK1 
6 HBA1///HBA2 14 GUCY1B3 
6 NR4A3 14 TAF5 
6 BMP6 14 TDP1 
6 CDC42 14 TUBG1 
6 LOC100507672 14 PAGR1 
6 BEX5 14 XRCC4 
6 CDC14B 14 SRSF10 
6 NEDD4L 14 CENPM 
6 HBG1///HBG2 14 WDHD1 
6 DLK1 14 PANK1 
6 PPBP 14 LCMT2 
6 G0S2 14 PSAT1 
6 TMEM163 14 EXO1 
6 TNIK 14 C12orf4 
6 THSD7A 14 C18orf54 
6 LIMS3///LIMS3L 14 MED11 
6 ARHGEF12 14 EXOSC3 
6 FOXO1 14 GEMIN6 
6 FAM65C 14 UMPS 
6 PDZD2 14 TRIP13 
6 EREG 14 CDC6 
6 HBB 14 MCM10 
6 LOC254057 14 CHAC2 
6 PEAR1 14 CLUAP1 
6 FCHO2 14 RAD54B 
6 CRHBP 14 SAPCD2 
6 MYCT1 14 GINS4 
6 DNAJC6 15 CD1C 
6 BEX2 15 SMPD3 
6 ACSL1 15 CD1E 
6 BEX1 15 HHIP-AS1 
6 H1F0 15 CHI3L2 
6 KLF3 15 SYNE2 
6 LRP5L 15 TNRC6C 
6 PRKACB 15 ARPP21 
6 NLK 15 LOC100130503 
6 C7orf41 15 DOCK9 
6 MAGI2-AS3 15 OTTHUMG00000176181///RP11-119F7.5 
6 OTTHUMG00000176268///RP11-18F14.2 15 CCR9 
6 SLC35D2 15 GSDMB 
6 LOC285812 15 CTC1 
6 PTX3 15 HS3ST3B1 
6 GBP2 15 ZBTB1 
6 ABCB1 15 FAM69A 
6 CEBPB 15 RUFY3 
6 FGD5 15 CCNG2 
6 ABHD17C 15 PVRIG 
6 MPP7 15 NOTCH3 
6 IRS2 15 HDAC4 
6 PPM1H 15 LRRC28 
6 PLOD2 15 ACPL2 
6 RBPMS 15 LINC00226 
6 HLF 15 CR2 
6 PBX1 15 ZC3H6 
6 CALN1 15 NKD2 
6 GPR126 15 GLRB 
6 GNAI1 15 OTTHUMG00000017520///RP11-144L1.4 
6 ALDH1A1 15 CX3CR1 
6 TNFRSF10A 15 LOC101060391 
6 GATA2 15 CCR8 
6 TNFRSF10D 15 TMSB15A///TMSB15B 
6 CNRIP1 15 SLC16A10 
6 ITGA9 15 CD1B 
6 TAL1 15 RAG2 
6 TCF7L2 15 AQP3 
6 DACH1 15 CD1A 
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6 LRP6 15 GRAP2 
6 ZNF521 15 CD3E 
6 NPR3 15 SLC7A3 
7 SOCS2 15 RAPGEF5 
7 ARMCX1 15 ATP6AP1L///FLJ41309 
7 MEST 15 SRPK2 
7 CXCR7 15 TRBC1 
7 HSPA1A///HSPA1B 15 TRBC2 
7 C11orf96 15 MAL 
7 GSTM3 15 ID3 
7 FHL1 15 UBASH3A 
7 SNTB1 15 TLR5 
7 BSPRY 15 TSHR 
7 EPCAM 15 IRS1 
7 HBD 15 HHIP 
7 UCHL1 15 PTCRA 
7 NRIP3 15 SLC8A1-AS1 
7 PDE4DIP 15 PAFAH2 
7 MATR3///SNHG4 15 RAG1 
7 AC005682.5///OTTHUMG00000152563 15 CD1D 
7 TMEM220 15 MME 
7 GYPC 15 PLCL1 
7 FAM171B 15 SH3TC1 
7 ADM 15 SPRED2 
7 SMIM3 15 BCL2L11 
7 CRYGD 15 FOXO6///FOXO6 
7 RIPK2 15 CYP2U1 
7 ZBTB8A 15 PPP1R1C 
7 GBP4 15 LOC79015 
7 DRAM1 15 STAG3 
7 MPL 15 CRNDE 
7 ICA1 15 ADAMTS1 
7 CMBL 15 WT1 
7 SYNGR1 15 LOC283788 
7 FAM69B 15 LOC728613 
7 TCTEX1D1 15 SLC16A6 
7 SDPR 15 IPP 
7 OTTHUMG00000020937///RP11-251M1.1 15 TFDP2 
7 CPA3 15 SBK1 
7 KBTBD11 15 POU2AF1 
7 SLC22A15 15 ITK 
7 RAB13 15 RASGRP1 
7 GRB10 15 CAMK4 
7 SLC2A5 15 TCF7 
7 ELK3 15 PCDH10 
7 PVRL2 15 PTPRK 
7 SORL1 15 CD96 
7 PROK2 15 GATA3 
7 GPR27 15 IL32 
7 SNORD3A///SNORD3B-1///SNORD3B-2///SNORD3C///SNORD3D 15 TMOD2 
7 PRSS2 15 PLCG1 
7 MSRB3 15 NMT2 
7 NAP1L3 15 P2RX5 
7 TPM1 15 IKZF2 
7 HMGA2 15 FAM63B 
7 NUDT11 15 DGKA 
7 CABLES1 15 RGPD1///RGPD2 
7 CKAP4 15 LAT 
7 RAMP1 15 BCL11B 
7 TFPI 15 ZAP70 
7 IL1RAP 15 THEMIS 
7 IRAK3 15 CD247 
7 GBP5 15 SLFN5 
7 FOSL2 15 LEF1 
7 SLC22A4 15 CD3G 
7 TRH 15 LDLRAD4 
7 TTC7B 15 AEBP1 
7 HOXB2 15 SLC4A4 
7 ME3 15 GALNT2 
7 CHRM3 15 KIF3A 
7 MECOM 15 PARP8 
7 MEIS1 15 RIMS3 
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7 PHTF1 15 FYB 
7 LOC100505573 15 YPEL1 
7 LATS2 15 KIAA0226L 
7 MBOAT7 15 NEDD9 
7 LPCAT2 15 CD72 
7 AAED1 15 ATM 
7 WHAMMP2///WHAMMP3 15 IPCEF1 
7 SEMA4C 15 APBA2 
7 KIT 15 SERHL2 
7 HOPX 15 CD79A 
7 HOXA3 15 EBF1 
7 HOXA5 15 CDH2 
8 C11orf21 16 KBTBD6 
8 GSAP 16 FRMD4A 
8 GATM 16 DLEU2 
8 STAP1 16 NAPEPLD 
8 LYN 16 EVL 
8 ALCAM 16 LOC100506776 
8 VCL 16 SLC4A7 
8 MEF2C 16 NREP 
8 BTK 16 KATNBL1 
8 MGLL 16 AHRR 
8 B3GNT7 16 FANCA 
8 FAM49A 16 POLQ 
8 PLXNB2 16 ZNF519 
8 PHACTR1 16 LOC100507312 
8 PLEK 16 ASPM 
8 BASP1 16 ESCO2 
8 IRF5 16 FAM111B 
8 DUSP6 16 ATAD2 
8 CD300LF 16 RHOU 
8 RAB31 16 LYST 
8 PIK3AP1 16 LOC284757 
8 MYO1F 16 GTF2H2B 
8 CTBP2 16 TXLNG2P 
8 CDC42BPA 16 DSERG1 
8 IPO11///LRRC70 16 PLGLB1///PLGLB2 
8 DUSP10 16 SEPT1 
8 C1orf186 16 HOMER1 
8 RPS11 16 RRN3P3 
8 BHLHE40 16 UGP2 
8 SPRY1 16 LOC100996511 
8 NFIL3 16 MIR181A2HG 
8 KLF11 16 GOLGA2P5 
8 SPRY2 16 OTTHUMG00000183913///RP11-932O9.10 
8 CD69 16 EPM2AIP1 
8 EGR1 16 C1orf132 
8 DUSP5 16 CD28 
8 FXYD5 16 DHFRL1 
8 CD44 16 SUV420H1 
8 OTTHUMG00000176545///RP11-510J16.3 16 AKAP2///PALM2-AKAP2 
8 MAML3 16 TRAF3IP3 
8 LAPTM5 16 SATB1 
8 CRIM1 16 INPP4A 
8 IGHM 16 ITGAL 
8 SNX9 16 CDC25B 
8 FLT3 16 SH3KBP1 
8 HLX 16 NDST3 
8 TCF4 16 HNRNPR 
8 NFKBIZ 16 ARHGAP19 
8 CAPN2 16 GRSF1 
8 MAP3K8 16 CEP70 
8 ADAM28 16 WDR7 
8 MYLIP 16 CEP78 
8 KLF9 16 STAU2 
8 LILRA2 16 TBCD 
8 HPGDS 16 LRRC1 
8 CD302///LY75-CD302 16 WBP1L 
8 HHEX 16 SELPLG 
8 TNS3 16 JPH1 
8 SH3RF1 16 PRKCA 
8 ANKRD33B 16 BIK 
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8 NLRP3 16 OTTHUMG00000178927///RP11-196G18.23 
8 GNG11 16 CHST2 
8 ARSD 16 STS 
8 FNDC3B 16 RHBDD1 
8 SLC25A13 16 OXNAD1 
8 GOLIM4 16 MNS1 
8 TIMP1 16 PSRC1 
8 NEK3 16 CDC25C 
8 C10orf54 16 LOC100288637 
8 DUSP3 16 FBXO43 
8 TNFRSF1B 16 MYBL1 
8 IL18 16 LEF1-AS1 
8 ITPRIPL2 16 NEIL3 
8 CEBPD 16 LOC100506100 
8 FAM46A 16 KIAA0922 
8 CTNNA1 16 MTA3 
8 LMO2 16 CEP128 
8 TNFRSF10B 16 ITPR2 
8 CFD 16 TCFL5 
8 SLC7A5 16 STK11IP 
8 BATF 16 ZNF280D 
8 LOC729680 16 APOLD1 
8 EIF4EBP1 16 ZEB1-AS1 
8 TRIM6 16 CD2 
8 MGST1 16 LOC100507600 
8 MPO 16 CAPSL 
8 SLC22A16 16 MGAT4A 
8 FAH 16 NDFIP2 
8 BCAT1 16 HIVEP3 
8 MTHFD1L 16 PCSK5 
8 TNFAIP2 16 IGHG1 
8 TNFSF13B 16 IGH///IGHA1///IGHA2///IGHD///IGHG1///IGHG3///IGHG4///IGHM///IGHV3-23///IGHV4-31 
8 CD33 16 MAP1A 
8 PLA2G4A 16 RCAN1 
8 MOB3B 16 SH2D1A 
8 KCNK17 16 PBK 
8 GCSAML 16 IL7R 
8 NFE2 16 ADA 
8 HSH2D 16 LCK 
8 LAT2 16 LIG4 
8 P2RY2 16 CDKN2C 
8 SIGLEC17P 16 E2F2 
8 ACY3 16 NETO2 
8 S100Z 16 GAS7 
8 PAM 16 FXYD2 
8 CD34 16 IGF2R 
8 C11orf74 
  8 PYGL 
  8 CLDN10 
  8 CYB561 
  8 CLEC11A 
  8 MYCN 
  8 SPON1 
  8 ANGPT1 
  8 PTPRD 
  8 SPINK2 
  8 KIAA0125 
  8 EFHC2 
  8 MCTP2 
  8 AP001171.1///OTTHUMG00000074606 
  8 ERG 
  8 IGFBP7 
  8 ARHGEF40 
  8 MYLK 
  8 LYL1 
  8 PRAM1 
  8 SERPINB1 
  8 ATP8B4 
  8 XBP1 
  8 LAMC1 
  8 C19orf77 
  8 MAP7 
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8 PROSER2 
  8 HTR1F 
  8 SPARC 
  8 SHANK3 
  8 F2RL1 
  8 ZC3H12C 
  8 CNKSR3 
  8 MN1 
  8 TUSC1 
  8 C1QTNF4 
  8 C9orf43 
  8 KIF13A 
  8 BAALC 
  8 PROM1 
  8 IQCJ-SCHIP1///SCHIP1 
  8 IL1B 
  8 B3GNT5 
  8 NIPAL2 
  8 DEPTOR 
  8 STOM 
  8 SERPINB6 
  8 CREG1 
  8 CD63 
  8 C17orf58 
  8 MYO5C 
  8 RAB3D 
  8 ASB9 
  8 SETD9 
  8 CYTL1 
  8 DPPA4 
  8 KCTD15 
  8 PDGFC 
  8 MATR3 
  8 CCND2 
  8 CPXM1 
  8 SLC39A8 
  8 SERPINE2 
  8 LAPTM4B 
  8 KIAA1211 
  8 STON2 
  8 LDLRAD3 
  8 KCNQ5 
  8 SLC27A2 
  8 KIF9 
  8 SLC35F2 
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Table S2: Gene set enrichment on gene expression of murine T-cell development, Figure 2B 
         
Gene Signatures #7 and #8 
 
Gene Signatures #2, #15 and #16 
Gene Symbol Rank in gene list Running ES Core enrichment 
 
Gene Symbol Rank in gene list Running ES Core enrichment 
RAB31 0 0.023 Yes 
 
CD72 21 0.021 No 
PLEK 2 0.043 Yes 
 
PARP8 369 0.016 No 
HHEX 4 0.061 Yes 
 
TFDP2 399 0.026 No 
KIT 9 0.079 Yes 
 
ACPL2 587 0.027 No 
LYN 10 0.096 Yes 
 
SLC4A7 818 0.025 No 
MEF2C 12 0.113 Yes 
 
PAFAH2 851 0.032 No 
BTK 14 0.131 Yes 
 
STAU2 1238 0.022 No 
LYL1 15 0.147 Yes 
 
KIF3A 1913 -0.002 No 
ANGPT1 19 0.164 Yes 
 
ARRDC4 1914 0.003 No 
CD34 28 0.179 Yes 
 
CAPSL 2025 0.004 No 
PLA2G4A 32 0.194 Yes 
 
FAM69A 2152 0.004 No 
KIF13A 45 0.207 Yes 
 
SH3TC1 2312 0.002 No 
PLXNB2 54 0.220 Yes 
 
FRMD4A 2418 0.002 No 
ERG 63 0.233 Yes 
 
SLC16A6 2503 0.003 No 
MYO1F 69 0.245 Yes 
 
SYNE2 2504 0.007 No 
PYGL 72 0.257 Yes 
 
EBF1 3291 -0.023 No 
CTBP2 82 0.269 Yes 
 
STK11IP 3359 -0.023 No 
B3GNT5 99 0.280 Yes 
 
ALOX5 3451 -0.023 No 
CABLES1 101 0.291 Yes 
 
RASSF6 3470 -0.021 No 
IRF5 103 0.303 Yes 
 
NMT2 3613 -0.024 No 
CD44 108 0.314 Yes 
 
IL10RA 3730 -0.026 No 
PIK3AP1 114 0.325 Yes 
 
CEP70 3799 -0.025 No 
VCL 126 0.336 Yes 
 
PGM2L1 3814 -0.023 No 
MYCN 133 0.346 Yes 
 
UGP2 4240 -0.039 No 
MPO 142 0.357 Yes 
 
GRK5 4308 -0.039 No 
ALCAM 148 0.367 Yes 
 
ATM 4523 -0.046 No 
NFE2 171 0.377 Yes 
 
RUFY3 4632 -0.049 No 
TCF4 284 0.381 Yes 
 
DUSP16 4635 -0.047 No 
SNX9 290 0.389 Yes 
 
CD79A 4710 -0.048 No 
ZC3H12C 330 0.396 Yes 
 
GRSF1 4822 -0.051 No 
IL18 335 0.404 Yes 
 
DOCK9 4974 -0.055 No 
HOXA5 344 0.412 Yes 
 
HNRNPR 4991 -0.054 No 
SLC25A13 354 0.420 Yes 
 
PLEKHG1 5034 -0.054 No 
FAM69B 355 0.428 Yes 
 
CEP78 5175 -0.058 No 
CTNNA1 360 0.436 Yes 
 
MTA3 5189 -0.057 No 
FAM49A 370 0.444 Yes 
 
INPP4A 5287 -0.060 No 
TRIM6 386 0.451 Yes 
 
ARHGAP29 5378 -0.062 No 
CNKSR3 392 0.459 Yes 
 
PALLD 5420 -0.062 No 
LMO2 394 0.467 Yes 
 
RHBDD1 5450 -0.062 No 
LAT2 452 0.472 Yes 
 
LRRN3 5481 -0.062 No 
HLX 467 0.479 Yes 
 
NINL 5490 -0.061 No 
P2RY2 501 0.485 Yes 
 
CR2 5603 -0.064 No 
IL1RAP 519 0.491 Yes 
 
RAPGEF5 5719 -0.068 No 
EIF4EBP1 523 0.498 Yes 
 
OXNAD1 5783 -0.070 No 
ICA1 539 0.505 Yes 
 
EFNB2 5905 -0.074 No 
MEIS1 573 0.510 Yes 
 
ITGA6 6036 -0.078 No 
LPCAT2 595 0.516 Yes 
 
TBCD 6251 -0.087 No 
ITPRIPL2 613 0.523 Yes 
 
RDH10 6597 -0.101 No 
HPGDS 628 0.529 Yes 
 
JPH1 6862 -0.113 No 
FLT3 631 0.536 Yes 
 
ZC3H6 6869 -0.112 No 
CKAP4 636 0.542 Yes 
 
SLFN5 6938 -0.115 No 
PAM 649 0.549 Yes 
 
ID1 6951 -0.115 No 
GATM 669 0.555 Yes 
 
CRIP1 7203 -0.126 No 
ARMCX1 717 0.559 Yes 
 
FHIT 7332 -0.131 No 
HMGA2 755 0.564 Yes 
 
FAIM3 7477 -0.138 No 
GSTM3 763 0.570 Yes 
 
PSRC1 7753 -0.150 No 
GOLIM4 779 0.576 Yes 
 
BCL2L11 7796 -0.151 No 
CD33 892 0.577 Yes 
 
CHST2 8127 -0.166 No 
NAP1L3 901 0.582 Yes 
 
YPEL1 8448 -0.179 No 
MAML3 963 0.585 Yes 
 
SCN7A 8951 -0.201 No 
MGST1 1076 0.586 Yes 
 
AGBL3 9194 -0.210 No 
GBP5 1077 0.592 Yes 
 
STAG3 9339 -0.216 No 
SEMA4C 1117 0.595 Yes 
 
AHRR 9658 -0.229 No 
DUSP3 1147 0.599 Yes 
 
NDFIP2 9800 -0.234 No 
MSRB3 1181 0.603 Yes 
 
RCAN1 9909 -0.238 No 
IRAK3 1227 0.607 Yes 
 
NDST3 10158 -0.247 No 
RAB3D 1254 0.611 Yes 
 
NSG1 10250 -0.250 No 
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KIF9 1313 0.613 Yes 
 
POU2AF1 10391 -0.255 No 
CD63 1317 0.618 Yes 
 
APBA2 10449 -0.256 No 
FNDC3B 1320 0.623 Yes 
 
GAL3ST4 10611 -0.262 No 
FAM46A 1328 0.628 Yes 
 
GAS7 10758 -0.267 No 
TNFAIP2 1332 0.633 Yes 
 
CX3CR1 10866 -0.271 No 
SPRY2 1338 0.638 Yes 
 
S1PR1 11101 -0.279 No 
TFPI 1404 0.640 Yes 
 
ADAMTS1 11356 -0.289 No 
MPL 1418 0.645 Yes 
 
EVL 11375 -0.288 No 
MECOM 1498 0.646 Yes 
 
IKZF2 11638 -0.298 No 
KLF11 1547 0.648 Yes 
 
TSHR 11754 -0.302 No 
CDC42BPA 1691 0.647 Yes 
 
PCSK5 11874 -0.305 No 
GRB10 1809 0.646 Yes 
 
SLC7A3 12006 -0.309 No 
LATS2 1823 0.650 Yes 
 
NETO2 12466 -0.328 No 
TNS3 1912 0.650 Yes 
 
TMOD2 12502 -0.328 No 
SHANK3 1915 0.654 Yes 
 
GLRB 12787 -0.338 No 
MN1 2041 0.653 Yes 
 
SUV420H1 12849 -0.339 No 
MCTP2 2067 0.656 Yes 
 
PLCL1 13625 -0.371 No 
MAP3K8 2115 0.657 Yes 
 
NEIL3 13626 -0.369 No 
MYO5C 2194 0.658 Yes 
 
SYNM 13747 -0.372 No 
SNTB1 2261 0.659 Yes 
 
WT1 14113 -0.386 No 
NFIL3 2317 0.660 Yes 
 
MBD5 14171 -0.387 No 
FXYD5 2391 0.660 Yes 
 
ID2 14366 -0.393 No 
CPXM1 2433 0.662 Yes 
 
PCDH9 14484 -0.396 No 
DUSP6 2633 0.657 Yes 
 
ATAD2 14940 -0.414 No 
CRIM1 2660 0.659 Yes 
 
SCN3A 15277 -0.426 No 
NFKBIZ 2740 0.659 Yes 
 
PCDH10 15373 -0.428 No 
RPS11 2789 0.660 Yes 
 
DLEU2 15620 -0.436 No 
GYPC 2795 0.663 Yes 
 
HHIP 15683 -0.436 No 
FOSL2 2804 0.666 Yes 
 
MME 15763 -0.437 No 
LAPTM4B 2869 0.666 Yes 
 
NAPEPLD 15833 -0.438 No 
GNG11 2870 0.669 Yes 
 
CDH2 15903 -0.438 No 
MYLK 2886 0.672 Yes 
 
CYP2U1 15979 -0.439 No 
TNFRSF10B 3083 0.666 Yes 
 
FANCA 16117 -0.442 No 
BATF 3145 0.666 Yes 
 
VCAN 16153 -0.441 No 
SDPR 3180 0.668 Yes 
 
PBK 16185 -0.440 No 
UCHL1 3306 0.665 Yes 
 
IL7R 16226 -0.439 No 
SOCS2 3468 0.660 Yes 
 
FXYD2 16538 -0.450 No 
HSH2D 3496 0.662 Yes 
 
IPCEF1 16750 -0.457 No 
CPA3 3506 0.664 Yes 
 
AEBP1 16869 -0.459 No 
FHL1 3516 0.666 Yes 
 
SLC4A4 16978 -0.461 No 
CD69 3519 0.669 Yes 
 
POLQ 17262 -0.471 No 
TPM1 3521 0.671 Yes 
 
HOMER1 17373 -0.472 No 
CAPN2 3524 0.674 Yes 
 
ASPM 17379 -0.470 No 
BHLHE40 3525 0.676 Yes 
 
PTPRK 17490 -0.472 No 
DUSP5 3586 0.676 No 
 
PPP1R1C 17543 -0.471 No 
EFHC2 3800 0.669 No 
 
RHOU 17688 -0.474 No 
NLRP3 3826 0.670 No 
 
AQP3 17833 -0.478 No 
MATR3 3861 0.671 No 
 
BIK 17936 -0.479 No 
BASP1 3921 0.671 No 
 
NKD2 17946 -0.476 No 
ATP8B4 4068 0.666 No 
 
LRRC1 17995 -0.476 No 
NUDT11 4182 0.663 No 
 
MAL 18144 -0.479 No 
SLC22A15 4250 0.662 No 
 
MYBL1 18292 -0.482 No 
MBOAT7 4381 0.658 No 
 
FBXO43 18398 -0.484 No 
DRAM1 4441 0.658 No 
 
GALNT2 18506 -0.485 No 
SLC27A2 4640 0.651 No 
 
NEGR1 18581 -0.485 No 
FAM171B 4755 0.647 No 
 
LRRC28 18595 -0.482 No 
PDGFC 5119 0.633 No 
 
P2RX5 18891 -0.492 No 
RIPK2 5382 0.622 No 
 
SMPD3 18946 -0.491 No 
FAH 5468 0.620 No 
 
MGAT4A 19097 -0.494 No 
CCND2 5470 0.621 No 
 
CCNG2 19220 -0.496 No 
EGR1 5727 0.611 No 
 
CCR8 19280 -0.495 No 
TMEM220 5735 0.611 No 
 
ESCO2 19389 -0.497 No 
SLC39A8 5887 0.605 No 
 
RBMS3 19530 -0.499 No 
HOXB2 5890 0.606 No 
 
BACH2 19576 -0.498 No 
ACY3 5923 0.606 No 
 
NEDD9 19624 -0.496 No 
CEBPD 6050 0.601 No 
 
DNTT 19641 -0.493 No 
TUSC1 6088 0.600 No 
 
CDKN2C 19717 -0.493 No 
CYB561 6104 0.600 No 
 
CDC25C 19833 -0.494 No 
STOM 6658 0.576 No 
 
ZBTB1 19978 -0.497 No 
STAP1 6893 0.566 No 
 
PDE4D 20213 -0.503 Yes 
KCNQ5 7180 0.554 No 
 
EPM2AIP1 20231 -0.500 Yes 
HOPX 7376 0.545 No 
 
TANC1 20370 -0.502 Yes 
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ANKRD33B 7426 0.543 No 
 
WDR7 20405 -0.499 Yes 
BSPRY 7520 0.539 No 
 
FAM63B 20481 -0.499 Yes 
MTHFD1L 7705 0.531 No 
 
IRS1 20511 -0.496 Yes 
PHACTR1 7887 0.523 No 
 
TCFL5 20559 -0.494 Yes 
LDLRAD3 7926 0.522 No 
 
NOTCH3 20582 -0.491 Yes 
B3GNT7 8251 0.508 No 
 
RIMS3 20758 -0.494 Yes 
LAMC1 8390 0.502 No 
 
COX6A1 20841 -0.493 Yes 
SPRY1 8581 0.494 No 
 
HDAC4 20879 -0.491 Yes 
SLC22A4 8690 0.490 No 
 
SEC31B 21056 -0.494 Yes 
RAB13 8804 0.486 No 
 
APOLD1 21084 -0.490 Yes 
TNFRSF1B 9005 0.477 No 
 
CDC25B 21224 -0.492 Yes 
SPARC 9169 0.471 No 
 
GAS2 21363 -0.493 Yes 
RAMP1 9170 0.471 No 
 
ARHGAP19 21464 -0.493 Yes 
XBP1 9206 0.470 No 
 
NCALD 21545 -0.491 Yes 
MYLIP 9290 0.467 No 
 
HS3ST3B1 21595 -0.488 Yes 
CHRM3 9431 0.462 No 
 
ITGAL 21773 -0.490 Yes 
CD300LF 9453 0.462 No 
 
PTCRA 21814 -0.487 Yes 
CMBL 9680 0.452 No 
 
SEPT9 21820 -0.481 Yes 
TNFSF13B 9730 0.451 No 
 
LYST 21843 -0.477 Yes 
NIPAL2 9768 0.450 No 
 
MNS1 21880 -0.473 Yes 
IL1B 9901 0.445 No 
 
PRKCA 21923 -0.469 Yes 
ZBTB8A 10028 0.441 No 
 
SLC16A10 21982 -0.465 Yes 
SORL1 10148 0.436 No 
 
SPRED2 22073 -0.463 Yes 
IGFBP7 10154 0.437 No 
 
LBH 22103 -0.459 Yes 
LAPTM5 10199 0.436 No 
 
TUBB2A 22278 -0.460 Yes 
SLC35F2 10335 0.431 No 
 
RAG2 22294 -0.454 Yes 
SERPINE2 10478 0.425 No 
 
CD2 22351 -0.449 Yes 
C1QTNF4 11047 0.402 No 
 
ADA 22414 -0.445 Yes 
SLC7A5 11283 0.392 No 
 
E2F2 22506 -0.441 Yes 
S100Z 11421 0.387 No 
 
ARPP21 22519 -0.434 Yes 
PVRL2 11712 0.376 No 
 
SBK1 22543 -0.427 Yes 
NEK3 12156 0.358 No 
 
PLCG1 22551 -0.420 Yes 
PRSS2 12402 0.348 No 
 
CD96 22585 -0.413 Yes 
STON2 12861 0.329 No 
 
TNRC6C 22588 -0.405 Yes 
SPINK2 13304 0.311 No 
 
SELPLG 22617 -0.398 Yes 
ADM 13365 0.310 No 
 
CCR9 22628 -0.390 Yes 
CXCR7 13385 0.311 No 
 
UBASH3A 22639 -0.383 Yes 
PROM1 13415 0.311 No 
 
CD8A 22641 -0.374 Yes 
CLEC11A 13474 0.310 No 
 
TRERF1 22661 -0.367 Yes 
ADAM28 13623 0.305 No 
 
SIPA1L2 22711 -0.360 Yes 
ASB9 13845 0.297 No 
 
DGKA 22740 -0.352 Yes 
CFD 14062 0.289 No 
 
ID3 22806 -0.345 Yes 
TTC7B 14669 0.264 No 
 
CD28 22808 -0.335 Yes 
CRYGD 14848 0.258 No 
 
SATB1 22813 -0.325 Yes 
PTPRD 15343 0.238 No 
 
SH2D1A 22825 -0.316 Yes 
SLC22A16 15517 0.232 No 
 
LIG4 22828 -0.305 Yes 
BAALC 17146 0.163 No 
 
SH3KBP1 22829 -0.295 Yes 
NRIP3 17299 0.158 No 
 
HIVEP3 22835 -0.285 Yes 
MGLL 17390 0.157 No 
 
IKZF3 22863 -0.275 Yes 
TRH 17667 0.147 No 
 
CAMK4 22868 -0.264 Yes 
KBTBD11 18498 0.113 No 
 
GRAP2 22873 -0.253 Yes 
CYTL1 18655 0.108 No 
 
THEMIS 22876 -0.241 Yes 
PDE4DIP 18952 0.098 No 
 
GATA3 22878 -0.230 Yes 
F2RL1 19071 0.095 No 
 
ITK 22887 -0.218 Yes 
PROK2 19095 0.097 No 
 
RASGRP1 22899 -0.206 Yes 
KCTD15 19117 0.098 No 
 
FYB 22904 -0.193 Yes 
HTR1F 19175 0.098 No 
 
TCF7 22907 -0.180 Yes 
SPON1 19237 0.098 No 
 
IGF2R 22910 -0.166 Yes 
TIMP1 19830 0.075 No 
 
LCK 22911 -0.153 Yes 
SLC2A5 20039 0.069 No 
 
ITPR2 22915 -0.139 Yes 
PRAM1 20423 0.055 No 
 
ETS1 22918 -0.125 Yes 
SYNGR1 20540 0.053 No 
 
CD247 22923 -0.110 Yes 
DPPA4 20676 0.050 No 
 
ZAP70 22928 -0.095 Yes 
ME3 20966 0.041 No 
 
BCL11B 22932 -0.080 Yes 
EPCAM 20977 0.043 No 
 
LEF1 22933 -0.064 Yes 
GPR27 21492 0.025 No 
 
LAT 22938 -0.046 Yes 
TCTEX1D1 21586 0.024 No 
 
CD3E 22939 -0.026 Yes 
PHTF1 21786 0.020 No 
 
CD3G 22941 0.000 Yes 
BCAT1 22231 0.005 No 
     SH3RF1 22848 -0.014 No 
     DUSP10 22869 -0.007 No 
     GBP4 22905 0.002 No 
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Table S3: Gene Symbols in Gene Clusters I-V from Figure 2C 
     Gene Cluster I Gene Cluster II Gene Cluster III Gene Cluster IV Gene Cluster V 
SNTB1 CRIM1 KATNBL1 RCAN1 IPP 
DRAM1 CYTL1 OTTHUMG00000176181///RP11-119F7.5 PAFAH2 SLC16A10 
IL1RAP TNS3 GRSF1 SPRED2 STAG3 
SDPR PROM1 STAU2 GAS2 GSDMB 
ARHGAP29 BAALC TXLNG2P CX3CR1 CD8A 
HLX LMO2 POU2AF1 NLGN4X CD8B///LOC100996919 
MEIS1 LAPTM4B GATA3 NINL LYST 
NFIL3 BASP1 BATF SMPD3 IRS1 
KIT FNDC3B SPON1 SH3TC1 AQP3 
IRAK3 FAM46A DUSP6 CD1E NCALD 
TFPI CREG1 SCN3A CD1A GAL3ST4 
SLC22A4 BSPRY HSPA1A///HSPA1B CD1B CCR9 
CPA3 HOXA5 ADAMTS1 CD1D CTC1 
RIPK2 FLT3 CDH2 CD1C PTPRK 
PVRL2 RAB13 NDST3 AEBP1 SATB1 
BHLHE40 CD302///LY75-CD302 RIMS3 E2F2 CD79A 
PHACTR1 IL1B TBCD GTF2H2B SEC31B 
KLF9 EFHC2 APBA2 DOCK9 PARP8 
FOSL2 SLC35F2 NSG1 DSERG1 TLR5 
ARHGEF40 MCTP2 CR2 CDKN2D PLCG1 
CEBPD ADAM28 SLC4A7 CD72 IKZF2 
HBD PHTF1 ZBTB1 PCDH9 IKZF3 
CHRM3 IL18 WDR7 EFNB2 INPP4A 
RAMP1 GNG11 NMT2 CYP2U1 ETS1 
CRYGD MN1 SUV420H1 GPR27 CD28 
SYNGR1 HMGA2 WBP1L MAML3 IL10RA 
WHAMMP2///WHAMMP3 PDGFC KIF3A FRMD4A PLCL1 
MECOM SLC27A2 SELPLG RPS11 GRK5 
CDC42BPA KLF11 NREP MAP1A CRIP1 
CFD ATP8B4 UGP2 CCR8 NETO2 
C11orf21 MAP3K8 MATR3///SNHG4 HIVEP3 MBD5 
CD69 SLC25A13 HDAC4 BCL2L11 AGBL3 
TUBB2A ARMCX1 SRPK2 SLC16A6 PRKCA 
S1PR1 PAM EPM2AIP1 BIK TMOD2 
SERPINE2 F2RL1 ITPR2 DUSP5 CD3E 
ELK3 GSAP ZNF280D DUSP3 DGKA 
PDE4D DPPA4 ITGA6 SCN7A TRBC1 
EGR1 CXCR7 CCNG2 HOXA3 GRAP2 
ID2 NAP1L3 FANCA RAB3D FAM63B 
MYLIP GATM GOLGA2P5 MYCN FYB 
SPRY2 ASB9 ARPP21 TNFRSF10B LEF1 
LAPTM5 PLA2G4A POLQ ICA1 SEPT9 
CD44 IQCJ-SCHIP1///SCHIP1 STS NRIP3 LIG4 
TNFRSF1B RAB31 CDKN2C MOB3B SYNE2 
KBTBD11 NUDT11 PSRC1 ARSD TCF7 
HOXB2 XBP1 DLEU2 PDE4DIP SH2D1A 
SEMA4C EPCAM NEIL3 UCHL1 LCK 
CCND2 SLC39A8 ASPM VCAN PVRIG 
FXYD5 MEST PBK ADM BCL11B 
GYPC CD63 ATAD2 HS3ST3B1 EVL 
FHIT SPRY1 APOLD1 ALOX5 CD96 
DUSP10 STOM PTCRA RBMS3 RASGRP1 
CAPN2 SORL1 TSHR KIF13A IL7R 
HOPX SERPINB1 RAPGEF5 KCTD15 CD3G 
TIMP1 SPINK2 KIAA0226L IGHG1 ITK 
GRB10 MYO1F RAG2 CDC25C CHST2 
CKAP4 LYL1 RAG1 NIPAL2 CD2 
CTNNA1 CD34 NOTCH3 GLRB ZAP70 
TPM1 MPO LRRC1 
 
CD247 
 
SERPINB6 IGF2R 
 
IL32 
 
BTK KIAA0922 
 
PCSK5 
 
CLDN10 LOC79015 
 
HOMER1 
 
MYO5C MAL 
 
NEDD9 
 
HPGDS ARHGAP19 
 
CHI3L2 
 
MGLL MYBL1 
 
ITGAL 
 
NFE2 COX6A1 
 
MGAT4A 
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FAH CDC25B 
 
LAT 
 
ANGPT1 YPEL1 
 
LBH 
 
SLC2A5 MME 
 
ID3 
 
PYGL AKAP2///PALM2-AKAP2 
 
FAM69A 
 
CTBP2 GALNT2 
 
CAMK4 
 
VCL LDLRAD4 
 
UBASH3A 
 
IGFBP7 CEP70 
 
ATM 
 
SPARC DNTT 
 
IPCEF1 
 
DEPTOR ADA 
 
BACH2 
 
KIAA0125 MNS1 
 
FAIM3 
 
PRSS2///PRSS3 TFDP2 
 
LRRN3 
 
MYLK FXYD2 
 
TRAF3IP3 
 
PRSS2 SLC4A4 
 
P2RX5 
 
LILRA2 RUFY3 
 
GBP1 
 
LAMC1 GAS7 
  
 
HTR1F HNRNPR 
  
 
MPL IGHM 
  
 
NLRP3 PALLD 
  
 
MBOAT7 SERHL2 
  
 
CYB561 
   
 
TRH 
   
 
WT1 
   
 
GSTM3 
   
 
SYNM 
   
 
LAT2 
   
 
PTPRD 
   
 
MAP7 
   
 
P2RY2 
   
 
ERG 
   
 
CD33 
   
 
GOLIM4 
   
 
IRF5 
   
 
TNFAIP2 
   
 
EIF4EBP1 
   
 
ID1 
   
 
FHL1 
   
 
BCAT1 
   
 
SLC7A5 
   
 
FAM49A 
   
 
TCF4 
   
 
PLEK 
   
 
PLXNB2 
   
 
LYN 
   
 
MEF2C 
   
 
ALCAM 
   
 
HHEX 
   
 
STAP1 
   
 
NEK3 
   
 
ME3 
   
 
SOCS2 
   
 
CLEC11A 
    
  
176 
 
 
 
 
Chapter 6 
Supplementary Figures  
 
177 
 
 
 
 
 
178 
 
 
 
 
 
 
179 
 
 
 
 
Supplemental Tables  
 
Table S1: Gene Symbols in each of the 4 gene groups (IV) from Figure 1d  
 
Gene Group // Gene Symbol  
1 BIK 
1 CCR9 
1 KIAA0226L 
1 TFPI 
1 LATS2 
1 LMO2 
1 B3GNT5 
1 MAP3K8 
1 FOSL2 
1 BHLHE40 
1 ID2 
1 SPINK2 
1 HOPX 
1 DUSP5 
1 HHEX 
1 CD69 
1 GATA3 
1 MYLIP 
2 NFIL3 
2 IGFBP7 
2 LAT2 
2 P2RX5 
2 ZBTB8A 
2 GBP1 
2 HIVEP3 
2 NFKBIZ 
2 CCND2 
2 SOCS2 
2 NDFIP2 
2 DUSP6 
2 TNFRSF10B 
2 TIMP1 
2 BCAT1 
2 NREP 
2 TCF4 
2 FHIT 
2 KCNK17 
2 NSG1 
2 MSRB3 
2 ARRDC4 
2 MME 
2 EGR1 
2 NCALD 
2 RPS11 
2 CAPN2 
2 LAPTM4B 
2 PRKCA 
2 GALNT2 
2 NOTCH3 
2 CR2 
2 RHOU 
2 NETO2 
2 SPRY2 
2 RAB13 
2 GAS2 
2 MEST 
2 FRMD4A 
2 LOC101060391 
2 ID3 
2 ID1 
2 IGHG1 
2 SH3TC1 
3 CD1A 
3 RCAN1 
3 CD1E 
3 CD1B 
3 OTTHUMG00000017520 /// RP11-144L1.4 
3 DNTT 
3 CEP128 
3 TSHR 
3 FYB 
3 TXLNG2P 
3 TXLNG2P 
4 ARHGAP29 
4 RASGRP1 
4 PBK 
4 LEF1 
4 MAL 
4 THEMIS 
4 CD8A 
4 AQP3 
4 IL32 
4 LIG4 
4 SH2D1A 
4 ITGAL 
4 CD2 
4 HHIP 
4 SCN3A 
4 NAP1L3 
4 CD28 
4 SPRED2 
4 TRBC1 
4 CRIP1 
4 LCK 
4 CHI3L2 
4 FHL1 
4 FXYD2 
4 LOC728613 
4 CRNDE 
4 CLEC11A 
4 C11orf96 
4 NUDT11 
4 TUBB2A 
4 HSPA1A /// HSPA1B 
4 HSPA1A /// HSPA1B 
4 PGM2L1 
4 BCL2L11 
4 NEDD9 
4 PCDH10 
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